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ABSTRACT 
Laura C. Pinheiro: Predicting Health-Related Quality of Life Changes and Endocrine Therapy 
Under-Utilization in Breast Cancer 
(Under the direction of Bryce B. Reeve) 
Women with breast cancer (BC) experience HRQOL decrements following diagnosis, 
which can extend into treatment and survivorship. Poorly managed HRQOL during primary 
treatment is associated with under-utilization of adjuvant treatments. As such, preemptively 
identifying women who are at risk for poor HRQOL and providing targeted management early in 
the care continuum may support women to appropriately receive adjuvant therapies, thus 
improving outcomes. 
 The objectives of this dissertation were to 1) identify HRQOL patterns after diagnosis 
and treatments and determine predictors of patterns, 2) examine racial/ethnic differences in 
HRQOL throughout the care continuum, and 3) assess if early HRQOL patterns were predictive 
of under-utilization of endocrine therapy (ET) during survivorship.  This dissertation used the 
Carolina Breast Cancer Study, a population-based study including 3,000 women diagnosed with 
BC from 2008-2013 across North Carolina. 
 In Aim 1, we identified four subgroups of women with BC who experienced different 
HRQOL trajectories from 5- to 25-months post-diagnosis. We found younger age, lack of social 
support, and having public insurance or being uninsured was associated with an increased 
likelihood of poor HRQOL.  
 In Aim 2, we assessed if racial disparities existed between Non-Hispanic White and 
Black women in physical, social, emotional, functional, and spiritual well-being, and BC specific 
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domains between 5- and 25-months post-diagnosis. At 5-months, White women reported better 
physical and functional HRQOL, but Blacks reported greater spiritual well-being. At 25-months, 
White women’s HRQOL scores rebounded above U.S norms, but Blacks reported physical 
HRQOL scores below U.S. norms and their White counterparts. 
 In Aim 3, using HRQOL subgroups identified in Aim 1, we estimated associations 
between 5-month HRQOL and ET use among women with hormone-receptor positive tumors. 
Poor HRQOL was not significantly associated with a woman’s likelihood of ET initiation, but 
was significantly associated with lower likelihood of adherence.  
 This dissertation’s contributions have important implications for clinical practice, health 
policy and future research. Our findings provide insights on targeted HRQOL management for 
women with BC. We identified associations between poor HRQOL and under-use of adjuvant 
treatment. Developing more equitable approaches to managing HRQOL for women with BC has 
the opportunity to improve outcomes. 
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CHAPTER 1: INTRODUCTION 
 Over 3 million women in the United States live with breast cancer (BC), yet this group 
has poorly understood physical and psychosocial needs.1, 2 3 As screening, diagnosis and 
treatment strategies improve, we expect the number of women living with BC to increase. 
Women with BC experience psychosocial and physical decrements in health-related quality of 
life (HRQOL) throughout surivorship.3 In fact, having BC or having had BC is a significant risk 
factor for poor mental and physical well-being relative to the general population.4, 5 Women 
experience HRQOL decrements before, during, and after their BC treatments.3, 6 Specific patient 
concerns include fear of BC recurrence or death, lymphedema, fatigue, early menopause, and 
difficulty returning to work 1, 4, 5, 7 Poorly managed HRQOL in the 36-months following a cancer 
diagnosis may impact long-term HRQOL and increase the risk of mortality.8 Incorporating non-
monetary costs to patients (i.e., decrements in expected HRQOL) into cancer treatment decisions 
may help deliver more patient-centered BC care.  Cancer care that reflects patient needs and 
preferences is consistent with the national emphasis on patient-centered care.9-11 12, 13 
 Racial/ethnic gaps in HRQOL are known to exist in the cancer and general U.S 
populations, but disparities are not uniform across cancers, age groups, and HRQOL domains.14, 
15 Understanding how racial groups, both young and old, are affected differently by cancer will 
help researchers and clinicians to more equitably manage cancer’s impact on HRQOL. Previous 
research indicates Black women with BC report worse HRQOL than Whites.3, 16-21 However, a 
retrospective case-control study of nearly 2,000 Medicare beneficiaries found that while racial 
disparities in HRQOL are prevalent among individuals before cancer diagnosis, gaps in certain 
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domains narrow following exposure to the cancer care system.14 Specifically, pre-diagnosis 
differences in some domains were 10 points (with Whites having higher scores than Blacks) and 
following diagnosis/treatment gaps narrowed to 1 point or less.14 A possible explanation for the 
narrowing gaps following cancer diagnosis/treatment is that minority groups such as Blacks may 
have more social support throughout cancer treatment, which helps to manage the impact of 
cancer on HRQOL.22 Another potential explanation is that, in general, Blacks tend to have less 
access to health care than Whites.23, 24 Thus, once Black women are diagnosed with BC and enter 
into the health care system, HRQOL differences between Blacks and Whites may narrow 
because Blacks previously unaddressed needs are now being met, which impacts their HRQOL. 
Through this dissertation, we gained a greater understanding of racial gaps in changes in 
HRQOL and potentials target for improving equity in HRQOL management for women with 
BC.20 To date, no study has assessed racial disparities in changes in individual domains of 
HRQOL in a relatively younger (i.e., not exclusively Medicare), multi-payer, racially diverse BC 
population.  
 Nearly 80% of BC cases are hormone receptor positive (HR+), meaning tumors have 
receptors for estrogen or progesterone hormones.25 To reduce risk of BC recurrence, women with 
HR+ BC are recommended to take endocrine therapy (ET) for 5 years after primary BC 
treatment.26 Despite clear benefits associated with ET (e.g., 40% reduction in 5-year risk of BC 
recurrence and 30% reduction in BC-related mortality), up to 30% of HR+ women never initiate 
therapy and, among those who do, nearly 50% are non-adherent by 5 years.27-31 Once women 
make it through primary treatment-induced side effects, it is challenging to begin and continue 
adjuvant treatments that may lead to more symptoms and potentially worse HRQOL.32, 33 Poor 
HRQOL prior to ET initiation may be an indicator of future under-utilization of life-saving 
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adjuvant therapies, as women struggle to acclimate to “normal” life.32-38 Under-utilization is 
defined as not initiating or not adhering to therapy.39 Preemptively identifying women at risk for 
poor HRQOL allows for targeted HRQOL management from BC diagnosis, which may reduce 
HRQOL decrements throughout care.40, 41 Targeted HRQOL support may increase the likelihood 
that women adhere to adjuvant treatments. Therefore, a better understanding of patient-level 
characteristics associated with HRQOL patterns in women with BC and of whether HRQOL 
profiles predict if women are less likely to initiate and adhere to ET can help improve quality of 
BC care in the United States. 
 Numerous studies have shown differences in both health care use and HRQOL by race.3, 
16, 18, 29, 42-48 Overall, Black women are less likely to receive appropriate primary and adjuvant BC 
treatments.48 Under-utilization of ET has been shown to be associated with worse BC outcomes 
(survival and BC recurrence).47 Racial disparities in ET use are known to exist with Black 
women being less likely to initiate and adhere to therapy.36, 39, 47, 49 Previous work has also shown 
the presence of primary BC treatment side effects (especially related to chemotherapy) and 
HRQOL during ET may lead to discontinuation or non-adherence.32, 50-53 It is possible that such 
symptoms may impact Black women differently than White women, thus increasing the 
likelihood of inappropriate ET use. To our knowledge, no studies have explored associations 
among race, pre-ET HRQOL and likelihood of initiation of and adherence to ET. Furthermore, 
previous work in this line of research was done in small samples of older, primarily White 
women, which may not be generalizable to many women with BC in the United States.36, 53 
Exploring associations between HRQOL and ET use in an age and racially diverse sample is 
especially important, as racial disparities in HRQOL are known to exist and may impact ET use 
differently.3, 19, 43, 48, 53 A greater understanding of predictors of HRQOL and ET use throughout 
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the cancer care continuum offers valuable insights on how best to provide targeted care 
management for women most susceptible to HRQOL decrements.  
 The overall objectives of this work were to identify subsets of women experiencing 
different HRQOL patterns during the trajectory of diagnosis and treatment, determine 
demographic characteristics associated with HRQOL profiles, and assess whether pre-ET 
HRQOL patterns were predictive of under-utilization of ET. The central hypothesis was that 
patient-specific characteristics (e.g., age at diagnosis, race, socioeconomic status) could be used 
to preemptively identify subsets of women with BC who experience different HRQOL 
trajectories and that HRQOL profiles following diagnosis were significantly associated with ET 
initiation and adherence. This dissertation determined demographic predictors of HRQOL 
patterns as well as whether HRQOL was associated with ET initiation and adherence among 
nearly 3,000 women diagnosed with invasive BC from 2008 to 2013 in North Carolina through 
the following specific aims: 
Aim 1 
Identify profiles of women with BC who experience different HRQOL trajectories 
from 5 to 25-months post-diagnosis.  
 HRQOL is often presented as a global measure, but this traditional approach does not 
allow for an understanding of domain-specific decrements that may be experienced among 
women with BC. For example, a woman may not experience poor physical well-being 
throughout treatment, but her emotional well-being may suffer considerably. An overall score 
masks this important finding, and clinicians are unaware that patients experienced a HRQOL 
decrement.  In fact, a systematic review of HRQOL among women with BC concluded that 
evaluating HRQOL as a single, global measure often leads clinicians to miss granular HRQOL 
decrements captured by individual domains.3 This dissertation employed innovative structural 
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equation modeling techniques such as latent profile analysis (LPA) and latent transition analysis 
(LTA) to allow scores for each domain to be controlled for simultaneously. LPA is an appealing 
technique, as it allows us to consider scores on individual HRQOL domains, accounting for 
individual heterogeneity that may be masked by using a single score to represent multiple 
domains of HRQOL.54 LPA is more patient-centered than traditional approaches to assessing 
HRQOL and identifying women that are most susceptible to decrements, as it takes individual 
HRQOL patterns into account rather than aggregating across HRQOL domains into a single 
index.55 Through LPA, 5- and 25-month post-diagnosis HRQOL measures were used to identify 
HRQOL profiles of women with BC.  The approach in Aim 1 allowed for a deeper 
understanding of whether specific limitations (e.g., functional mobility, body image concerns) 
were predictive of HRQOL profiles among women with BC.  As each of the time points 
represents different points in the cancer care continuum, it was possible that women were in one 
HRQOL profile during active treatment and transitioned to another profile during adjuvant 
treatment or survivorship. To predict such transitions, LTA, a longitudinal extension of LPA, 
was also used. In addition, through multinomial logistic regression models, non-modifiable 
characteristics associated with membership in a HRQOL group and transition from one profile to 
another over time were identified.54  
Aim 2 
Determine whether racial disparities exist in changes in six HRQOL domains (i.e., 
physical, social, emotional, functional, and spiritual well-being, and breast cancer specific 
concerns) between 5 and 25-months post-diagnosis.  
 Aim 2 used analysis of covariance models to assess racial variations in changes in 
HRQOL among women with BC. This dissertation specifically looked at differences between 
Non-Hispanic White (White) and Non-Hispanic Black (Black) women. Aim 2 evaluated each 
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HRQOL domain separately, in order to tease out domain-specific patterns, which have been 
shown to vary considerably by race.14 As the approach in Aim 2 aggregated HRQOL as a single 
score for each domain, which is a more traditional method, conclusions were also compared to 
those from the innovative methods employed in Aim 1.  Such a comparison informs the 
understanding of predictors of HRQOL in our sample. That is, it indicated racial variations in the 
impact of cancer on HRQOL. 
Aim 3 
Evaluate the association between pre-ET (within 9-months of diagnosis) HRQOL 
profiles and ET use following primary BC treatment among women with HR+ BC.   
 Understanding the relationship between pre-ET HRQOL and ET use allows us to identify 
women who are more likely to experience under-utilization. Aim 3 fills an important gap in the 
literature, offering a potential mechanism to identify women who may under-utilize ET based on 
HRQOL within 6-months of diagnosis. Aim 3 assessed whether a woman’s HRQOL following 
diagnosis (i.e., HRQOL profile) was significantly associated with under-utilization of ET. Aim 3 
built on Aim 1 analyses, as it used 5- month latent profiles identified in Aim 1 to determine if 
there was a link between active-treatment HRQOL and adjuvant treatment decisions.  Logistic 
regression models (adjusting for demographic, treatment and tumor characteristics) were used to 
predict ET non-initiation and non-adherence separately. As non-initiation and non-adherence are 
less common, we selected these as our outcomes to minimized the degree to which odds ratios 
over-estimated risk. Results from Aim 3 offer a new way to identify women who might benefit 
from domain-specific HRQOL management, thus potentially increasing the likelihood of 
appropriate ET use.  Using post-diagnosis HRQOL screening as an indicator for poor ET use is 
potentially inexpensive and easy to do with validated HRQOL instruments, which makes 
findings from Aim 3 particularly appealing.  
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 Data for this dissertation came from the third phase of the Carolina Breast Cancer Study 
(CBCS-III), which was funded by The University Cancer Research Fund of North Carolina and 
the Susan G. Komen Foundation. Three datasets were combined for analyses: the CBCS-III 
baseline (within 9-months post-diagnosis) survey, medical record abstractions and CBCS-III 25-
month follow-up (within 36-months of diagnosis) mail-in survey data. All three aims were 
restricted to women who completed both a 5-month and 25-month follow-up HRQOL survey. 
Aim 3 had two additional eligibility criteria: all women must have a HR+ tumor to ensure they 
were recommended to receive ET and they could not have initiated ET prior to their first CBCS-
III survey.  
 Previous work in this field is limited, as studies were done in small samples of older, 
primarily White populations using generic HRQOL instruments (e.g., Short Form-36) and 
treating HRQOL domains independently. This dissertation used HRQOL measures from a BC-
specific instrument: the Functional Assessment of Cancer Therapy for Breast Cancer (FACT-B), 
which was designed to be more sensitive to changes women with BC experience as well as a 
chronic disease instrument: the spiritual well-being domain from the Functional Assessment of 
Chronic Illness Therapy for Spiritual Well-Being (FACIT-SP).56 Through this work, we gained a 
deeper understanding of specific demographic and clinic predictors of a composite measure of 
HRQOL among a large, age and racially diverse population of women with BC in North 
Carolina. The racial composition of the 3,000-person sample (i.e., 50% Black) offered an ideal 
platform to assess racial disparities in changes in HRQOL in hopes of informing strategies to 
more equitably manage cancer’s impact on HRQOL among women with BC.  As poorly 
managed HRQOL during primary treatment may lead to under-utilization of adjuvant treatment, 
preemptively identifying women at risk for poor HRQOL and providing targeted HRQOL 
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management early in the BC treatment process may support women to appropriately receive life-
saving adjuvant therapies such as ET.32-36, 38 This dissertation’s contribution is significant, as it 
provides valuable insights on targeted HRQOL management for women susceptible to poor 
HRQOL. 
 This dissertation is organized as follows: Chapter 2 discusses the current peer-reviewed 
literature in BC on HRQOL, racial disparities and endocrine therapy utilization. Through our 
careful review, the gaps in the literature are clearly described and the unmet need that this 
dissertation fills is clearly explained. Chapter 3 outlines the overall methods used in this 
dissertation. For each aim, this includes study design, hypotheses, data source, study sample, 
power, and analytic approaches. Chapter 4, 5, and 6 are the manuscripts corresponding to the 
three aims of this dissertation, respectively. The study described in Chapter 4 has been published 
in Breast Cancer Research and Treatment. The studies in Chapters 5 and 6 All are currently 
under review in peer-reviewed journals for publication. Finally, Chapter 7 summarizes important 
findings from each aim, highlights clinical, health policy, and research implications of the work, 
notes limitations, and discusses potential opportunities for future research. Tables and figures are 
included at the end of each chapter. Cited references are numbered in order of their appearance 
in the text and are listed in the reference section at the end of the dissertation.  
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CHAPTER 2: BACKGROUND AND LITERATURE REVIEW 
 This comprehensive literature review summarizes peer-reviewed evidence on three topics 
related to this dissertation: breast cancer (BC), health-related quality of life (HRQOL) and racial 
disparities in health care. Literature for this review was identified from searches in PubMed, The 
Cumulative Index to Nursing and Allied Health Literature, Google Scholar, and PsycInfo.  This 
review focuses on English-language publications in the United States written in the last 30 years.  
Each section below goes into detail regarding work within specific topic areas.  The first section 
covers BC burden and biology as well as primary treatments and endocrine therapy (ET). The 
next section provides background regarding patient-centered care and HRQOL among women 
with BC. We then describe race as a social construct as well as how racial disparities are 
traditionally assessed in the health care disparities literature. Finally, this chapter outlines racial 
disparities in BC risk, screening, primary treatment patterns, HRQOL, and ET utilization. We 
discuss gaps in the current literature and how this dissertation fills an important unmet need by 
contributing to a greater understanding of predictors of change in HRQOL throughout the BC 
care continuum and determining whether HRQOL is associated with under-utilization of ET.   
Breast Cancer 
Burden 
 BC is the most common cancer in the world among women and is responsible for 29% of 
all female cancers.57 In the United States, there were 246,660 new invasive female cases of BC 
and 40,890 BC-related deaths recorded in 2015.57 Given that the 5- and 10-year BC survival 
rates in the U.S are 90% and 80%, respectively, the majority of women diagnosed with BC will 
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not die from their disease.58, 59 As of January 1, 2014, there were over 3 million women in the 
U.S living with BC or who had a history of BC.60 With advancements in BC screening, diagnosis 
and treatments, we anticipate the number of women living with BC will grow. In spite of the size 
and growth of the population of women living with BC, this group does not have well 
understood physical and psychosocial needs.1, 2 3 A greater understanding of HRQOL patterns of 
women with BC will inform care that is more in line with patient needs and values.  
Biology 
 Within BC there are 21 histological and 4 molecular subtypes.57. Each clinical subtype 
presents itself and responds differently to treatment modalities.57 Four primary molecular 
subtypes, identified through biological markers, which identify whether tumors have hormone 
receptors (HR) or human epidermal growth factor receptor 2 (HER2), are used to direct 
treatment selection.57 The Luminal A subtype accounts for 74% of all BC and indicates that 
tumors have positive receptors for either estrogen or progesterone hormones, but not for 
HER2.57, 61 Luminal A BCs are considered hormone receptor positive (HR+) and respond well to 
endocrine therapy (ET), making them the subtype with the best prognosis for BC recurrence and 
survival.57, 61 The Luminal B subtype accounts for 10% of all BCs and, like Luminal A, also 
includes tumors that HR+. Luminal B subtype tumors differ from Luminal A in that they can 
also be HER2 positive.57, 61 Luminal B subtypes are known to be more aggressive than Luminal 
A, but they also respond well to ET.57, 61 As such, Luminal A and Luminal B subtypes are often 
grouped together as HR+ BCs and account for 80% of all BCs.25 The third subtype is the HER2 
enriched group, which includes tumors that do not have receptors for estrogen or progesterone, 
but are HER2 positive.57 This subtype accounts for 4% of all BCs, and has generally worse 
prognosis compared to the Luminal A and B subtypes.57 The fourth subtype is Triple Negative 
tumors, which accounts for 12% of BCs and does not have receptors for estrogen, progesterone 
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or HER2.57, 61  The Triple Negative subtype is twice as common among Black women in the U.S 
(compared to White women) and has the worst prognosis of all subtypes, as they do not respond 
to targeted therapies such as ET.57  
Primary BC Treatments 
 Surgery is the most common primary treatment approach among women with BC. 
Surgical treatment modalities include lumpectomy, mastectomy without reconstruction, and 
mastectomy with reconstruction.62 Breast conserving approaches such as lumpectomy with 
radiation have been shown to achieve the similar long-term survival rates as mastectomy.63-66 
There are conflicting conclusions regarding the impacts of breast conserving and mastectomy 
surgical approaches on HRQOL among women with BC.4, 67 There are studies which conclude 
that there is no difference in HRQOL impact between the two approaches, while other studies 
find that women undergoing mastectomy have better or worse HRQOL compared to women who 
received a lumpectomy.4, 67 These mixed conclusions highlight the need for additional research 
to understand how BC treatments contribute to HRQOL over time and how such treatments are 
impacted by patient-level characteristics such as age, race and socioeconomic status. 
 Through this literature review, we found evidence that HRQOL following primary 
treatment varies by whether a woman received radiation or chemotherapy. 68, 69 HRQOL has also 
been shown to vary by the type of radiation or chemotherapy received, which many previous 
studies neglect to account for in their analyses.68, 69 Radiation therapy following lumpectomy is 
considered guideline recommended, as it reduces the risk of BC recurrence and mortality.70, 71 
Similarly, chemotherapy following primary BC treatments among women with HR negative 
disease has been shown to be associated with improved BC outcomes.72 In the last two decades, 
novel BC treatments, such as Herceptin, have been developed and are now used in clinical 
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practice.1 While previous work provides valuable insights into treatment-related impacts on 
HRQOL, they may not reflect current concerns for women with BC.2 In addition, most work was 
done in small samples of primarily non-Hispanic White women, which may not be generalizable 
to all women with BC in the U.S. Furthermore, many published studies comparing BC 
treatments by HRQOL did not use a patient-reported outcome (PRO) measure that had been 
validated in a BC population, which limits the strength and interpretability of findings.62, 73 In 
addition, we should not rely solely on these older publications to inform our perceptions of short 
and long-term treatment-related HRQOL among women with BC.62  
Types of ET 
 Endocrine therapies (ET) for the prevention of BC-recurrence following primary BC 
treatment are widely used for HR+ BCs.25 These adjuvant therapies work by either blocking 
estrogen production (Tamoxifen) or by inducing estrogen biosynthesis (aromatase inhibitors).74 
Numerous options exist including selective estrogen receptor modulators (SERMs), both non-
steroidal and steroidal aromatase inhibitors (AIs), estrogen receptor antagonists, progestins, and 
luteinizing hormone-releasing hormones (LHRH) agonists.75 ET options differ for 
premenopausal and postmenopausal women. Typically, premenopausal women take Tamoxifen 
and postmenopausal women take AIs.36, 76 ET regimens are taken as daily pills for 5 years 
following completion of primary BC treatments.76 36, 77 
Initiation of ET  
  ET is regarded as a highly effective adjuvant treatment strategy (i.e., 40% reduction in 
BC recurrence and 30% reduction in BC-related mortality) for women with HR+ disease.27-31, 78 
According to clinical practice guidelines, ET is indicated for all HR+ BC patients to reduce the 
risk of BC recurrence.76 Despite the well-established benefits of ET, 10-30% of eligible women 
never initiate the therapy.27-31 Studies conducted in more affluent populations have shown higher 
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rates of ET initiation (around 80%), but studies focused on low-income women have found rates 
of initiation below 70%.  The difference in initiation rates in these studies indicates that low 
socioeconomic status may be a risk factor for lower likelihood of ET initiation.79 Self-reported 
reasons for non-initiation vary with women reporting fear of side effects, personal decision or 
high costs.36 An observational study focusing on low-income women on Medicaid found that 
receipt of chemotherapy, being married, and younger age at diagnosis were significant predictors 
for non-initiation of ET.80 Among women on Medicaid, receipt of breast conserving surgery as 
well as not receiving radiation therapy have also been shown to decrease the likelihood that a 
woman initiates ET.79  
ET Side Effects  
 ET does not come without meaningful side effects, as it is induces both short and long-
term estrogen deprivation.74 ET side effects and symptoms have been shown to impact a 
woman’s HRQOL.75 Tamoxifen, the most widely used SERM, has been associated with hot 
flashes, vaginal dryness, dyspareunia, and decreased interest in sexual activity.74, 81 Studies have 
shown that these symptoms are more prevalent in younger women taking Tamoxifen.74 AIs are 
also associated with similar side effects, but because postmenopausal women typically take AIs, 
early menopausal symptoms that bother younger women may be of less concern for older 
populations.75   Though the type and severity of side effects associated with Tamoxifen vs. AIs 
vary considerably, two large clinical trials assessing HRQOL among women taking AIs versus 
Tamoxifen for adjuvant ET found no significant differences between the two types of ET at 2 
and 5 years.75, 82-84 ET-related side effects and HRQOL decrements may also be further 
exacerbated by receipt of chemotherapy, which has been shown to have severe short- and long-
term impacts on HRQOL.75 Poorly managed side effects may lead women to be non-adherent to 
their ET. A prospective study found that side effects were significantly associated with 
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inappropriate ET use.32 That is, women who experienced side effects were more likely to 
discontinue use of ET.32 One study found that unpleasant side effects accounted for nearly 40% 
of patient-reported reasons for non-adherence to ET.78  
Adherence to ET 
 Non-adherence and non-persistence to ET treatment regimens are of great concern, as 
women who are inconsistent in medication use or do not take the therapy for the full five years 
will not realize the full benefits of ET.31, 34, 78 That is, women who do not take ET for entirety of 
the time recommended are known to have worse BC outcomes (i.e., recurrence and survival) 
compared to women who take ET for the prescribed 5 years.34, 85 Patient-reported rates of non-
adherence in clinical trials range from 23-40%.31, 32 This rate is expected to be higher in clinical 
practice with estimates of non-adherence ranging from 35% at 3.5 years to 50% by 5 years.31, 34, 
86 These high non-adherence rates highlight the need for efforts targeting women who are less 
likely to adhere in hopes of increasing the number of women who are able to realize the full 
benefits of ET. This dissertation examined rates of ET initiation and adherence in an age and 
racially diverse sample of women with BC in an attempt to identify an early indicator (i.e., 
HRQOL) of ET under-utilization.  
Health-Related Quality of Life 
 The last decade has seen a nation-wide emphasis on patient-centered care.87 The Institute 
of Medicine (IOM) defines patient-centered care as, “care that is respectful and responsive to 
individual patient preferences, needs, and values, and ensuring that patient values guide all 
clinical decisions.”88 Traditionally, medical encounters are represented from the clinician and 
payer perspectives.89 Now, however, the patient perspective is increasingly being considered 
through the use of PROs in clinical practice.89 A PRO is defined as, “a report of the status of a 
patient’s health condition that comes directly from the patient without interpretation of the 
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patient’s response by a clinician or anyone else.” 90 The patient-centered movement has 
tremendous potential to improve the quality of care patients receive, as clinicians will be able to 
make treatment decisions that best reflect patient needs and values.91, 92  
 To ensure physicians understand patient preferences, information about patient 
experience must be collected directly from the patient. Collecting and utilizing PRO data is a 
way for patients to communicate their HRQOL to clinicians.93 HRQOL is a multidimensional 
concept and is defined as “one’s subjective sense of well-being in response to a major illness 
encompassing spiritual, functional, cognitive, emotional, psychological, physical and social well-
being.” 7 94 HRQOL is often presented as a global measure, but this traditional approach does not 
allow for an understanding of domain-specific decrements. For example, a patient may not 
experience poor physical well-being throughout treatment, but their emotional well-being may 
suffer considerably. An overall score masks this important finding, making it difficult for 
clinicians to realize that their patient has experienced a HRQOL decrement.  In fact, a systematic 
review of HRQOL among women with BC concluded that evaluating HRQOL as a single, global 
measure often leads clinicians to miss granular HRQOL decrements captured by individual 
domains.3 This dissertation assessed individual HRQOL domains separately as well as 
simultaneously in order to better understand the domain-specific decrements as well as identify 
patient-level factors that were associated with particular HRQOL domains.  
HRQOL of Breast Cancer Survivors 
 Because BC impacts the breasts, which are a defining characteristic of the female body, 
the physical and psychosocial stresses related to a BC diagnosis and treatment are considered, 
“intimately associated with self-image, self-esteem, sexuality, femininity, and reproductive and 
nurturing capacity.”95 As such, 30% of women with BC report emotional and/or physical 
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function limitations following a BC diagnosis.96 HRQOL concerns that arise following a 
diagnosis often continue to impact women for up to 20 years following the conclusion of BC 
treatments, especially if they are poorly managed.96-98 Women with BC consistently report 
greater levels of physical and menopausal symptoms compared to healthy women their age.99 
These symptoms have been attributed to treatment regimens such as surgery, chemotherapy and 
ET.99-101 Studies have also shown that having BC is a significant risk factor for poor mental well-
being relative to the general population, and rates of depression are twice as high among 
individuals with cancer compared to adults without cancer.4, 5, 102 As the number of women with 
BC grows and we aim to improve the quality of BC care, we must better understand and predict 
HRQOL impacts during cancer care, as HRQOL has been shown to significantly impact BC 
outcomes such as survival.  
Physical and Functional Well-Being  
 Women with BC consistently report decrements in physical function during and after 
treatment.103 Certain treatments, including mastectomy and chemotherapy, have been associated 
with particularly large declines in physical functioning.100 Although physical well-being returns 
to pre-treatment levels in most women with BC within a few months of the conclusion of 
therapies, for some women physical well-being remains poor and may continue to worsen over 
time.103, 104 Identifying predictors of worsening physical well-being among women with BC is 
critical, as poor physical well-being may negatively impact BC outcomes. One study found that 
physical functioning decrements in the two years following BC diagnosis are significantly 
associated with greater risk of 10-year mortality.103 Another study concluded that functional 
limitations have been shown to be associated with worse overall survival among women with 
BC.105 Physical and functional decline have also been shown to be significantly associated with 
greater risk of mortality in different race and age groups.106 Thus, targeted support is needed for 
17 
women who are at risk for physical and functional well-being decrements during their cancer 
care.99 
Mental Well-Being 
 Psychological stress is the most prevalent co-morbid condition reported by BC survivors 
following treatment.107 Self-reported depression and anxiety have shown to be common 
conditions among women with BC.108 However, emotional concerns impacting a woman’s 
mental, emotional or social well-being are often not shared with physicians.96 That is, women 
tend not to alert clinicians that they are experiencing decrements in psychosocial HRQOL and 
providers are less likely to ask patients about these types of symptoms. Obtaining this 
information and sharing it with providers may alert clinicians of patients who are experiencing 
particular decrements. Previous studies have found no significant differences in mental HRQOL 
among BC treatment groups, which may make it difficult to identify women based solely on 
treatments received.100 For example, receipt of chemotherapy has been show to be significantly 
associated with worse HRQOL, but a longitudinal study comparing mental health by receipt of 
chemotherapy found no significant differences.104 However, this study used the SF-36, a generic 
measure of HRQOL, which may not be sensitive to BC-specific decrements in mental well-
being. Further work using appropriate HRQOL instruments is needed to better understand the 
mental health impacts associated with exposure to the cancer care continuum.  
 Although decrements in mental well-being following a BC diagnosis are common, some 
women also experience positive growth during cancer care, which may help ameliorate the 
impact of cancer on their mental health.99 That is, some BC survivors have reported that, 
although BC diagnosis and treatment challenged them, it also gave their lives a new sense of 
meaning and purpose.99 This is referred to as “posttraumatic growth (PTG)” and is defined as 
“positive changes in self-perception, interpersonal relationships or life philosophy following a 
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traumatic life event.”109, 110 PTG has been shown to mitigate the negative impacts of BC on 
mental well-being.110, 111 Interventions supporting PTG among women with BC may help reduce 
mental HRQOL decrements associated with BC diagnosis and treatment.111  
HRQOL Differences by Age  
 Most studies consider the cutoff between “younger” versus “older” women with BC to be 
age 50 years, as this is the average age when menopause begins in the U.S.112 A systematic 
review of HRQOL in younger women with BC published in 2012 found that, overall, women 
with BC under age 50 years report worse HRQOL compared both to the general population as 
well as to women with BC over age 50 years.112, 113 In general, HRQOL gaps between younger 
and older women were larger in mental well-being than in physical well-being.112, 113 Some 
studies that indicated that older women experienced slightly worse physical well-being, while 
other studies found no significant differences between older and younger BC patients.112, 113 
Across studies reviewed, younger women experienced more frequent and severe treatment-
related symptoms as well as psychosocial HRQOL decrements related to fear of recurrence, early 
menopause and infertility.112 The most prevalent psychosocial concerns across articles were 
depression, stress and anxiety.112  
 A proposed explanation for age-related HRQOL differences is that, compared to older 
women with BC, younger women struggle more in adapting to life with BC.114 That is, as 
younger women are more likely to work outside of the home, care for children, and have more 
financial responsibilities; they report higher levels of disruption of these activities compared to 
older women.102, 114 Fertility complications and early menopause following treatments are also 
more concerning for younger women.114-116 Such treatment-related side effects are considered 
“age-inappropriate” and have been shown to negatively impact mental health in women under 
age 50 years.114 Mental well-being decrements (e.g., depression) in women experiencing such 
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age-inappropriate impacts of BC were even greater among women under age 35 years.114 
Younger women are also known to present with more aggressive BC and are more likely to 
undergo aggressive BC treatments in order to increase chance of survival, which may lead them 
to experience greater HRQOL impacts than older women.  
 Several studies showed that older women had mean scores across HRQOL domains that 
were not significantly different from non-cancer populations.112, 113, 117 A potential explanation 
for this is that among older women, a BC diagnosis is not as surprising, as the risk of BC is 
known to increase with age.102 Conversely, younger women do not often perceive themselves at 
risk for BC so their diagnosis may be rather emotionally disruptive.102 Regardless of age, social 
support and optimism have been shown to help women cope with BC and have better HRQOL 
outcomes.102, 108  
HRQOL and Chemotherapy Use 
 Chemotherapy is used following breast conserving surgery to prevent disease 
recurrence.98 Chemotherapy is especially important with HR negative tumors, as these tumors do 
not respond to ET.70 Although the clinical (e.g. survival and recurrence) benefits of 
chemotherapy make it quite appealing, women receiving chemotherapy may be at greater risk for 
HRQOL decrements compared to women who do not undergo this therapy.98 Receipt of 
chemotherapy has been associated with long-term body image concerns, fear of recurrence and 
worse sexual functioning.118 101 A study of disease-free BC survivors found that women with no 
history of chemotherapy had significantly better overall HRQOL compared to women who had 
received chemotherapy.119 That is, after adjusting for demographic, clinical and treatment 
characteristics, receipt of chemotherapy was a significant predictor of poorer long-term 
HRQOL.119 Given the link between receipt of chemotherapy and poorer HRQOL, it is important 
to determine whether associations between HRQOL and ET use vary by receipt of 
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chemotherapy. Providing HRQOL support to women undergoing chemotherapy may help 
support these women to continue their chemotherapy regimens and to initiate and adhere to ET. 
HRQOL and ET Initiation 
 Psychosocial decrements in HRQOL, which arise following BC diagnosis and during 
treatment, such as anxiety, depression and distress, have been shown to interfere with BC 
treatment decisions. 95, 108 These factors also impact a woman’s ability to cope with and adjust to 
her disease.108 Women identified at risk for HRQOL decrements should receive targeted 
HRQOL support to reduce the risk of inappropriate treatment decisions. Although several studies 
have collected and continue to collect data on side effects and HRQOL while women take ET, to 
our knowledge, no studies have examined whether HRQOL prior to ET initiation is associated 
with ET initiation.  As such, this dissertation fills an important knowledge gap as it identifies a 
potential early indicator of inappropriate ET initiation in women with BC.  
HRQOL and ET Adherence 
 Some work has been done examining the association between HRQOL and ET 
adherence.  One study examined the association between pre-ET depression, anxiety, and 
physical functioning and ET adherence and found that the presence of these conditions was 
significantly associated with non-adherence.50 However, this study only included 91 women with 
early-stage BC and did not use a validated BC-specific instrument to measure depression, 
anxiety or physical functioning.50 Furthermore, only 3 of the women were “non-White”, which 
does not lend itself to reliable examination of sub-group variation in ET use by HRQOL.50 
Another study examined the association between HRQOL and ET discontinuation and did not 
find significant associations.35 However, this study collected HRQOL data following ET 
initiation so assessments may have been confounded by ET symptoms, which have been shown 
to be associated with non-adherence.35, 75 Another study conducted in Australia examined the 
21 
association between pre-ET anxiety, depression, hot flashes, musculoskeletal pain, osteoporosis 
and vaginal atrophy (measured by prescriptions for drugs dealing with these conditions) and ET 
adherence.120 This study did not find that pre-existing conditions were predictive of ET 
adherence.120 However, the study did not collect any self-reported HRQOL information to 
identify psychosocial and physical limitations. Although conclusions from this study are 
informative, due to differences in health care system structure and treatment practices, 
conclusions from this study may not be generalizable to women with BC in the U.S. Finally, a 
recent study examined the association between psychosocial HRQOL and ET non-persistence 
and concluded that better HRQOL was significantly associated with lower likelihood of ET non-
persistence.121 This study also found that greater levels of distress were associated with non-
persistence.121 Findings from this study help inform this dissertation, as the study used the same 
HRQOL instrument (FACT-B), however, the study only included 601 older (50% over 60 years) 
women with HR+ BC, of which only 7% were Black.121 Chapter 6 of this dissertation presents 
the first study to examine associations between ET use and pre-ET HRQOL (measured by a 
validated, BC-specific instrument) in a large, multi-payer cohort of women with BC. Given the 
age and racial diversity of this cohort, the findings of this study are more generalizable to women 
with BC across the U.S., compared with previous studies. 
Racial Disparities in Health Care 
 The National Cancer Institute (NCI) defines health disparities as, “differences in the 
incidence, prevalence, mortality and burden of cancer and related adverse health conditions that 
exist among specific groups in the U.S.”122  In the disparities literature, there are four competing 
approaches to assessing racial disparities in health and health care.123 Each of these approaches 
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has its strengths and limitations, which are discussed below.  
Race as Biology  
 The first approach views race as biological category and believes that differences in 
health outcomes by race can be explained by biology.123 However, research indicates there are no 
biological criteria that can be universally applied to assign persons to specific racial groups.”124, 
125 That is, there is a great deal of biological heterogeneity within a particular racial group, 
therefore, assuming that everyone belonging to the same racial group has the same genetic 
characteristics is not reasonable.124 As such, the health services research field has mostly 
abandoned the biological view of race. 
Race As a Social Construct  
 In contrast to race as biology, race has been described as a “complex multidimensional 
construct reflecting the confluence of biologic factors and geographical origins, culture, 
economic, political and legal factors, as well as racism.”124 In essence, race functions as a form 
of social stratification, as it impacts one’s access to both goods and services.126, 127 In the U.S, 
racial categories are linked to various important societal factors that may impact health 
including: socioeconomic status, racism, culture, social and economic progress, discrimination, 
and identity.124  Thus, race is considered a master social category, as it is a “central determinant 
of social identity and obligations, as well as of access to societal rewards and resources.”124 In 
this dissertation, the definition of race as a social construct will be used to frame the 
understanding of how race impacts HRQOL and health care utilization among women with 
BC.124, 126 We assessed whether there were racial disparities in changes in HRQOL among 
women with BC.  
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The Residual Direct Effect of Race on Health Care 
 The residual direct effect (RDE) of race on health care is another approach to assessing 
racial disparities in health care that, to some extent, operationalizes race as a social construct.128-
130 The RDE approach controls for all other mediators of the relationship between race and the 
outcome (i.e., socioeconomic status, education) and allows one’s “race” to represent the 
unmediated effect of race on health outcomes.128 Typically the RDE approach compares the 
“race” coefficient in a model that does not control for socioeconomic factors to the “race” 
coefficient in model that does adjust for socioeconomic factors.130 According to the RDE, if the 
differences between two racial groups disappears after adjusting for socioeconomic factors, a 
racial disparity does not exist, although disparities by socioeconomic groups may.130 The race 
coefficient in the RDE approach would still encompass unmeasurable factors such as 
institutional racism, different care seeking behavior and access to health care networks that are 
not determined by insurant status and income. A strength of the RDE approach is that it isolates 
the independent effect of race (from other factors) on health outcomes.130 However, critics of this 
approach have said the RDE does not account for the effects of race on health outcomes that are 
mediated by socioeconomic factors, which may offer potential opportunities for intervention 
through increased education, access and social support.130  
Institute of Medicine Approach  
 The Institute of Medicine’s (IOM) definition of racial disparities in health care, truly 
conceptualizes race as a social construct linked to a range of mediating factors, including 
socioeconomic staus.123, 125 The motivation behind this third disparities approach is that minority 
groups are overrepresented in lower socioeconomic groups and if we adjust for both race and 
socioeconomics, we may underestimate racial differences in health outcomes.123 For example, 
Blacks have more than double the poverty rate compared to Whites.124 According to McGuire 
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and colleagues, the IOM defines a disparity as the “difference in treatment provided to members 
of different racial or ethnic groups that is not justified by the underlying health conditions or 
treatment preferences of patients.” 128, 131, 132 That is, a racial disparity is the difference in quality 
of care between two racial groups that cannot be explained by either clinical differences (i.e., 
disease severity), health status (i.e., comorbid conditions) or patient preference.128, 131 When 
determining if racial disparities in health outcomes exist, controlling for both race and 
socioeconomic status may lead us to “over control” for the “causal effect of race on health.”123, 
133 This approach views race as preceding socioeconomic status on the casual pathway to health 
outcomes.133 That is, socioeconomic factors such as income and education are considered 
mediators of racial disparities.128, 131, 133 Although the framework does not assume that race 
causes lower income, it acknowledges that minority groups are more likely to be of lower 
socioeconomic status, thus leading them to consume lower levels of health services.128 McGuire 
and colleagues implemented the IOM’s definition of disparities in a previous study by only 
controlling for clinical characteristics and patient preferences (not socioeconomic factors) and 
assessing racial disparities in mental health service use. This study found larger racial disparities 
using the IOM’s definition than the RDE, which controls for socioeconomic mediators of health 
service use.128 This is not surprising, as the IOM’s definition of disparities allows “race” to 
encompass all mediating factors of health care outcomes that are not explained by an individual’s 
clinical characteristics, health status and preferences whereas the RDE controls for all 
socioeconomic mediators.128, 132, 134 A limitation of the IOM definition is that it does not 
acknowledge that factors such as comorbidities, disease prognosis and patient preferences are 
often affected by socioeconomic factors such as income, education and insurance status. For 
example, rates of diabetes and hypertension (comorbid conditions) are known to be higher 
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among Blacks than Whites and this may be attributed to not only race, but also socioeconomic 
factors including income and insurance.  
Race and Socioeconomic Interactions  
 Finally, the fourth approach to assessing racial disparities considers race and 
socioeconomic status as distinct constructs, which have both independent and interactive effects 
on health outcomes.123 That is, socioeconomic status is on the causal pathway between race and 
health status and it moderates the association between race and health outcomes.124 One might 
also argue that race moderates the association between socioeconomic status and health 
outcomes. When determining differences in health outcomes between two racial groups, one 
should not ignore the important contribution that differences in socioeconomic status 
contribute.123, 125 In fact, racial gaps may actually be exacerbated among higher or lower 
socioeconomic groups.124, 125 For example, the difference in low birth weight between Blacks and 
Whites may be larger or smaller depending on the mother’s highest level of education, indicating 
that race and educational attainment may have an interactive effect on low birth weight.123 A 
distinct difference between this approach to measuring racial disparities in health care and the 
other three approaches described above is that it supports the use of examining the interactive 
effects of race and socioeconomic factors on health outcomes. Given that socioeconomic factors 
and race are both associated with HRQOL, it is likely that each of these factors moderates the 
association between the other and HRQOL. As such, this is the primary approach implemented 
in the assessment of racial disparities in changes in HRQOL described in Chapter 5 of this 
dissertation.   
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Racial Disparities in BC 
 The risk and burden associated with BC has been shown to vary systemically between 
Black and White women in the U.S.135 According to the American Cancer Society, although 
White women are more likely to be diagnosed with BC, Black women are more likely to die 
from the disease.57 Among White women, the 5-year relative survival rate was 92%, but it was 
only 81% among Black women.57, 59 The disproportionate burden of BC experienced by Black 
women can be partially explained by genetic risk factors, access to screening and treatment 
patterns.48 As these factors are unable to explain all of the racial differences in BC outcomes, we 
aimed to better understand other factors, such as HRQOL, which may help inform more 
equitable cancer care management.  
Biological Risk Factors 
 The overall association between BC and age is well-established, with risk of being 
diagnosed with BC increasing with each additional year of life.136 Younger age at BC diagnosis 
is also significantly associated with more aggressive disease and increased risk of death.136 
Overall, the median age at diagnosis is 61 years, but this varies between Black and White women 
with medians of 58 and 62 years, respectively.57, 59 Black women are more likely to be diagnosed 
at younger ages and with more aggressive BC tumors.48, 137, 138 A large population-based study 
using NCI’s Surveillance, Epidemiology, and End Results (SEER) data found that more than 
33% of the Black women diagnosed with BC are diagnosed before age 50 years, compared to 
less than 25% of the White population.138 This SEER study also found that there was a larger 
representation of Black women in advanced BC stages compared to White women.138 The racial 
gap widens among younger ages, as the incidence and BC mortality rates are two and three times 
(respectively) greater among Black women under 35 years compared to White women.48 
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Relatedly, Black women are more likely to be diagnosed with BC subtypes such as triple 
negative BC that are less responsive to targeted therapies such as ET and have worse overall 
prognosis.48, 138 
Disparities in Screening Practices 
 In the last two decades, efforts to improve BC awareness and screening have increased 
considerably, and the rates of mammography are now similar between White and Black women 
in the U.S.24, 48, 139 Therefore, we assume that screening does not explain a large proportion of the 
racial gap in BC outcomes.48 Although racial gaps in mammography appear to have narrowed, 
previous studies have identified widening gaps in screening between socioeconomic groups.24, 
135, 139 That is, low-income women (especially without health insurance) are significantly less 
likely to receive mammograms compared to higher-income women.24, 135 As Blacks are 
overrepresented in low socioeconomic groups and present with more aggressive BC they may be 
impacted differently. This highlights the importance of evaluating both the independent and 
interactive effects of race and socioeconomic status on health outcomes.  
Disparities in Primary Treatment Patterns 
 Delays in BC diagnosis and treatment initiation have been shown to be associated with 
worse survival.140 A meta analysis found that treatment delays of 3-6 months (as compared to <3 
months) from initial consultation to treatment initiation have been shown to be associated with a 
12% reduction in rates of survival.141 Treatment delays in BC are known to exist among women 
who are medically underserved.140, 142 As Blacks are over-represented in lower socioeconomic 
groups, they may be more likely to experience barriers related to diagnosis and treatment 
delays.46 A population-based study found that even after accounting for socioeconomic status 
(i.e., poverty index) and access to health care (i.e., insurance coverage) Black women 
experienced more treatment delays in both BC diagnosis and treatment initiation compared to 
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White women.142 Another study found that after accounting for demographic and clinical 
characteristics, Black women were 3 times more likely than White women to experience a delay 
in surgery of 2 months or more.140 As Black women tend to present with more advanced and 
aggressive disease, disparities in treatment delays are of particular concern.46, 142-145  
 Inappropriate use of chemotherapy and radiation following surgery are known to occur 
among Black women and may contribute to racial disparities in BC recurrence and mortality.70, 72 
However, evidence regarding which racial group is less likely to receive chemotherapy is mixed. 
Adjusting for clinical and tumor characteristics, several studies concluded that Black women 
were less likely than White women to receive adjuvant chemotherapy following surgery.70, 72, 143 
Another study found that Black are not less likely to receive chemotherapy.146 Among women 
who do initiate chemotherapy, Black women are more likely to prematurely discontinue 
treatment, which is significantly associated with greater risk of death.144 Black women have also 
been shown to be more likely to receive “suboptimal” chemotherapy (i.e., fewer cycles of 
chemotherapy than recommended), which is known to increase risk of mortality.27, 147 A study 
examining racial disparities in dose and intensity of adjuvant chemotherapy concluded that Black 
women received lower doses of chemotherapy compared to White women.70, 148 Two other 
studies confirmed that Black women were less likely than White women to receive 
recommended radiation therapy following breast-conserving surgery, which is considered 
guideline recommended.147, 149 Black women were found to be less likely to receive surgery at 
“high-quality” hospitals, which authors defined as hospitals that have higher rates of radiation 
after breast-conserving surgery.150 These systematic differences in treatments received by Black 
and White women with BC may help explain contemporary disparities in BC mortality.  
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 Beyond delays and inappropriate care, there are also differences in the type of surgery 
that Black and White women receive, which may also impact outcomes.  However, evidence 
regarding racial differences in treatment patterns vary based on year of study publication, age 
and socioeconomic composition of the sample and by type of insurance coverage. For example, a 
multi-payer study of young and old women published in 2015 found that, compared to White 
women, Black women were 18% more likely to receive breast conserving surgery and 6% less 
likely to have a mastectomy, but 21% more likely to experience surgical complications and have 
longer hospital stays.151 Two other studies of elderly Medicare populations published in 2002 
and 2003 found that Black women were less likely to receive both breast conserving surgery and 
radiation therapy.152, 153 Patterns observed in these two Medicare studies were consistent with 
those in a non-Medicare study published in 2006 including both young and old women in SEER, 
which found that Black women were more likely to receive mastectomy, less likely to have 
lumpectomy, and even less likely to have lumpectomy with radiation.154 Another study from 
1997, which was also conducted in an elderly BC population, found Black women were 25% less 
likely to undergo any kind of definitive primary therapy.150 Structural and organizational 
characteristics of the health care system may partially explain racial disparities in health care 
service use.145 
 This mix of evidence may reflect primary treatment practice changes that have occurred 
over the last two decades. A particular strength of this dissertation is that women in our dataset 
were diagnosed with invasive BC between 2008-2013, so treatment patterns should reflect 
contemporary trends in North Carolina. Much of the previous work done in this area was limited 
to single insurance providers, Non-Hispanic White women and older age groups (i.e., Medicare 
only populations). Through the availability of medical record abstraction data in the Carolina 
30 
Breast Cancer Study (used for this dissertation), we were able to account for both timing and 
receipt of all BC treatments received in a multi-payer (e.g., private, Medicare, Medicaid) cohort 
of age and racially diverse women with BC, making this dissertation innovative.  
Disparities in HRQOL  
 Racial disparities present in diagnosis and treatment may extend into survivorship and 
impact both short and long-term HRQOL among women with BC.155 Racial gaps in HRQOL are 
known to exist, but disparities are not uniform across cancer types or even HRQOL domains.14, 15 
On average, Black women experience greater socioecological burdens that are not as common 
among White women.156 Financial stressor, job insecurity, and balancing multiple 
responsibilities (e.g., house, parental, job) make dealing with BC more difficult for Black 
women.42, 44, 156 Following diagnosis, Black women continue to struggle with these challenges, 
further exacerbating HRQOL decrements associated with BC diagnosis and treatment.42, 156 In 
addition, Black women are less likely to be married or partnered, which may contribute to 
HRQOL disparities due to lack of social support in the home. Understanding how racial groups, 
both young and old, are affected differently by BC will help researchers and clinicians to more 
equitably manage cancer’s impact on HRQOL. 
Physical Well-Being 
 Previous research has indicated that, overall, Black women tend to report worse HRQOL 
than White women.3 16-21 Physical and functional well-being among Black women with BC are 
particularly worse than their White counterparts.42, 156 Functional limitations following BC 
treatments, such as trouble pushing/pulling objects or lifting less than 10 pounds, and difficulty 
walking half a mile are known to be more common and severe in Black women with BC.106 One 
study assessing upper-body limitations in women with BC found that after adjusting for 
demographic and treatment characteristics, Black women were more likely to report limitations 
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than White women.157 Such limitations are of particular concern as they may make activities of 
daily living (e.g., showering, bathing, getting dressed) more difficult.157 Lack of energy is seen as 
a greater concern among Black women than among White women.156 Black women with BC also 
tend to report lower levels of physical activity, which has been associated with better physical 
functioning and greater overall HRQOL.3, 20, 158 Studies have also confirmed that although BC 
survivors report lower levels of physical activity compared to the general population, White 
women have higher levels of physical activity in comparison to Black.20, 42, 156, 158 Increased 
physical activity has also been shown to be associated with better physical well-being and 
vitality.20, 42, 156, 158  
Mental Well-Being 
 Compared to Black women without a BC diagnosis, Black BC survivors have been 
shown to report greater levels of fatigue, hot flashes and poorer sleep quality.22 However, Black 
women with BC also report greater social support (with their church, communities and God) as 
well as positive growth following BC diagnosis/treatment compared to White women.22, 159 
Social support and positive growth may help mitigate depression that is often associated with a 
BC diagnosis and may reduce cancer-related stress.22 Increased community support and positive 
growth experienced by Black women with BC may also help explain why this group tends to 
report fewer mental and emotional decrements compared to White women diagnosed with BC.22, 
42, 156 For example, a study of Medicare beneficiaries found that although Blacks had lower 
HRQOL across eight subscales in the Short Form 36 prior to cancer diagnosis, Blacks also 
experienced smaller declines in role emotional, mental health and social functioning domains 
compared to Whites.14 In addition, there are some psychosocial concerns that have been shown 
to burden White women more than Black women.44 For instance, a systematic review found that 
White women were more likely to experience fear of BC recurrence and issues with body image 
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compared to Black women.44 Coping mechanisms may help explain the smaller decrements in 
mental well-being experienced by Black women following exposure to the cancer care 
continuum.14, 22 
Spiritual Well-Being 
 Spirituality is defined as, “experiencing a meaningful connection to our core selves, 
others, the world and/or a greater power.”160, 161  Spirituality is considered distinct from 
religiosity, which is “structured worship and practice and theological beliefs.”160 Black women 
with BC consistently report the importance of spirituality in coping with their disease.156, 160, 162 
Spirituality may help mitigate the effects of BC on psychosocial well-being.44 A systematic 
review found that across all studies evaluated, spirituality, faith and reliance on God were critical 
to coping,44 spirituality and a perceived relationship with God were thought to provide hope and 
comfort for women struggling with BC diagnosis and treatment and also helped manage the 
psychosocial burden of the disease.159 A limited body of evidence has also supported the 
association between spirituality and better health status among Blacks.163, 164 Previous work in 
the area of spirituality of women with BC has recommended that clinicians promote the use of 
spirituality as a coping mechanism among Black women with BC.159  
 The richness of the dataset used for this dissertation makes it an ideal platform to better 
understand racial disparities in BC.  To our knowledge, this is the first study to assess racial 
disparities in changes in individual domains of HRQOL in a large, relatively younger (i.e., not 
exclusively Medicare), multi-payer, racially diverse BC population. In doing so, we were able to 
tease out domain-specific decrements and determine whether Black or White women were more, 
less or equally susceptible to such decrements. By gaining a better understanding of racial gaps 
in changes in HRQOL, findings from this dissertation will help support more equitable HRQOL 
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management for women with BC.20 
Disparities in ET Initiation 
 Previous work has identified racial disparities in adjuvant therapy initiation between 
Black and White women with BC.72 Several studies have assessed disparities in adjuvant 
chemotherapy and radiation and some have examined disparities in ET initiation.48, 72 Evidence 
on whether Black women are more, less or equally as likely as White women to initiate ET have 
been mixed and dependent on the population of women studied.  For instance, a SEER study of 
women diagnosed with BC in 2005-2007 in Detroit and Los Angeles found that Black women 
were 3 times more likely to initiate ET compared to White women.36 This was the only study that 
found that Black women were more likely to initiate ET than White women. Several studies 
reported no difference in ET initiation between Black and White women. In a low-income, 
Medicaid-insured population in North Carolina, unadjusted differences in ET initiation were 
found between Black and White women diagnosed in 2003-2007. Once demographic and clinical 
characteristics were adjusted for, however, no significant racial disparities were seen.39 Another 
Medicaid-insured study of women in North Carolina diagnosed with BC between 1998-2002 also 
found that there were no significant differences in ET initiation between Black and White 
women.80 The lack of differences in ET initiation by race was confirmed in a larger study of 
women on Medicaid.79 A Medicare study evaluating the association between race and ET 
initiation also failed to find an association, but did find that insurance status and higher level of 
education were significantly predictive of ET initiation.165 Another Medicare study published in 
February 2016 reported racial gaps in ET initiation with Black women being 30% less likely to 
initiate Tamoxifen than White women.166 Finally, a study assessing racial disparities between 
Black and White, commercially insured women (under age 64 years) in North Carolina found 
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that Black women were 17% less likely to initiate ET compared to White women.47 This study 
stratified analyses by receipt of chemotherapy, as chemotherapy was significantly associated 
with lower likelihood of ET initiation.47  
 The association between receipt of chemotherapy and lower likelihood of ET initiation 
has been documented in other studies as well.80 In chemotherapy-stratified models, the racial gap 
in ET initiation was even more pronounced among women who received chemotherapy, but non-
significant among those not receiving chemotherapy.47 As Black women tend to present with 
more aggressive BC and may be more likely to receive chemotherapy, this important finding 
highlights a need to address racial gaps in ET initiation among Black women undergoing 
chemotherapy. As chemotherapy is associated with additional treatment burden, it may serve as a 
barrier to ET initiation.47, 80 Chemotherapy-related burdens include missed days of work, lack of 
transportation to numerous appointments and additional costs.47 Given the higher representation 
of Blacks in lower socioeconomic groups, Black women with BC may be more vulnerable to 
chemotherapy-related barriers to ET initiation.167 As each of the previous studies examining 
racial disparities in ET initiation looked at different insurance populations separately (i.e., 
Medicaid, Medicare and commercially insured), this dissertation fills an important knowledge 
gap, as it examines racial disparities in ET initiation in an age-diverse, multi-payer group of 
women in North Carolina.  
Disparities in ET Adherence  
 Once a woman initiates ET, she will either take the medication diligently as intended 
(adhere), not take the medication as prescribed (non-adherent), or stop taking the medication 
entirely (discontinue). In this dissertation, we focus on non-adherence to ET, as across diseases, 
poor adherence is associated with worse health outcomes.168 Given data limitations, we 
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operationalize ET non-adherence and discontinuation as “non-adherence”, but recognize that 
there are differences between discontinuation and non-adherence. Within BC, women with poor 
adherence are known to be at increased risk of death.28 Adherence is often measured as the 
number of days of medication supplied divided by total days.33 Traditionally, patients with 
adherence rates lower than 80% are considered “non-adherent”.33, 169 Patients vulnerable to poor 
adherence should be preemptively identified and provided additional support to ensure 
adherence.31, 168 Part of identifying which patients are likely to be non-adherent is determining 
characteristics associated with non-adherence or discontinuation.  Previous studies have 
attempted to identify demographic and clinical characteristics associated with non-adherence to 
ET and have had varying conclusions regarding racial disparities.27, 30-33, 36, 45, 50, 53, 80, 170 A recent 
systematic review of racial disparities in ET adherence found that, in the majority of studies 
reviewed, racial disparities existed, with Black women being less likely to adhere than White 
women.170 Looking closer at individual studies, some concluded that there was no evidence of 
racial differences in ET adherence, but noted differences by socioeconomics, age and other 
treatments received.30, 33, 34, 36, 45, 80 Other studies found large and significant differences in ET 
adherence between Black and White women with BC.27, 31 The mix of evidence of differences 
between races in ET adherence highlights an opportunity to assess associations between race and 
ET adherence in a multi-payer cohort with an over-representation of Black women in hopes of 
informing the literature on racial disparities in ET non-adherence.  
Conclusion   
 Cancer care that considers HRQOL reflects patient needs and is consistent with the 
national emphasis on patient-centered care.9-11 12, 13 As the number of women with BC in the U.S. 
continues to grow, understanding patient-level factors that are predictive of HRQOL trajectories 
throughout the cancer care continuum will help inform targeted HRQOL management for 
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women with BC. As discussed, there is a great deal of variation in HRQOL by demographic, 
socioeconomic and treatment characteristics as well as by HRQOL domain.  In general, previous 
work reflects non-contemporary treatment patterns, uses generic HRQOL instruments, and focus 
on single payer groups of women that lacked large representations of Black women and/or 
women under age 50 years.  A greater understanding of predictors of HRQOL and ET use 
throughout the cancer care continuum will offer valuable insights on how to provide targeted 
care management for women most susceptible to HRQOL decrements. The demographic 
diversity of the dataset used in this dissertation to assess racial disparities in HRQOL and 
identify an early screener for inappropriate ET use make this dissertation a departure from the 
status quo of research in HRQOL in BC.   
37 
CHAPTER 3: METHODS 
 A methodological approach that accounts for heterogeneity of women with BC while 
parsing out nuances using specific HRQOL domains contributes to a deeper understanding of 
patient-level factors explaining HRQOL across BC patients of different ages and races. 
Furthermore, determining if HRQOL can be used as a screener for future health behaviors such 
as initiating and adhering to ET offers an opportunity to intervene with women who are most 
susceptible to under-utilization of ET.  Chapter 3 describes the various approaches taken in this 
dissertation to examine predictors of latent HRQOL sub-groups during active treatment and 
survivorship, assess racial disparities during these two distinct phases of BC care, and determine 
if HRQOL measured during active treatment is predictive of adjuvant therapy initiation and 
adherence. First, as the three aims employ the same conceptual framework, a discussion of the 
overall conceptual model guiding this dissertation is provided. The dissertation’s study design, 
data source, sampling and eligibility, sample size and power, and key measures are described in 
detail. Then, each specific aim’s research questions, hypotheses, descriptive statistics and 
analytic approaches are explained separately. Finally, limitations to the study design, data source 
and analytic approach are discussed. Figures and tables referenced in Chapter 3 can be found at 
the end of the chapter.  
Conceptual Framework 
 The conceptual framework used to guide this dissertation was a modified version of 
Andersen’s Behavioral Model (Figure 1).171 Broadly, the framework postulates that individual 
characteristics and health behaviors influence outcomes.171 Specifically, the framework suggests 
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how individual predisposing (e.g. race, age), enabling (e.g. marital status, level of education, 
income, insurance status) and need (e.g. comorbidities, tumor characteristics) factors impact 
individual use of health services (e.g., treatments).  Presumably, all of these factors and practices 
have effects on health outcomes (e.g., HRQOL), which can in turn influence future health 
service use.171  
Predisposing Characteristics 
 Race has been considered a form of social stratification, as it may impact one’s access to 
both goods and services.126 In this dissertation, the definition of race as a social construct was 
used to frame the understanding of how race impacts HRQOL and use of health services.124, 126 
Numerous studies have shown differences in health care use by race.3, 16, 18, 29, 42-48 Overall, Black 
women are less likely to receive appropriate primary and adjuvant BC treatments such as 
chemotherapy, radiation, and ET.48 Under-utilization of ET has been shown to be associated with 
worse BC outcomes (e.g., survival and BC recurrence).47  Racial gaps in HRQOL are also known 
to exist with White women generally reporting better HRQOL than Black women; however, the 
extent of such disparities in vary across age groups, cancer type, and HRQOL domain.14, 15  
 Age-related difference in BC treatment utilization and HRQOL are also well-documented 
in the literature.4, 172-175 Specifically, older women are less likely to receive certain treatment 
modalities (e.g., breast conserving surgery) and chemotherapy, and also experience varying 
decrements in HRQOL compared with younger women with BC.4, 172-174 In general, younger 
women report worse mental and emotional well-being, but better physical and functional well-
being compared to older women with BC.112, 113  
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Enabling Resources 
 Enabling resources such as social support (i.e., marital status), highest level of education 
attained, insurance status, urban/rural residence, and family income may impact use of health 
services as well as HRQOL.176, 177 As enabling resources temporally “occur” after predisposing 
factors (e.g., race), they are considered mediators of the relationship between race and HRQOL. 
Socioeconomic status is often captured with measures of income, education and occupational 
status.126 Among other reasons, accounting for socioeconomic may be important because 
treatment delays in BC are known to exist among women who are medically underserved (e.g., 
lower income).140, 142 As Blacks are over-represented in lower socioeconomic groups, they may 
be more likely to experience barriers related to diagnosis and treatment delays.46 For example, 
Blacks are over represented in uninsured and Medicaid populations, and lack of insurance or 
underinsurance has been known to be associated with worse BC outcomes.178 Lower 
socioeconomic status has also shown to be significantly associated with poorer HRQOL.177, 179 In 
this dissertation, insurance status, family income, and highest level of education attained were 
used to account for enabling resources that reflect socioeconomic status.  Marital status was also 
controlled for, as, among cancer patients, marital status, a measure of social support, has been 
shown to significantly impact physical and psychological health throughout the cancer care 
continuum.40, 176, 179, 180 Furthermore, whether or not a woman resided in an urban or rural 
environment was also controlled for, to help account for cultural norms as well as access to care.  
For example, previous studies have reported that women residing in rural versus urban regions 
are less likely to receive certain recommended treatments or delay care.181 Predisposing 
characteristics such as race and age may also impact enabling resources as shown in Figure 1.123, 
124 Racial gaps in HRQOL and use of health services may differ among higher or lower 
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socioeconomic groups; thus it is important to account for the impact of both predisposing and 
enabling factors when assessing changes in HRQOL.124, 125 
Perceived and Evaluated Need 
 A woman’s comorbid conditions (e.g., diabetes, heart disease, hypertension) as well as 
tumor characteristics (e.g., tumor stage, tumor size, tumor grade, nodal status, and hormone 
receptor status) affect her use of health services as well as her HRQOL.176, 182 Within the BC 
disease group, there are a number of histological and molecular subtypes.57. Each clinical 
subtype presents and responds differently to treatment modalities.57 Therefore, accounting for 
tumor characteristics such as tumor stage and grade, as well as hormone receptor status is 
essential to examining their influences on HRQOL and adjuvant treatment under-utilization. A 
previous study in women with BC found that comorbidities such as diabetes, mental health 
problems and hypertension were significantly associated with women receiving less aggressive 
BC treatments.174 Certain comorbidities such as obesity are also known to be related to worse BC 
outcomes, as obesity is strongly associated with advanced BC stage among Black women.183 
Comorbid conditions and tumor characteristics are also impacted by predisposing characteristics 
and enabling resources. Specifically, compared to White women, Black women are more likely 
to be diagnosed with invasive BC at younger ages and with present with more aggressive tumors, 
making them less likely to receive breast-conserving treatments.48 In addition, Black women are 
less likely to receive certain recommended treatments such as surgery, radiation and 
chemotherapy compared to their White counterparts.48 
Use of Health Services 
 The types of treatment a woman with BC receives have both short and long-term impacts 
on BC recurrence, survival and HRQOL.4, 67, 101 Although studies have shown differences in 
HRQOL by treatment modality and HRQOL domains, there is no overall consensus regarding 
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the effects of BC treatments on HRQOL, as different studies have yielded conflicting 
conclusions.63, 67-69, 98, 175, 184-186 With respect to longer-term ET specifically, no studies have 
examined the association between pre-ET HRQOL and ET initiation and adherence in a large, 
age and racially diverse multi payer cohort of women with BC.  
Health-Related Quality of Life 
 A patient-reported outcome (PRO) is defined as, “a report of the status of a patient’s 
health condition that comes directly from the patient without interpretation of the patient’s 
response by a clinician or anyone else.” 90 PROs are considered the gold standard for reporting a 
patient’s HRQOL.  Previous studies have shown that using PRO data in oncology settings can 
increase clinicians’ awareness of symptoms and improve patient well-being.11, 13, 92, 187 HRQOL 
is a multidimensional concept and is defined as, “one’s subjective sense of well-being in 
response to a major illness encompassing spiritual, functional, cognitive, emotional, 
psychological, physical and social well-being.” 7 94 HRQOL outcomes in this dissertation were 
measured by the Functional Assessment of Cancer Therapy for Breast Cancer  (FACT-B) and the 
Functional Assessment of Chronic Illness Therapy for Spiritual Well-Being (FACIT-SP). More 
detailed descriptions of the HRQOL measures used are included below.  
BC Care Timeline 
 The median time from diagnosis to the initial survey among women in CBCS-III was 5.1 
months, with 75% of women having their survey within 6.2 months of diagnosis and 91% 
completing the survey within 9 months.46  “5-months post-diagnosis” represents a time period 
where women are typically in an active treatment phase (i.e., receiving surgery, radiation, 
chemotherapy). As this first assessment point occurs after diagnosis and likely after treatment 
initiation, many women will have experienced initial treatment-related decrements in HRQOL. 
Therefore, we anticipate that most women will experience a HRQOL rebound by their second 
42 
assessment point. That is, we anticipate that many women will experience improvements in 
HRQOL from the active to survivorship phases of assessment. “25-months post-diagnosis” 
indicates a time where most women have concluded active treatment and may be receiving 
longer-term adjuvant treatments such as ET, but may still be recovering from complex active 
treatment plans. This may also represents a time where women are in post-active treatment 
survivorship phases of care, which may include ongoing adjuvant endocrine therapy. As the 
second HRQOL assessment point occurs on average 25 months after BC diagnosis, we anticipate 
many women will experience improvements in HRQOL from the first assessment point 
Considering these two distinct time periods in the cancer care continuum for women with BC is 
important when conceptualizing the three aims for this dissertation.  
Study Design 
 This dissertation was an observational longitudinal cohort study using existing, secondary 
data from the third phase of the Carolina Breast Cancer Study (CBCS). Data were collected at 
two time points with the first being on average 5 months after BC diagnosis and the second on 
average 25-months from BC diagnosis. For this study, all women had their first survey 
completed by 9 months from diagnosis and their second survey completed by 36 months from 
diagnosis. Since the average time to first survey was 5-months, we refer to this as the “5-month 
survey” and the average time to the follow-up survey was 25 –months we refer to this survey as 
the “25-month survey.” Aim 1 used demographic, clinical, tumor, and HRQOL data from both 
time points to identify latent HRQOL subgroups of women with BC (via latent profile analysis) 
and determine predictors of subgroup membership as well as transitions between subgroups over 
time. Aim 2 assessed differences between Black and White women’s HRQOL changes from 5 to 
25-months following diagnosis, adjusting for demographic, clinical, and tumor characteristics 
from the first time point.  Finally, Aim 3 used subgroups constructed from the HRQOL measures 
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at the first time point to predict use of health services (i.e. ET initiation and adherence) at the 
second time point, adjusting for demographic, clinical, and tumor characteristics from time one.  
Data Source 
 Data for this dissertation came from the third phase of the Carolina Breast Cancer Study 
(CBCS-III) (funded by The University Cancer Research Fund of North Carolina and the Susan 
G. Komen Foundation). For my analyses, I compiled data from four distinct data sources: CBCS-
III baseline (within 9-months of diagnosis), medical record abstraction, pathology report, and the 
25-month follow-up telephone and mail-in survey. 
 CBCS-III includes 3,000 women diagnosed with invasive BC for the first time between 
2008 and 2013 across 44 counties in North Carolina.46 The study team collaborated with the 
North Carolina Cancer Registry to identify women across the state via rapid case 
ascertainment.188 Women enrolled in CBCS-III were 20-74 years old North Carolina residents at 
the time of diagnosis with an incident, pathologically confirmed invasive BC.46 To ensure 
representation of younger Black women, eligible women were sampled from four strata 
(sampling fractions indicated in parentheses): Black women under 50 years (100%), Black 
women 50 years and older (60%), Non-Hispanic White women under 50 years (40%), and White 
women 50 years and older (15%).46 Through this sampling strategy, 50% of the overall cohort is 
composed of Black women. Women included in the CBCS-III are intended to represent women 
across North Carolina and, therefore, include women in rural and urban settings, privately and 
publically insured (and uninsured), of varying income levels and residing across 44 counties of 
the state.46 Data were collected in-person by nurses within 9-months of diagnosis.46, 189 
Participants also completed a HRQOL questionnaire (FACT-B and FACIT-SP surveys) and 
consented for researchers to abstract their medical record data.46, 188, 189 On average, 20 months 
after the first survey and 25-months after diagnosis, women completed a follow-up mail-in 
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survey, which included ET adherence questions, FACT-B and FACIT-SP surveys and a 
Disability of Arm, Hand and Shoulder (DASH) survey. 
Sample and Eligibility Criteria 
 As this dissertation was focused on changes in HRQOL over time, all three study aims 
were restricted to women who completed both a 5-month and 25-month follow-up mail-in 
survey. A flow diagram of the exclusions made to construct the final study cohort is shown in 
Figure 2. Of the 2,998 women who completed an initial survey, 2,561 (85.4%) completed a 25-
month follow-up mail-in survey. Of the 2,561 women who completed both surveys, 67 (2.6%) 
women were excluded because they identified as “other race.” Since this dissertation was 
specifically focused on racial gaps between Non-Hispanic Black and Non-Hispanic White 
women, 30 women identifying as “Hispanic” were excluded leaving 2,464 women. Since women 
with distant stage BC made up a small proportion (<3%) of the cohort, these women were 
excluded so the cohort would be more homogenous in tumor and treatment characteristics. As 
such, there were 2,142 women eligible for analyses. The third aim includes two additional 
eligibility criteria. First, all women must have a HR+ tumor to ensure they would have been 
eligible to receive ET.  This group was eligible for the ET adherence analyses. Second, women 
could not have initiated ET before their first survey so that taking ET, which is associated with 
worse HRQOL and side effects, would not confound the first HRQOL assessment. Of the 2,142 
women included in Aims 1 and 2, 1,599 had HR+ disease, 1,114 initiated ET, and of these, 953 
women did not initiate ET before their first CBCS survey. Of the 953 women who initiated after 
5-months, 799 women initiated ET within 36 months and 154 did not. Thus, the cohort for the 
Aim 3 ET adherence analyses included 1,114 women who initiated ET and the Aim 3 ET 
initiation analyses included 953 women who initiated after 5-months.  
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Statistical Power 
 Sample size and statistical power requirements are not well established in the latent 
profile analysis literature.190 A recent literature review of the 38 studies using latent profile 
analysis between 2007 and 2010, found that the median sample size was 377 individuals.190 A 
key element to determining the correct sample size is the distance between latent profiles, which 
cannot be determined a priori. A review of the literature concluded that a sample size of at least 
500 individuals is prudent for latent profile analysis.190 For Aim 1, we included 2,142 women, 
which we assumed was a large enough sample to perform our analyses.  
 For Aim 2, there were 2,142 women (1,037 or 48% Non-Hispanic Black and 1,105 or 
52% Non-Hispanic White) who met the eligibility criteria described above. Given the fixed 
sample size, with a significance level of 5%, we were powered at nearly 100% to detect effect 
sizes of 2-3 points (the meaningfully important differences for each of the six FACT HRQOL 
domains). For Aim 3, of the 953 women with HR+ disease who did not initiate ET by their first 
survey, 799 (84%) initiated ET by 36-months and 154 (16%) never initiated ET. With a sample 
size of 953 women and a significance level of 5%, we were powered at nearly 100% for Aim 3 
ET initiation analyses. For the ET adherence analyses, we included all HR+ women who initiated 
ET (1,114 women) and were also powered at nearly 100%.  
Key Variables and Measures 
 All variables listed in Table 1 for the three specific aims came from the CBCS-III 5-
month post-diagnosis survey, 25-month telephone or mail-in follow-up survey, pathology report 
and medical record abstraction datasets. 
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HRQOL Measures 
 The two HRQOL instruments used in this dissertation were the Functional Assessment of 
Cancer Therapy for Breast Cancer  (FACT-B) and the Functional Assessment of Chronic Illness 
Therapy for Spiritual Well-Being (FACIT-SP). The FACT-B is a 37-item BC-specific instrument 
including 5 domains: physical (PWB), social (SWB), emotional (EWB), and functional well-
being (FWB) and BC-specific concerns (BCC).191 PWB includes 7 items, SWB 7 items, EWB 5 
items, FWB 7 items and BCC 9 items.56 The FACT-B has been previously validated and shown 
to be sensitive to change for women with BC, reliable and easy to use.56 The FACT-B overall 
score ranges from 0 to 148 with higher scores indicating better HRQOL.192, 193 The minimally 
important differences (MIDs) or the smallest difference that clinicians or patient perceive as 
clinically meaningful or important, for FACT-B domains are: BCC (2-3 points), PWB (2-3 
points), EWB (2 points), and FWB (2-3 points).194, 195 The SWB domain does not have a 
previously identified MID. 194, 195 
 The FACIT-SP is a 12-item instrument specific to a chronic disease and includes the 
spiritual well-being domain (SPWB).56 The FACIT-SP has also been previously validated and is 
the most commonly used instrument to measure spiritual well-being among individuals with 
cancer.192, 196 The FACIT-SP includes three factors to measure overall SPWB: meaning, peace 
and faith, which have been shown to be independent predictors of HRQOL and not encompassed 
in the EWB and MWB domains.193, 196, 197 The overall FACIT-SP ranges from 0 to 48 with 
higher scores representing better SPWB.192 Each of the factors (meaning, peace, faith) range 
from 0 to 16.192 As with the FACT-B, high scores on the FACIT-SP Higher scores on both the 
FACT-B and FACIT-SP indicate better HRQOL.192, 193 The SPWB domain does not have an 
established MID.194, 195  
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Demographic Covariates 
 The self-reported demographic characteristics included in our analyses were age at 
diagnosis, race, smoking status, and body mass index (BMI), which were obtained from the 
CBCS-III 5-month survey. We also adjusted for a pre-specified list of comorbid conditions (e.g., 
diabetes, chronic obstructive pulmonary disease, obesity, hypertension, and heart disease), which 
came from the medical record abstraction dataset.  
Socioeconomic Covariates 
 The socioeconomic covariates in Aims 1-3 include: marital status, level of education, and 
insurance status (all measured at 5-months). Given the high degree of collinearity between 
urban/rural residence, family income, insurance and education, socioeconomic covariates were 
ultimately limited to marital status, education and insurance status. Consistent with prior studies, 
the preliminary analyses suggested that the combination of education and insurance status was 
generally representative of socioeconomic status.135 Furthermore, neither education nor 
insurance status exhibited missing values, whereas missing data were evident for the family 
income and urban/rural residence variables.  
Treatment Covariates 
 We adjusted for surgery type (e.g., lumpectomy, mastectomy and mastectomy with 
reconstruction), and receipt of radiation, chemotherapy, and Herceptin. Treatment characteristic 
variables were obtained from the medical record abstraction dataset. 
Tumor Covariates 
 In Aims 1 and 2, we examined unadjusted racial differences in tumor stage, tumor size, 
tumor grade, nodal status, and hormone receptor status (ER+, PR+, HER2+). However, due to 
high degrees of correlation between tumor stage, size, grade and nodal status, we only controlled 
for tumor stage and grade in our analyses. In addition, we constructed a “HR+” variable that 
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combined women who were ER or PR positive or borderline. Finally, because women who were 
HER2+ are often recommended to receive Herceptin, but all HER2+ women may not receive 
Herceptin, we only controlled for receipt of Herceptin in Aim 1-3 analysis since treatment rather 
than the marker itself would be more plausibly tied to the outcome of HRQOL. As Aim 3 only 
included women with HR+ disease, the tumor variables examined for this aim were tumor stage, 
tumor size, tumor grade and nodal status. Consistent with Aims 1 and 2, tumor stage and grade 
were included in Aim 3 analyses. Tumor stage and grade were obtained from the CBCS-III 
medical record abstraction and ER, PR and HER2 status came from the pathology report data.  
Analytic Approach 
 The following section describes analytic approaches for Aims 1-3. For each aim, specific 
hypotheses tested, variables used in analyses, descriptive statistics, and models run are outlined. 
Aim 1 latent profile and latent transition analyses were performed in R. The multinomial logit 
models were performed in SAS Version 9.4. All Aim 2 and 3 analyses were performed in SAS 
version 9.4 with two-sided statistical tests and a significance level of 5%. 
Aim 1 
Hypotheses  
 The structural equation modeling (SEM) approaches used in Aim 1 analyses were 
exploratory in nature, as they identified latent sub-groups of women who experienced different 
HRQOL trajectories during their exposure to the cancer care continuum. Before conducting our 
analyses, we were unsure of exactly how many latent profiles would arise at each time point. 
However, given our thorough literature review, we formulated several hypotheses for what we 
expected to see in our analyses.  
These a priori hypotheses are described below.  
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 Hypothesis 1: Non-modifiable characteristics including age at diagnosis, race, and 
socioeconomic status will be significantly associated with membership in HRQOL profile 
groups. 
 Hypothesis 1a: Older age at diagnosis (older than 50) will be significantly related to 
profiles associated with better emotional, social and spiritual well-being, but worse physical and 
functional well-being HRQOL profiles.173  
 Hypothesis 1b: White race (compared to Black race) will be significantly associated with 
better physical and functional well-being HRQOL profiles.19 
 Hypothesis 1c: Black race (compared to White race) will be significantly associated with 
better emotional, social, and spiritual well-being HRQOL profiles.155 
 Hypothesis 1d: Lower socioeconomic status will be significantly associated with worse 
physical, functional, social and emotional well-being HRQOL profiles.177, 198 
Dependent Variables 
 The dependent variables for the latent profile analyses in Aim 1 were the six HRQOL 
domains (FACT-B and FACIT-SP): physical, social, emotional, functional, and spiritual well-
being and BC-specific concerns. For the latent transition analyses in Aim 1, the categorical 
variable constructed from latent profiles at the second time point was used as the dependent 
variable in our models.  
Key Independent Variables 
  Key independent variables for Aim 1 were non-modifiable patient-level factors including 
age at diagnosis, race and socioeconomic factors (e.g., education, insurance status, marital status) 
shown in Table 1. For the latent transition analysis, the key independent variable was the 
categorical variable constructed from the latent profile at the first time point.  
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Descriptive Statistics 
 First, we examined the overall distribution of demographic, socioeconomic, tumor and 
treatment characteristics within our cohort. Then we compared unadjusted mean HRQOL scores 
for each domain by non-modifiable patient-characteristics (e.g., age at diagnosis, race, education 
level attained, urban/rural community, income, marital status).   
Cluster Analysis in Cancer 
 Studies using cluster analysis of symptoms to identify groups of patients at increased risk 
of poor outcomes were first published in the field of chronic pain, with the expectation of 
tailoring treatment choices to better meet patient needs.40 Years later, cluster analysis was 
extended to cancer by a handful of studies, identifying patient subgroups based on coping 
strategies, psychosocial well-being, symptoms, and quality of life.40, 41, 199-201 Overall, studies 
concluded that meaningful, distinct subgroups of patients could be identified and clinical 
interventions might actually have improved outcomes if they considered an individual’s HRQOL 
status or coping strategy.40, 41 For example, women who were in an emotionally unhealthy cluster 
could have been supported with therapy sessions following BC diagnosis to ameliorate the 
emotional impact of cancer and help them cope with their diagnosis and treatment.40, 41 
Preemptive identification of women who were at risk for decrements in mental and physical 
well-being during cancer care could allow clinicians to provide more patient-centered care.  
 More recent work used cluster analysis to identify symptom clusters and assess the 
impact of cluster membership on HRQOL and other health outcomes among women with BC.202-
204 Findings from such studies were quite valuable, as HRQOL has been shown to be 
significantly associated with cancer survival.54 However, these studies only focused on two or 
three symptoms and most did not extend cluster analyses to measures of HRQOL, which can be 
more representative of an individual’s overall well-being than isolated symptoms.203 Of the 
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studies that did focus on identifying clusters of women with BC using HRQOL measures, several 
combined multiple cancer types together, many were conducted outside of the U.S, most were 
cross sectional and all had sample sizes of fewer than 200 women. Previous work concluded that 
the next step in this line of work is to explore associations between specific patient clusters and 
treatment decisions (i.e., ET use).40 As such, this dissertation extends this novel methodology to 
identify latent HRQOL sub-groups of women with BC in a large, population-based cohort.  
Latent Variables  
 Latent variables are unobserved constructs that are represented by two or more observed 
variables.205, 206 Visually, latent variables are represented by ovals or circles.205 The observed 
measures are also referred to as indicators of the latent construct.205 In this dissertation, the 
observed measures were the individual domains on the FACT-B and FACIT-SP such as PWB, 
SWB, EWB, FWB, BCC and SPWB (described above). The specific questions that make up 
each domain are referred to as domain indicators.205 Conceptually, latent variable models assume 
that the HRQOL domain items measure the latent constructs, but do not cause them.205, 206 
Latent Profile Analysis  
 Building on traditional cluster analyses, latent profile analysis (LPA) is a latent variable 
model that uses continuous observed measures (i.e., PWB, SWB, EWB, FWB, BCC, SPWB) to 
identify categorical clusters of women who experience distinct HRQOL patterns and group them 
together as a “HRQOL profile” at each of the two time points.54, 190, 205, 207 This type of approach 
is optimal for identifying latent patterns within large, heterogeneous groups of individuals.190 
Because LPA takes individual HRQOL patterns into account rather than aggregating across 
individuals, it is considered more patient-centered than traditional approaches for assessing 
HRQOL and identifying women who are most susceptible to HRQOL decrements.55, 205 
Approaches that compare means and standard deviations have been criticized for not truly 
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representing HRQOL experienced by individuals.75 Simply looking at changes in mean HRQOL 
scores leads us to miss individuals who experience decrements, as a group’s average score may 
mask small decrements.75 That is, small changes tend to disappear when comparing mean scores 
and outliers who may be of interest to researchers are often ignored.75 Unlike regression 
techniques that model mean trend across the entire sample, LPA allows us to account for 
heterogeneity in HRQOL among women with BC.41, 199  
 Latent variable models such as LPA or latent class analysis (used for categorical 
observed measures) have also been used to address limitations in using single indices to 
represent abstract, multidimensional concepts such as HRQOL.208 HRQOL is often presented as 
a single measure, but this approach does not allow for an understanding of domain-specific 
decrements that may be experienced among women with BC. Recent work criticized the 
evaluation of HRQOL as a single, global measure as it leads clinicians to miss decrements in 
individual domains.3 For example, a woman may not experience poor physical well-being 
throughout treatment, but her emotional well-being may suffer considerably. An overall score 
would not allow us to glean this important finding, and clinicians would be unaware that their 
patient experienced a HRQOL decrement.   LPA considers scores on individual domains that 
could be masked by using a single score to represent the multiple domains of HRQOL, making it 
a strong approach to studying HRQOL in women with BC.54, 208  
LPA Assumptions  
 There are some assumptions that must be satisfied in order to use LPA. First, we assume 
that individuals within a latent profile are generally homogenous in their HRQOL distributions 
or that there is homogeneity within each profile.205, 209 Homogeneity is important because it 
implies that patterns observed within a profile are characteristic of that particular profile, which 
helps us to identify distinct patterns in the data.205 We must also assume that variances are 
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homogenous across latent profiles, but this assumption can be violated and addressed through 
weighting and transformations.190 Another assumption is that of local or conditional 
independence within latent profiles.190, 209 The premise for this assumption is that after adjusting 
for an individual’s latent profile membership, the values of the indicators within a particular 
latent profile are assumed to be independent (i.e., the errors are not correlated).190, 209 While this 
assumption is necessary for latent class models, it can be relaxed somewhat for LPA models.190 
Finally, we also assume that there is latent profile separation or that item-response probabilities 
allow us to clearly differentiate between profiles.205 When there is latent profile separation, if one 
conditions on a specific latent profile membership, a particular item-response pattern should be 
much more likely among one latent profile than among another latent profile.205 That is, one 
profile should be more likely to have high HRQOL across all 6 observed measures than another 
profile if one conditions on being in the “high HRQOL profile.” Latent profile separation or the 
“distance” between latent profiles is difficult to quantify a priori, but can be visually assessed 
when comparing item-response probabilities across latent profiles.190 
LPA Model Selection  
 As LPA is an inherently exploratory research method, a combination of the underlying 
theory and model fit indices must be used to guide the selection of the best model and the ideal 
number of latent profiles at each time point.205 To compare models and determine the appropriate 
number of profiles, we initially considered traditional fit indices including the Likelihood Ratio 
Test (LR Test), Akaike Information Criterion (AIC), Bayesian Information Criteria (BIC), 
Tucker-Lewis Index (TLI), Comparative Fit Index (CFI), and Root Mean Square Error of 
Approximation (RMSEA) 54 The fit indices were used to evaluate the various LPA model 
solutions (with increased number of profiles). For the AIC and BIC, models with lower values 
for these indices suggest better model fit.205 For the TLI and CFI indices, a threshold of 0.90 was 
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set for good fitting models. A RMSEA below 0.05 as well as an insignificant p-value (i.e., above 
0.05) for the likelihood ratio test were also used to determine models with good fit.  
 Consistent with the literature, the BIC was considered the most important index to 
determine the optimal model and thus, number of latent profiles.190 The BIC is the most 
commonly used fit index across the LPA literature.190 The BIC is calculated by using the 
following formula: -2LL + m*ln(n), which translates to (-2) multiplying the log-likelihood of the 
estimated model, m denotes the number of estimated parameters in the model and n is the 
number of observations.190 By multiplying the number of estimated parameters by the natural log 
of the number of observations, the BIC penalizes over fitting models to improve fit.190 Models 
with lower BICs were considered as fitting the data better.  
 We also used the BIC to compare the fit of models with different covariance structures. 
The covariance structures evaluated are shown in Table 2.210 The most restrictive covariance 
structure is denoted by the letter “E” and assumes equal variances.210 This structure is also 
referred to as K-means. The additional models allowed variance (E), volume (V) and orientation 
(I) to vary across profiles.210 Ultimately, we selected the covariance structure and number of 
profiles with the lowest BIC. 
 In addition to the fit indices, we also considered the theory behind the LPA and the 
number of profiles that we anticipated would exist at each time point. As such, we used the 
number of women in each latent profile to help determine the appropriate number of profiles. 
That is, when there were too few women in a profile, we collapsed profiles together to facilitate 
interpretability of the results. Decisions to collapse groups were made carefully and in 
consultation with a breast oncologist.  
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 Once the model with the best fit was selected, we calculated latent status prevalence for 
each time point. Latent status prevalence is the proportion of women with BC who we expected 
to be in a profile at a given time.55, 205 We also computed mean scores for each of the 6 HRQOL 
domains in order to tease out which specific domains were most important to the particular 
profile. That is, we wanted to determine if particular profiles could be characterized with lower 
or higher mean HRQOL scores on certain FACT-B and FACIT-SP domains.  Examining mean 
HRQOL domains in each profile allowed us to characterize the profile and better identify the 
HRQOL patterns experienced by individuals within a profile.  
Latent Transition Analysis 
 After identifying the latent profiles at each time point, we used a latent transition analysis 
(LTA) to assess the probability of a woman remaining in the same latent HRQOL profile or 
transitioning to another HRQOL profile from 5- to 25-months after diagnosis.54 LTA is 
considered a longitudinal application of LPA or latent class analysis (used for categorical 
observed measures) with two or more time points.55 This type of approach allows us to 
conceptualize how individuals change over time and what characteristics are associated with 
change.205 LTA is a type of latent Markov model and uses full information maximum likelihood 
estimation with the time 2 latent profile variable as the dependent variable and the time 1 latent 
profile variable as the explanatory variable.54, 205 In order to determine the best model, we ran 
both models that constrain slope parameters to be equal at the two time points as well models 
that freely estimated parameters at both time points.54 As described above, we used fit indices 
(LR test, AIC, BIC, TLI, CFI, and RMSEA) to choose the LTA model that fit the data the best.54 
When the indices yielded conflicting results, the BIC was ultimately used to determine the best 
model.  
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 It is possible for two LPAs to yield different numbers of profiles at each time point.205 
This would indicate that the number of profiles varies over time.55 Initially in LTA we assume 
the structure of HRQOL is constant over time, but this is not always the case as certain exposures 
(i.e., cancer treatments) may impact HRQOL trajectories.55 In addition, the LTA may also yield 
different number of latent profiles at each time point than the two cross sectional LPAs.205 The 
reason for this is that sometimes considering data from two different time points allows the 
number of latent profiles to be different at time 1 and time 2 because there is more variance 
explained in the models.205 We formally tested the assumption that the number of latent profiles 
was the same at the two time points using a Chi-Square test comparing one model that allowed 
the item-response probabilities at the two time points to be different (i.e., vary over time) to 
another model that constrains the two probabilities to be the same.55 Changes in the number of 
profiles over time suggests that exposure to the cancer care continuum impacts the HRQOL 
distribution. That is, if a particular number of HRQOL profiles existed at the first time point and 
new profiles emerged or previously existing profiles were no longer applicable at the second 
time point, it would suggest that the distribution changed over time. As HRQOL at time 1 is 
measured when a woman is undergoing active treatment and HRQOL at time 2 is measured 
when she is receiving adjuvant treatments or in survivorship, it is likely that the HRQOL 
distributions at these two points would differ. Having different number of profiles at the two time 
points has no bearing on whether we could perform the LTA. 
 Using LTA, we estimated two different parameters: latent status prevalence and transition 
probabilities.205 55 As described above, latent status prevalence is the proportion of women with 
BC who we expected to be in a profile at each time point.55, 205 Using this prevalence parameter, 
we can determine which latent profiles are most common among our sample.205 If latent status 
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prevalence was too small, we considered combining profiles in order to facilitate interpretation 
of our models.  
 A transition probability is the probability that a woman who is in one profile at time 1 
transitions to a different profile or remains in the same profile at time 2.55 This is arguably the 
most interesting parameter in a LTA.205 Transition probabilities are organized in a matrix with 
the rows representing latent profiles at time 1 and columns representing latent profiles at time 
2.205 As such, given a woman’s latent profile at time 1, we calculated the probability that she 
transitioned to the column latent status at time 2.205 The diagonal of the transition matrix 
represents women that remained in the same latent profile at the two time points.205 Given that 
we anticipated HRQOL to generally improve between the two time points as women move from 
active treatment to survivorship phases, remaining in a low HRQOL between time 1 and time 2 
would be of concern although it would not technically be a “decrement.”  That is, we expected 
there would be improvements in HRQOL across domains over time as woman moved further 
away from active treatments.  
 We tested differences in transition probabilities between age at diagnosis, race and 
socioeconomic status (e.g., income, education, martial status, insurance status) using Chi-Square 
tests, adjusting for multiple comparisons (e.g., Bonferroni adjustments).54 Transition 
probabilities differing by patient-level demographic characteristics implies that a woman’s non-
modifiable characteristics may impact the probability that she transitions from one profile to 
another between the two time points.  This would offer an opportunity for us to identify women 
who may be at risk of transitioning to a worse HRQOL profile or staying in a low HRQOL 
profile over time. The variation of transition probabilities by individual characteristics is an 
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important finding, as we can use an individual’s baseline demographic characteristics to predict 
their HRQOL trajectory during cancer care.   
Multinomial Logistic Regression  
 Multinomial logit models (MLM) are maximum likelihood estimator models that build 
upon binary logit models when the outcome of interest has more than two categories and are not 
ordered.211 Specifically, the outcome must not have an inherent order (e.g., underweight, normal 
weight, overweight), and must be discrete and nominal for a MLM to be most appropriate.211 In 
Chapter 4 (Aim 1), MLMs were used to determine patient-level characteristics (adjusting for 
treatment and tumor characteristics) associated with the latent profiles identified via LPA.54 
Using the latent profiles, we created a categorical variable for each time point with the number of 
categories corresponding to the number of latent profiles at that time point. A separate MLM was 
performed for each time point with latent profiles at that time point serving as the model 
outcome. The highest HRQOL latent profile was the reference group for all MLMs and the other 
latent categories were interpreted with respect to the highest profile. We also used MLMs to 
determine patient factors associated with transitioning from one latent profile to another. To do 
this, we used the categorical variable from the second time point LPA as the outcome measure, 
adjusting for the latent profiles time one, demographics, socioeconomics, tumor and treatment 
characteristics. We also considered ordered logit models due to the general ordinal nature of the 
latent profiles. However, given that not all indicators followed the ordinal pattern, we decided 
that MLM models were more appropriate.  
 In order to use MLMs, the independence of irrelevant alternatives (IIA) assumption must 
be met.211 This assumption states that, “the ratio of choice probabilities of any two alternatives 
(in response categories) are not influenced systematically by any other alternatives.”211, 212 That 
is, if one adds or drops an additional outcome category, the relative probabilities of the other 
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outcomes should remain the same.212 If the IIA assumption is violated, this would suggest the 
errors are not independent across the outcome levels.211, 213 To test the IIA assumption in Chapter 
4, we performed a Hausman Test and found that the IIA assumption was not violated.213  The 
Hausman Test compared estimated MLM coefficients of an unconstrained model to estimates 
from constrained models (i.e., ones that drop categories from the outcome).211, 213 A significance 
level of 5% was used for estimate comparisons. Comparisons with p-values above 0.05 were 
considered to satisfy the IIA assumption.   
 Once we finalized our three MLM models (one for the first HRQOL assessment, one for 
the second HRQOL assessment and one for both time points), we calculated predicted 
probabilities of membership in each of the latent profiles using sample means from our cohort. 
That is, we estimated the probability of a woman in our sample being in a particular latent profile 
given a set of characteristics.212 Predicted probabilities allowed us to identify which patient-level 
characteristics are most predictive of membership in a particular latent profile.212 These predicted 
probabilities also allow us to identify characteristics of women who are vulnerable to certain 
HRQOL decrements (or lack of improvement over time). Chapter 4 focuses on assessing the 
relationship between non-modifiable patient characteristics and membership in the latent 
profiles; as these characteristics are routinely collected in clinic and can easily be used to identify 
women most susceptible to membership in a poor HRQOL latent profile. Therefore, we 
calculated the marginal effect of age on the probability of being in a particular latent profile (at 
each time point) as well as the differential effects of race, marital status, insurance status, 
education level and family income on the probability of being in a latent profile at a given time 
point.  
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Expected Outcomes 
 The two expected outcomes for Chapter 4 were that through the LPA, we would identify 
multiple distinct HRQOL profiles of women with BC and that through LTA, we would be able to 
predict which women were most likely to transition from one profile to another between 5 and 
25-months post-diagnosis. Although LPA/LTA are empirically driven approaches, based on the 
literature, we expected four HRQOL profiles to emerge at each time point. This hypothesis was 
confirmed as we identified four profiles. There was: a high overall HRQOL (high scores in all 
domains), a low overall HRQOL group (low scores on all domains), a high physical functioning 
(high physical-well being HRQOL, but lower mental well-being) and a high psychosocial 
functioning profile (high emotional/social/spiritual well-being, but lower physical well-being). 
These expected outcomes allowed us to achieve a better understanding of HRQOL patterns 
among women with BC. Furthermore, we were also able determine associations between non-
modifiable demographic factors (age at diagnosis, race, socioeconomic status) and membership 
in HRQOL profiles, which informs future preemptive identification of women who are most 
susceptible to poor HRQOL. 
Aim 2 
Hypotheses  
 Results from the literature review presented in Chapter 2 of this dissertation guided the 
development of the hypotheses used for this aim. We employed the third definition of racial 
disparities presented in Chapter 2, treating race and socioeconomic status as distinct constructs, 
which have both independent and interactive effects on health outcomes.123 The seven 
hypotheses presented below reflect this approach to assessing racial disparities, as we anticipated 
the relationship between race and HRQOL to vary by socioeconomic status.  
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 Hypothesis 1a: Racial gaps in emotional and spiritual well-being HRQOL domains 
between Blacks and Whites will narrow from 5-months to 25-months post-diagnosis.14  
 Hypothesis 1b: Racial gaps in physical and functional well-being HRQOL domains 
between Blacks and Whites will remain the same or widen from 5-months to 25-months post-
diagnosis.14 
 Hypothesis 2a: Changes in racial gaps in HRQOL domains from 5-months to 25-months 
post-diagnosis between Blacks and Whites will vary by income level.123, 124, 128, 131  
 Hypothesis 2b: Changes in racial gaps in HRQOL domains from 5-months to 25-months 
post-diagnosis between Blacks and Whites will vary by education.123, 124, 128, 131  
 Hypothesis 2c: Changes in racial gaps in HRQOL domains from 5-months to 25-months 
post-diagnosis between Blacks and Whites will vary by marital status.123, 124, 128, 131 
 Hypothesis 2d: Changes in racial gaps in HRQOL domains from 5-months to 25-months 
post-diagnosis between Blacks and Whites will vary by insurance status.123, 124, 128, 131 
 Hypothesis 2e: Changes in racial gaps in HRQOL domains from 5-months to 25-months 
post-diagnosis between Blacks and Whites will vary by urban/rural community.123, 124, 128, 131 
Dependent Variables 
 The 25-month from diagnosis HRQOL domain scores were used as primary outcomes in 
six separate analysis of covariance models (one for each HRQOL domain) and the 5-month from 
diagnosis HRQOL scores were included as covariates. 
Key Independent Variables 
 The key independent variable for Aim 2 was self-reported race (Non-Hispanic Black or 
Non-Hispanic White). White was used as the reference category for this binary variable. Aim 2 
also tested interaction terms between race and socioeconomic factors (e.g., education, insurance 
status, marital status). Although these socioeconomic factors were measured at the same time as 
62 
race (i.e., in adulthood, not at birth), they occur “after” race and are therefore considered 
mediators of the relationships between race and HRQOL.214  
Descriptive Statistics 
 We compared demographic, socioeconomic, tumor and treatment characteristics between 
Black and White women in our sample using t-tests for continuous covariates (e.g., age, BMI) 
and chi-square tests for binary (e.g., marital status, chemotherapy) and categorical variables (e.g., 
education, insurance status). We compared unadjusted HRQOL scores for each FACT-B and 
FACIT-SP domain between Black and White women using t-tests. We also compared the 5- and 
25-month HRQOL scores in our sample to normed U.S general female population scores 
available for the physical, functional, social and emotional well-being domains.215 A significance 
level of 0.05 was used for all unadjusted analyses.  
Analysis of Covariance Models 
 Analysis of covariance (ANCOVA) models have continuous dependent variables and 
either continuous and/or categorical explanatory variables.216 These models are most appropriate 
in observational studies, where subjects are not assigned to particular groups at random and 
confounding may be of concern.216 The primary assumption of this statistical approach is that the 
slopes of the two comparison groups (e.g., Black and White women) are equal and only the 
intercepts differ.216  
 In Chapter 5 (Aim 2), we used ANCOVA models to examine changes in HRQOL over 
time, adjusting for HRQOL scores (within 9-months of diagnosis), demographic, socioeconomic, 
treatment and tumor characteristics. We ran one model for each HRQOL domain in order to 
tease out domain-specific predictors that may be masked when looking at an overall HRQOL 
score. Our outcome for each model was the 25-month HRQOL score. To calculate change, we 
subtracted the 5-month score from the 25-month score. As such, positive change scores reflected 
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improvements in HRQOL between 5- and 25-months and negative change scores denoted 
decrements in HRQOL between 5- and 25-months. We controlled for HRQOL at 5-months in 
each ANCOVA model.  
 To assess racial disparities we took a step-by-step approach. First, we ran models 
controlling for race only (no socioeconomic factors) and tested difference in adjusted Least 
Square Means (LSMs) between Black and White women for each HRQOL domain. Then, we ran 
6 additional models that controlled for race and socioeconomic factors and again tested the 
difference in adjusted LSMs between Black and White women. To implement the racial 
disparities approach described in Chapter 2, which considers both the independent and 
interactive effects of race and socioeconomic factors, we added interaction terms between race 
and socioeconomic factors and tested differences in adjusted LSMs for each HRQOL domain 
between Black and White women. From these models, we calculated the “direct effects” of the 
racial gap for each HRQOL domain by looking at the marginal effect of race.214 We also 
calculated “mediated effects” (through socioeconomic factors) of the racial gap. To do this, 
differences (for each HRQOL domain separately) were computed between the coefficient from 
Models 1 that did not adjust for socioeconomic factors and the coefficients from Models 2 and 
3a-3e that did adjust for socioeconomic factors. In these calculations, we assumed all potential 
confounders of the relationship between race and HRQOL were controlled for, which is a strong 
assumption.214 As the interaction terms were not statistically significant, we did not have 
sufficient evidence that the fundamental relationship between race and HRQOL was different for 
Black and White women with BC. Therefore, we did not stratify Aim 2 analyses by race, 
although we did run Models 4a and 4b (below) as sensitivity analyses and found that the 
associations between HRQOL and race did not vary significantly by socioeconomic factors.  
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 Our approach in Aim 2 differentiated between demographic (predisposing characteristics 
and evaluated need) and socioeconomic (enabling resources) factors. Demographic variables 
included age at diagnosis, smoking status, body mass index, and comorbid conditions. Evaluated 
need included a woman’s comorbid conditions as well as the tumor characteristics of her BC. 
Socioeconomic factors included marital status, level of education, and insurance status. The 
equations for our each of our models are listed below. In total, we ran 54 different models (9 
models for 6 HRQOL domains).  
1. No socioeconomic status: 25-month HRQOL Domains = β0 + β1BaselineHRQOL+ β2Race + 
β3Demographics +β4Treatment + β5Tumor + μ 
2. No interaction terms: 25-month HRQOL Domains = β0 + β1BaselineHRQOL+ β2Race + 
β3Demographics + β4Socioeconomics +β5Treatment + β6Tumor + μ 
3a. Race and Income: 25-month HRQOL Domains = β0 + β1BaselineHRQOL+ β2Race + 
β3Demographics + β4Socioeconomics+ β5Race*Income +β6Treatment + β7Tumor + μ 
3b. Race and Education: 25-month HRQOL Domains = β0 + β1BaselineHRQOL+ β2Race + 
β3Demographics + β4Socioeconomics+ β5Race*Education +β6Treatment + β7Tumor + μ 
3c. Race and Social Support: 25-month HRQOL Domains = β0 + β1BaselineHRQOL+ β2Race + 
β3Demographics + β4Socioeconomics+ β5Race*MaritalStatus +β6Treatment + β7Tumor + μ 
3d. Race and Insurance Status: 25-month HRQOL Domains = β0 + β1BaselineHRQOL+ β2Race 
+ β3Demographics + β4Socioeconomics+ β5Race*InsuranceStatus +β6Treatment + β7Tumor 
+ μ 
3e. Race and Urban/Rural: 25-month HRQOL Domains = β0 + β1BaselineHRQOL+ β2Race + 
β3Demographics + β4Socioeconomics+ β5Race*Urban/Rural +β6Treatment + β7Tumor + μ 
4a. Only White women: 25-month HRQOL Domains = β0 + β1BaselineHRQOL+ 
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β2Demographics + β3Socioeconomics +β4Treatment + β5Tumor + μ 
4b. Only Black women: 25-month  HRQOL Domains = β0 + β1BaselineHRQOL+ 
β2Demographics + β3Socioeconomics +β4Treatment + β5Tumor + μ 
Expected Outcomes 
 The expected outcome of Chapter 5 (Aim 2) was to determine whether or not racial 
disparities existed in changes in six HRQOL domains between 5- and 25-months post-diagnosis 
among women with BC. Determining whether racial disparities existed enabled us to attain Aim 
2’s objective of better understanding cancer’s impact on two racial groups (Blacks and Whites) 
through the cancer care continuum. Information gleaned from this study will be used to inform 
more equitable HRQOL management for racial groups most vulnerable to particular HRQOL 
decrements. 
Aim 3 
Hypotheses 
 Our review of previous work guided hypotheses for Aim 3. Below we present our 
anticipated associations between HRQOL profiles at 5-months and ET non-initiation and ET 
non-adherence, separately. We anticipated the relationship between HRQOL at 5-months and ET 
utilization to vary by race and receipt of chemotherapy. Additional a priori hypotheses are 
presented below.  
 Hypothesis 3a: Worse HRQOL profiles at 5-months will be significantly associated with 
a greater likelihood of not initiating ET among women with HR+ BC.30, 31, 33, 120 
 Hypothesis 3b: Worse HRQOL profiles at 5-months will be significantly associated with 
a greater likelihood of not adhering to ET among women with HR+ BC.30, 31, 33, 120 
 Hypothesis 3c: The association between HRQOL profiles at 5-months and likelihood of 
ET non-initiation will vary by race among women with HR+ BC.39, 47 
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 Hypothesis 3d: The association between HRQOL profiles at 5-months and likelihood of 
ET non-adherence will vary by race among women with HR+ BC.39, 47 
 Hypothesis 3e: The association between HRQOL profiles at 5-months and likelihood of 
ET non-initiation will vary by receipt of chemotherapy among women with HR+ BC.47 
 Hypothesis 3f: The association between HRQOL profiles at 5-months and likelihood of 
ET non-adherence will vary by receipt of chemotherapy among women with HR+ BC.47 
Dependent Variables 
 The dependent variables for Aim 3 were whether or not a woman initiated ET and 
whether or not she adhered to ET. As non-initiating and non-adhering are less common 
occurrences in our sample, we modeled the likelihood that a woman did not initiate ET and the 
likelihood that she did not adhere to ET in our logit models. ET initiation came from the medical 
abstraction dataset and adherence came from the CBCS 25-month mail-in follow-up survey. 
Given that the ET initiation measure came from the medical record, it is likely a reliable estimate 
of whether or not a woman initiated ET. In Aim 3 analyses, ET non-initiation was treated as 
binary (yes-1, no-0).  
 ET adherence data is self-report and comes with inherent limitations, which are described 
at the end of the chapter. In the CBCS-III 25- month follow-up survey, ET non-adherence was 
asked in several different ways, but ultimately this variable was dichotomized as yes/no. We 
used two variables from the CBCS-III 25-month survey to construct the ET non-adherence 
variable: “At this time, are you taking hormonal therapy pills?” and “Over the past two weeks, 
how many days did you miss your hormonal pills?” Response options for the first question were 
“Yes, I am taking them exactly as prescribed by my doctor,” “Yes, I’m taking them, but not 
every day,” and “No, I stopped taking those pills.” If a woman responded that she was taking the 
pills exactly as prescribed we considered her as “adherent” and if she responded that she stopped 
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taking the pills then we considered her “non-adherent.” For women who responded that they 
were not taking the pills every day, we assessed their responses to the second ET adherence 
question. Response options included 0 days, 1 day, 2 days, 3 days, 4 days, and 5 or more days. 
Among who reported not taking ET as prescribed, if they missed 0, 1 or 2 days in the last two 
weeks we classified them as “adherent” (took their pills more than 80% of the time) and if they 
reported missing 3 or more days in the last 2 weeks we grouped them in the “non-adherent 
group” (they missed more than 20% of the time in the last two weeks). As such, both non-
adheres and discontinuers are classified as “non-adherent” for the purposes of our analyses in 
Aim 3.  
Key Independent Variables 
 The key explanatory variables for Aim 3 were the HRQOL profiles at 5-months, which 
were identified through the Aim 1 LPA. The HRQOL explanatory variable came from HRQOL 
data in the CBCS-III 5-month survey. The variable was categorical with the number of 
categories determined by the number of latent profiles resulting from the analysis in Aim 1. As 
in Aim 1, the highest HRQOL profile served as the reference group for Aim 3 analyses. Aim 3 
also included interaction terms between the HRQOL profiles and race as well as interactions 
between HRQOL and receipt of chemotherapy. White was used as the reference category for the 
race variable.  
Covariates 
 We adjusted for age at diagnosis, smoking status, marital status, education, insurance 
type, comorbid conditions (i.e., obesity, hypertension, heart disease, diabetes and COPD), tumor 
stage, tumor grade, and receipt of surgery, chemotherapy, radiation and Herceptin. We did not 
adjust for urban/rural residence and family income due to high degrees of collinearity with 
education and insurance. Family income and urban/rural residence both had missing values, 
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whereas the insurance and education data were complete.  
Descriptive Statistics 
 First, we compared demographic, socioeconomic, tumor and treatment characteristics 
between women in each latent profile using t-tests for continuous covariates (e.g., age) and chi-
square tests for binary (e.g., race, marital status) and categorical variables (e.g., education, 
insurance status). Then, we tested differences in the patient-level characteristics mentioned 
above within each latent profile by receipt of chemotherapy and between Black and White 
women. We also compared patient-level characteristics between women who initiated ET by 5-
months and those who initiated after 5-months using chi-square tests. Finally, we also examined 
the distribution of patient-level characteristics between women who reported adhering to ET 
versus those who did not report adhering to ET using chi-square tests.   
Latent Profile Analysis 
 The methodology for LPA models used to construct the key independent indicator for 
this aim are described in detail above under the Aim 1 approach section.  In order to determine 
whether using the latent profiles from Aim 1 were appropriate for Aim 3, we explored 
unadjusted and adjusted differences in HRQOL between women with HR+ and HR- BC as well 
as between women who initiated ET before the 5-month survey and those who initiated after the 
5-month survey. Results from these analyses are presented in Chapter 6 (Aim 3). Given the 
results from these exploratory analyses, we decided the latent profiles constructed in Aim 1 were 
the most appropriate to use in Aim 3 analyses.  
Binary Logit Models  
 Binary outcome models are appropriate to use when the outcome of interest is binary.212, 
216 The three main types of binary models are linear probability, logit and probit models.212 
Linear probability models are the least sophisticated and involves estimating an Ordinary Least 
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Squares model for a binary outcome. This approach often leads to out of ranges predictions (i.e., 
predictions that are less than 0 or greater 1) and introduces heteroskedasticity into the model. 
Although the latter can be accounted for using robust standard errors, out of range predictions are 
an inherent limitation to linear probability models. As such, logit and probit models are most 
commonly used to model binary outcomes. Both of these models allow for continuous and 
categorical explanatory variables to be examined.212 Choosing between logit and probit models 
varies by discipline and is typically left up to the investigator. 
 In Chapter 6 (Aim 3), we used logit models to predict a woman’s likelihood of not 
initiating ET. In the initiation model, the outcome was whether the woman initiated ET 
according to the CBCS-III medical record abstraction data. The outcome was coded as 0/1 with 1 
denoting ET non-initiation and 0 meaning ET initiation (the more common outcome and 
therefore the reference category). In this model, the key independent variable was the four-level 
categorical HRQOL latent profile variable with the highest HRQOL serving as the reference 
category. Demographic, socioeconomic, treatment and tumor characteristics were also controlled 
for in this model, as they may potentially confound the association between HRQOL and ET 
non-initiation.  We also considered that the relationship between HRQOL and non-initiation 
could vary by race as well as by receipt of chemotherapy (potential effect modifiers). As such, 
we ran an additional model adding an interaction term between the profiles and race and another 
model that added an interaction term between the profiles and chemotherapy. We used the 
statistical significance of the interaction terms to determine if the interactions improved the 
overall fit of our models.  We also assessed model fit using the Hosmer and Lemeshow’s 
goodness of fit test, which is based on a chi-square distribution.216 With a p-value above the 0.05 
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threshold, we assumed our models fit the data well. Given the statistical significance of the 
interaction terms, we ran chemotherapy and race stratified models.   
 We also used logit models to determine a woman’s likelihood of not adhering to her ET. 
In this model, the outcome was whether or not the woman self-reported adhering to ET on the 
25-month follow-up mail in survey. We defined adherence as self-reporting that you took your 
ET pills more than 80% of the time. As described in the dependent variable section above, we 
had access to self-report adherence data in the last 2 weeks. We considered taking pills 12 of the 
14 days (86% adherence) as “adherent” and missing 3 or pills (78% adherence or less) as “non-
adherent”. As such, non-adhering included women who reported less than 80% adherence as 
well as those who discontinued all together. This outcome was coded was 0/1 with 1 meaning ET 
non-adherence or discontinuation and 0 meaning ET adherence. As with the initiation model, the 
key independent variable was the HRQOL latent profile. As described above, the reference 
group was the highest HRQOL latent profile and demographic, socioeconomic, treatment and 
tumor characteristics were adjusted for in all models. As with the ET initiation analyses, we ran 
additional models adding interaction terms between race and HRQOL profiles as well as 
chemotherapy and HRQOL profiles (one at a time), as two variables may be effect modifiers. 
Given the statistical significance of the interaction terms, we also ran chemotherapy and race 
stratified models.   
 Using sample means, we calculated predicted probabilities of not initiating and not 
adhering to ET, separately. We selected sample mean values for demographic, socioeconomic, 
treatment and tumor characteristics in our sample and predicted the probability that a woman 
would not initiate or not adhere to ET. Also using sample means of patient characteristics, we 
calculated the differential effect on the probability that a woman did not initiate or did not adhere 
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to ET by distinct HRQOL profiles. Essentially, this approaches used dummy variables (for the 
latent profile categories) to calculate the difference in predicted probabilities of a woman not 
initiating or not adhering to ET.212 In addition, as previous studies have documented racial 
differences in ET non-initiation and non-adherence, we tested whether or not the differential 
effects of HRQOL profiles membership on the probability of not initiating and not adhering 
differed by race. We also tested whether differential effects were significantly different between 
women who received chemotherapy and those that did not.  Finally, we calculated adjusted odds 
ratios (AORs) and 95% confidence intervals for all estimates. Models estimated  for Chapter 6 
analyses are listed below.  
1. ET initiation = β0 + β1 5-month HRQOL Profile + β2Demographics + β3Socioeconomics + 
β4Treatment+ β5Tumor + μ 
2. ET initiation = β0 + β1 5-month HRQOL Profile + β2Race + β3Demographics + 
β4Socioeconomics + β5Treatment+ β6Tumor + β7 5-month HRQOL Profile*Race +μ 
3. ET initiation = β0 + β1 5-month HRQOL Profile + β2Race + β3Demographics + 
β4Socioeconomics + β5Treatment+ β6Tumor + β7 5-month HRQOL 
Profile*Chemotherapy  +μ 
4. ET adherence = β0 + β1 5-month HRQOL Profile + β2Demographics + β3Socioeconomics + 
β4Treatment+ β5Tumor + μ 
5. ET adherence = β0 + β1 5-month HRQOL Profile + β2Race + β3Demographics + 
β4Socioeconomics + β5Treatment+ β6Tumor + β7 5-month HRQOL Profile*Race +μ 
6. ET adherence = β0 + β1 5-month HRQOL Profile + β2Race + β3Demographics + 
β4Socioeconomics + β5Treatment+ β6Tumor + β7 5-month HRQOL 
Profile*Chemotherapy  +μ 
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Note: Demographics and treatment covariates in equations 1-6 include main effects for race and 
chemotherapy for the models that include interaction terms. 
Expected Outcomes  
 The expected outcomes for Chapter 6 (Aim 3) were to determine if there were significant 
associations between a composite measure of HRQOL following BC diagnosis and under-
utilization of ET at 25-months after BC diagnosis among women with HR+ disease. These 
expected outcomes allow us to achieve Aim 3’s objective of determining whether pre-ET 
HRQOL can serve as a screener for women with BC who are less likely to initiate and adhere to 
ET. HRQOL following diagnosis can be used to identify women at risk of under-utilization early 
in the BC treatment process. This important finding offers an opportunity for future 
intervention’s to target women at risk for poor HRQOL with support to increase the likelihood of 
ET initiation and adherence.  
Limitations 
 There are some limitations to note in this dissertation. First, the CBCS-III dataset only 
includes women in North Carolina, thus limiting our generalizability to women outside of the 
state. We also excluded women who were not Non-Hispanic Black or Non-Hispanic White so we 
also cannot generalize to women beyond the two racial groups included in this dissertation. In 
addition, our first HRQOL assessment point occurred an average of 5.2 months (ranges from 1.8 
to 8.9 months) after BC diagnosis. By this point, many women will have initiated primary BC 
treatments so we were unable to reliably measure pre-treatment HRQOL. However, we do have 
access to treatment data from the medical record, which is considered complete and reliable, so 
we are able to control for primary and adjuvant treatments that women received. A limitation 
specific to Aim 3 ET initiation analyses is that women who initiated ET prior to their first survey 
were not included in ET initiation analyses. This led us to exclude 646 (30%) of the 1,599 
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women with HR+ BC who would have been ideally included in Aim 3 ET initiation analyses. 
However, we compared HRQOL between women who initiated before and after the 5-month 
survey and did not find statistically significant differences in multivariate models across any of 
the HRQOL domains. Because receipt of ET may impact HRQOL, we were interested in pre-ET 
HRQOL assessments and could not include women who had initiated ET prior to their first 
HRQOL assessment. We feel confident that this decision has led us to obtain an assessment of 
HRQOL that is not confounded by exposure to ET, but we recognize that this limits our 
generalizability to all women with HR+ BC. Finally, another limitation to Aim 3 analyses is that 
the ET adherence data comes from self-report. As such, we were unable to confirm the reliability 
of the adherence data. We also combined women who were non-adherent (continued to take 
medication at less than the prescribed dose and schedule) and those who were discontinuers in 
these analyses. However, we collaborated with investigators at UNC who are also working with 
the ET adherence data in the CBCS-III dataset and are confident that our ET adherence 
classification works well and represents women who were under-utilizing this therapy. 
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Figure 1. Modified Version of Andersen’s Behavioral Model for Health Care Utilization171 
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Figure 2. Modified Version of the Consolidated Standards of Reporting Trials Flow Diagram to 
Depict Study Sample and Eligibility217 
 
 
Note: NHW (Non-Hispanic Whites), NHB (Non-Hispanic Black), ET (Endocrine Therapy), HR+ 
(hormone receptor positive), BC (breast cancer), CBCS (Carolina Breast Cancer Study) 
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Table 1. Key Variables and Measures 
Variable Aims 
Type of 
Variable 
Values/Categories 
Data 
Source 
Key Explanatory Variables 
  Race 1, 2, 3 Binary White/Black 
5-Month 
Survey 
  
Socioeconomic 
characteristics 
1, 2 Categorical See below 
5-Month 
Survey 
  Age at diagnosis 1 Continuous 20-74 years 
5-Month 
Survey 
  Receipt of chemotherapy 3 Binary Yes/No 
Medical 
Record 
Abstraction 
  5-Month HRQOL profiles 3 Categorical TBD 
5-Month 
Survey 
Covariates - Demographic Characteristics  
  
5-Month HRQOL domains 
(physical, social, emotional 
functional, spiritual well-
being, BC-specific concerns) 
2 Continuous 
0-28 for first 4 domains, 0-
48 for spiritual domain, 0-
44 for BC-specific concerns 
5-Month 
Survey 
  Age at diagnosis 1, 2, 3 Continuous 20-74 years 
5-Month 
Survey 
  Race 1, 2, 3 Binary 
Non-Hispanic White/Non-
Hispanic Black 
5-Month 
Survey 
  Smoking status 1, 2, 3 Categorical Never/Former/Current 
5-Month 
Survey 
  Body Mass Index (BMI) 1,2,3 Continuous 14.2-73.96 
5-Month 
Survey 
  Comorbid conditions  1, 2, 3 Binary 
Heart disease, diabetes, 
hypertension, etc. 
5-Month 
Survey 
Covariates - Socioeconomic Characteristics  
  Marital status  1, 2, 3 Categorical 
Married or 
partnered/Single, separated, 
divorced, widowed 
5-Month 
Survey 
  Family Income 1, 2, 3 Categorical 
1: 15-30K, 2: 30-50K, 3: 
>50K, 4: <15K 
5-Month 
Survey 
  Level of education 1, 2, 3 Categorical 
HS & Post HS, College+, < 
HS 
5-Month 
Survey 
  Urban/Rural Environment 1, 2, 3 Binary Urban-1, Rural-0 
5-Month 
Survey 
  Insurance status 1, 2, 3 Categorical 
Privately insured (self or 
employer), Medicaid, 
Medicare, Dual eligible, 
Uninsured 
5-Month 
Survey 
Covariates - Treatment Characteristics  
  Surgery type 1, 2, 3 Categorical 
Mastectomy, Mastectomy 
& Reconstruction, 
Lumpectomy, None 
Medical 
Record 
Abstraction 
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Variable Aims 
Type of 
Variable 
Values/Categories 
Data 
Source 
  Receipt of radiation 1, 2, 3 Binary Yes/No 
Medical 
Record 
Abstraction 
  Receipt of chemotherapy 1, 2, 3 Binary Yes/No 
Medical 
Record 
Abstraction 
  Herceptin 1, 2, 3 Binary Yes/No 
Medical 
Record 
Abstraction 
 
 
Covariates - Tumor Characteristics  
  AJCC Tumor stage 1, 2, 3 Categorical 0/I/II/III/IV 
Medical 
Record 
Abstraction 
  Tumor size 1, 2, 3 Categorical T0/T1/T2/T3/T4 
Medical 
Record 
Abstraction 
  Tumor grade 1, 2, 3 Categorical G1/G2/G3/G4 
Medical 
Record 
Abstraction 
  Nodal status 1, 2, 3 Binary Yes/No 
Pathology 
Report 
  Estrogen receptor positive 1, 2 Categorical Yes/No/Borderline 
Pathology 
Report 
  
Progesterone receptor 
positive 
1, 2 Categorical Yes/No/Borderline 
Pathology 
Report 
  HER-2 positive 1, 2 Categorical Yes/No/Borderline 
Pathology 
Report 
Dependent Variables 
  
HRQOL profiles (at 5- and 
25-month surveys) 
1 Categorical TBD 
5-Month & 
25-Month 
Survey 
  
Change in HRQOL domains 
between 5- and 25-months 
2 Continuous 
0-28 for first 4 domains, 0-
48 for spiritual domain, 0-
44 for BC-specific concerns 
25-Month 
Survey  
  
Non-initiation of endocrine 
therapy 
3 Binary Yes/No 
Medical 
Record 
Abstraction 
  
Non-adherence to endocrine 
therapy 
3 Binary Yes/No 
25-Month 
Survey  
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Table 2. Parameterizations of the Covariance Matrix Σk for Multidimensional Data210 
 
Note: This table is from Technical Report No. 597 Version 4 for R: Normal Mixture Modeling 
for Model-Based Clustering, Classification and Density Estimation 
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CHAPTER 4: EXAMINING HEALTH-RELATED QUALITY OF LIFE PATTERNS IN 
WOMEN WITH BREAST CANCER 
Introduction 
 Women with breast cancer (BC) in the United States experience health-related quality of 
life (HRQOL) decrements following diagnosis, during active treatment, and through survivorship 
1-3. HRQOL concerns include fear of BC recurrence or death, lymphedema, fatigue, early 
menopause, and difficulty returning to work 1, 4, 5, 7. Poorly managed HRQOL is associated with 
increased mortality risk 8. Incorporating HRQOL assessments into treatment decisions may help 
ensure more patient-centered care and improve BC outcomes.  
 HRQOL is a multidimensional concept representing an individual’s perception of well-
being, including spiritual, functional, physical, emotional, and social well-being 7, 94. This 
abstract concept is often presented as a single global score, which limits understanding of 
nuances in HRQOL and the utility of such scores as screening tools for poor health outcomes.  
For example, a woman may experience optimal physical well-being throughout BC treatment, 
but suffer significant decrements in psychosocial well-being. Thus, by focusing on a single, 
overall score; a clinician may inadvertently overlook decrements in their patients HRQOL 3.  
 Although many studies continue to use a global indicator of HRQOL, domain-specific 
measures are also often used to represent the multidimensional nature of HRQOL. However, 
traditional methods to analyzing differences or changes in domain-specific HRQOL, which 
compare means and standard deviations, are criticized for not representing heterogeneity in 
HRQOL experiences 75. Examining mean differences in HRQOL scores alone may lead us to 
erroneous conclusions regarding outliers or subgroups 75. That is, small differences or patterns 
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may be masked and subgroups of women who experience improvements or decrements may be 
missed 75. While mean differences in HRQOL scores reflect group-level HRQOL effects of 
diagnosis or treatment, these overall scores may conceal subgroups of patients experiencing 
unusually large decrements in a particular domain, or decrements across multiple domains. Such 
patients may benefit from more targeted intervention. 
 To address such limitations, the objectives of this study were to 1) employ latent profile 
analysis (LPA) to identify subgroups of women with BC who experienced different HRQOL 
patterns at 5- and 25-months after diagnosis, 2) determine patient-level characteristics associated 
with membership in the HRQOL subgroups, 3) assess the probability of transitioning from one 
subgroup to another between the two distinct phases of the BC care continuum, and, finally, 4) 
identify patient-level characteristics associated with transitioning from one LP to another LP 
between 5- and 25-months. To our knowledge, no studies have used LPA and LTA in a large, 
population-based BC cohort to examine HRQOL pattern. The clinical meaningfulness of 
HRQOL subgroups will help inform and may improve targeted HRQOL management for women 
with BC in the U.S.    
Methods 
Data 
We used data from the third phase of the Carolina Breast Cancer Study (CBCS-III). 
Through rapid case ascertainment, CBCS-III enrolled 2,998 women diagnosed with incident, 
invasive, pathologically confirmed BC between 2008 and 2013 across 44 counties in North 
Carolina 46, 188. By oversampling young and Black women, the population-based CBCS-III 
cohort is 50% Black and 50% under the age of 50. CBCS-III intended to be representative of 
women across the state and, therefore, enrolled those in rural and urban regions, women with 
private, public or no insurance, and of varying income levels 46. Demographics, lifestyle factors, 
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and HRQOL data were first collected in-person by nurses within 9-months of BC diagnosis and 
at a median of 5.2 months post-diagnosis (range 1.8-8.9 months) 46, 189. At the initial interview, 
participants consented for researchers to abstract their medical records 46, 188, 189. Women also 
completed a follow-up survey, which included additional HRQOL questionnaires at a median of 
25 months post-diagnosis (range 20-36 months), which is referred to as the “25-month survey”. 
Medical record abstraction data included comorbidities and BC treatments. Pathology report data 
provided information regarding tumor stage and grade. This study was approved by the 
Institutional Review Board at the University of North Carolina at Chapel Hill. 
Participants 
We limited our sample to women who completed both 5-and 25-month surveys. 
Additional exclusions included: women identifying as Hispanic or “other race” due to their small 
representation (3%), distant stage BC (3%), women who completed their initial survey more than 
9 months after diagnosis (7%), and those who completed their follow-up survey more than 36 
months after diagnosis (<1%). Therefore, 2,142 Non-Hispanic Black and White women with 
Stage I-III BC were included.  
HRQOL Measures 
The Functional Assessment of Cancer Therapy for Breast Cancer (FACT-B) and 
Functional Assessment of Chronic Illness Therapy for Spiritual Well-Being (FACIT-SP) were 
used to measure HRQOL at both 5- and 25-months. The FACT-B is a BC-specific instrument 
with domains for: physical, social, emotional, and function well-being, and BC-specific concerns 
191. The FACT-B has been psychometrically validated and shown to be sensitive to changes over 
time in women with BC 56. The FACIT-SP is a validated chronic disease instrument commonly 
used to measured spiritual well-being 56, 192, 196. FACT-B and FACIT-SP domains are treated as 
continuous measures with higher scores indicating better HRQOL 56, 192, 193. Minimally important 
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differences (MID) or smallest differences in HRQOL that are considered meaningful to the 
patient or provider are 2-4 points per HRQOL domain 195. 
Independent Variables 
Primary predictors of HRQOL subgroup membership at 5- and 25-months reflect self-
reported individual characteristics captured on the 5-month survey, including age at diagnosis, 
race, marital status, education, and insurance status.  
Covariates 
 Self-reported smoking status, medical-record confirmed comorbid conditions (e.g., 
diabetes, chronic obstructive pulmonary disease, obesity, hypertension, heart disease), tumor 
stage and grade, surgery type, and receipt of radiation, chemotherapy, and Herceptin were 
included in analyses.  
Statistical Analysis 
Analyses were performed in R (Version 3.2.3) and SAS 9.3 with two-sided statistical 
tests and significance level of 5%.  
LPA 
Using the continuous FACT-B and FACIT-SP domains, we used the “mclust” model-
based clustering package in R to implement a latent profile analysis (LPA) to identify clusters of 
women who experienced distinct HRQOL patterns 218. Probabilistic clusters of women were 
grouped together as HRQOL latent profiles (LP) at 5 and 25-months post-diagnosis, separately 
54, 190, 205, 207. To perform the LPA, we assumed homogeneity within and across LPs, conditional 
independence, and LP separation (i.e., item-response probabilities allow for clear differentiation 
between LPs) 190, 205, 209. A combination of underlying theory, interpretability of findings, and 
model fit indices guided model selection and, thus, the ideal number of LPs at each time point 
205. We used the Bayesian Information Criteria (BIC) to compare fits of models with different 
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covariance structures and number of LPs and selected the model with the lowest BICS 190, 205. 
We then calculated prevalence rates or the proportion of women with BC expected in each LP at 
5- and 25-months 55, 205. We also determined mean FACT-B and FACIT-SP scores in each LP 
and compared scores across LPs and to U.S. norm scores (considering both MIDs and statistical 
significance).  
Predicting LP Membership 
We employed two approaches to determine if patient-level characteristics were 
significantly associated with LP membership, adjusting for smoking status, comorbid conditions, 
treatment, and tumor characteristics, which could influence HRQOL at a single time point and 
HRQOL changes over time. Variables presented in Table 1 were potential covariates for adjusted 
models. Before selecting which variables to include in the models, we conducted univariable 
analyses to determine covariates that were significantly associated with LP membership. We 
used a significance level of 0.05 to select relevant covariates to include in multivariable analyses. 
Next, we employed a one-step approach, which simultaneously estimates a LP model and a 
multinomial logit structural model to determine covariates associated with LP membership 219, 
220. Given our large sample, we also used multinomial logit models (MLMs) to examine 
associations between the relevant patient characteristics and LP membership. We estimated a 
separate MLM predicting LPs at each time point. Specifically, one MLM was estimated for the 
HRQOL LPs identified at 5-months and another MLM was estimated for the LPs identified at 
25-months. The highest HRQOL LP served as the reference category in each MLM. We 
performed Hausman Tests for each MLM to assess the independence of irrelevant alternatives 
assumption (IIA). The Hausman Test compared estimated MLMs coefficients of unconstrained 
models to estimates from constrained models (i.e., ones that dropped categories from the 
outcome) 211, 213. Comparisons with p-values above 0.05 were considered to satisfy the IIA 
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assumption. Given that the one-step approach is most commonly reported in the LPA literature, 
we present estimates obtained from this approach.  
LTA 
We used a longitudinal extension of LPA, latent transition analysis (LTA), to assess the 
transition probability (i.e., the probability of a woman remaining in the same HRQOL LP or 
transitioning to another LP from 5- to 25-months) 54, 55, 221. To determine patient-level 
characteristics associated with transitioning, we estimated four separate MLMs (one for each 5-
month LP) to predict LP transitions, adjusting for covariates presented in Table 1. In these 
models, 25-month HRQOL LPs (four categories) were used as the outcomes. The highest 
HRQOL LP at 25-months was the reference category in all MLMs. We also used MLM to 
examine patient-level predictors of improving to a better LP from 5- to 25-months, deteriorating 
to a worse LP, and remaining in the same LP from 5- to 25-months.  
Results 
Unadjusted 
 5-month LPs: We identified four HRQOL LPs at 5-months (Figure 3). LP1 had the 
poorest HRQOL scores across all domains (well below U.S. norms) and LP4 had the highest 
HRQOL scores across domains (well above U.S norms). The second poorest HRQOL LP (LP2) 
had physical and functional well-being scores below U.S. norms, but not as low as LP1 (Table 
4). Differences between LPs 1 and 2 exceeded MID thresholds of 2-points for every domain 
except physical well-being. LP3 had physical and functional well-being scores above U.S norms, 
but below LP4. Mean differences between LP 3 and 4 were above MID thresholds for social, 
functional, and spiritual well-being and BC-specific concerns. LP3 had mean BC-specific 
concerns scores 4-points higher than LP2 and 7-points higher than LP1, which both well exceed 
the MID threshold. Patient prevalence rates at 5-months for LPs 1-4 are as follows: 32%, 29% 
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28% and 11%, respectively. Over 60% of women with BC were in the two poorest HRQOL LPs 
during active treatment. 
 25-month LPs: We also identified four HRQOL LPs at 25-months (Figure 4). Similar to 
5-month LPs, the poorest HRQOL LP was LP1 and the highest HRQOL LP was LP4. Scores 
across all domains were low for LP 1, but especially in physical and functional domains, which 
are more than one standard deviation below U.S. norm scores. LP2 had physical and spiritual 
well-being scores higher than LP3, but lower functional, social and emotional well-being and 
BC-specific concerns (Table 4). LP2 scores in social and emotional HRQOL were below U.S. 
norms. LP3 scores were generally high across all domains, but lower than LP4 scores. The 
proportion of patients within each LP at 25-months for LPs 1-4 are as follows: 26%, 12%, 37% 
and 25%, respectively. More than 60% of the women with BC were in the highest HRQOL LPs 
at 25-months post-diagnosis.   
 5- to 25-month Transitions: Overall, mean HRQOL scores in LP1 were lower at 25-
months than at 5-months, but scores at 25-months were higher than 5-months in LP 4.  
Compared to mean scores at 5-months, scores 25-months in LP2 were higher for physical and 
functional well-being, lower for social, emotional and spiritual domains, and remained the same 
for BC-specific concerns. Mean scores at 5- and 25-months for LP3 were generally the same. 
There were 951 (44%) women who improved to a better HRQOL LP from 5- to 25-months, 864 
(40%) who remained in the same LP over time, and 327 (15%) who deteriorated to a worse 
HRQOL LP.  Among women in the poorest HRQOL LP at 5-months, 52% remained in LP1 at 
25-months, and 48% transitioned to a better HRQOL LP at 25-months (Table 5). Of the women 
in LP2 at 5-months, 11% remained in LP 2, 22% declined in HRQOL to LP1 and 67% 
transitioned to LP3 or LP4 at 25-months. We observed the largest change in mean domain-
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specific scores from 5- to 25-months in LP2 as well as the largest proportion of women 
transitioning to other LPs at 25-months. Among women in LP3 at 5-months, 18% declined in 
HRQOL to LPs 1 or 2 and 35% improved in HRQOL to LP4 at 25-months. Finally, among those 
in LP4 at 5-months most remained in the highest HRQOL LP (65%), 24% declined to LP3, and 
11% to LPs 1 or 2 at 25-months.  
Adjusted  
 Relevant covariates for adjusted models, which met the 0.05 threshold included: race, age 
at diagnosis, smoking status, marital status, education, insurance status, diabetes, COPD, heart 
disease, hypertension, obesity, surgery, chemotherapy, Herceptin, and stage of disease (Table 3). 
The IIA was satisfied for all MLMs with Hausman Test p-values greater than the 0.05 threshold. 
Estimates from MLM and one-step approaches were nearly identical.   
 5-month LPs: Compared to the highest HRQOL LP (LP4), White race, younger age at 
diagnosis, being unmarried, having public or no insurance (versus private), prevalence of COPD, 
and receiving chemotherapy were significantly associated with membership in the poorest 
HRQOL LP (LP1) (Table 6). Compared to LP4, membership in LP2 was significantly associated 
with younger age, COPD, obesity and receipt of chemotherapy. Membership in LP3 was 
significantly associated with White race, higher level of education, COPD, and not receiving 
chemotherapy compared to membership in LP4. 
 25-month LPs: Compared to LP4, membership in LP1 at 25-months was significantly 
associated with Black race, being a current or former smoker, COPD, heart disease, obesity, 
receiving chemotherapy and having more advanced stage BC (Table 7). Membership in LP2 was 
significantly associated with younger age, smoking, being unmarried, COPD, heart disease, 
obesity, chemotherapy, Stage 2 or 3 BC, and having public or no insurance (compared to 
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membership in LP4). Finally, relative to LP4, membership in LP3 was significantly associated 
with White race, younger age at diagnosis, higher education and prevalence of COPD. 
Transitions: There were no patient-level characteristics significantly associated with 
transitioning from a particular HRQOL LP to another LP from 5- to 25-months. Compared to 
women who improve from one HRQOL LP to a better LP or remain in the same LP, Black race 
aOR1.32, 95% CI 1.02-1.72 and being a current smoker aOR 1.54, 95% CI 1.13-2.12 were 
significant predictors of HRQOL LP deterioration from 5-to 25-months. Compared to women 
who improve to a better HRQOL, the only predictor of remaining in the same HRQOL over time 
was having public (versus private) or no insurance aOR 1.52, 95% CI 1.18-1.96 and aOR 2.10, 
95% CI 1.34-3.29, respectively.  
Discussion 
 The objective of this study was to employ a novel, patient-centered approach to 
characterizing HRQOL patterns in women from a large population-based BC cohort and to 
determine patient-level characteristics associated with patterns. We identified four distinct 
HRQOL LPs at 5- and 25-months. Membership in poorer HRQOL LPs at 5-months was 
significantly associated with younger age, White race, lack of social support, public insurance or 
being uninsured, comorbid conditions (e.g., obesity, COPD), being a smoker, and more intensive 
BC treatment. At 25-months, membership in poorer HRQOL LPs was associated with modifiable 
patient-level factors such as smoking and obesity, as well as non-modifiable factors such as 
younger age, Black race, and prevalence of comorbid conditions. More advanced stage of BC 
and receipt of chemotherapy was also associated with poorer HRQOL LPs at 25-months. To our 
knowledge, no previous study has used LPA and LTA in a BC cohort to describe and 
characterize HRQOL patterns 55. 
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 Cluster analysis has been used to identify subgroups of patients at increased risk of poor 
health outcomes with the expectation of tailoring treatment choices to patient-specific needs 40, 41, 
199-201 Previous studies found that meaningful subgroups of cancer patients could be identified 
and clinical interventions may have seen better outcomes if an individual’s HRQOL had been 
considered in care decisions 40, 41. For example, women who were identified to be in emotionally 
unhealthy clusters could have been supported with psychotherapy sessions following diagnosis 
to ameliorate the emotional impacts of BC and to help them cope with diagnosis and treatment 40, 
41, 222. However, the work that has focused on identifying clusters of women with BC using 
HRQOL measures has been somewhat limited. Several studies combined multiple cancer types, 
many were conducted abroad, most were cross sectional, and all had sample sizes of fewer than 
500 women 202-204, 223. Using a large, population-based study of over 2,000 women with BC 
offers an opportunity to expand upon previous HRQOL cluster analysis work and draw 
conclusions more generalizable to women with BC in the U.S.  
 LPA and LTA are viewed as patient-centered approaches to identifying women 
susceptible to poor HRQOL 55, 205. LPA is considered optimal for identifying patterns within 
large, heterogeneous groups of individuals because it takes individual HRQOL patterns into 
account rather than aggregating scores across individuals 55, 190, 205. This is a probabilistic model-
based approach, which groups patients together based on probabilities rather than grouping 
symptoms or HRQOL scores together based on pre-determined distances 222. Furthermore, LPA 
is considered to have stronger model fit statistics than traditional cluster analysis approaches, 
which supports the stability of the LPs identified through LPA 221, 224. Identifying subgroups of 
women with BC can offer clinically meaningful guidance on distinct HRQOL patterns 
experienced by this population 223. For example, a previous study in pediatric oncology 
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suggested that LPA could be used to develop prediction models that preemptively identify 
individuals who might be vulnerable to membership in poor HRQOL LPs so action can be taken 
early on in their care trajectories 222. Furthermore, LTA might be able to help predict patients 
who are likely to transition to poorer HRQOL LPs as they move through the cancer continuum. 
This type of prediction tool could be especially relevant for women with BC who are in the BC 
care continuum for several years and could benefit from targeted HRQOL management.   
 We also identified patient-level characteristics associated with membership in the 5- and 
25-month LPs, which offers insights for interventions wishing to target specific groups of 
patients who are risk for poor HRQOL. As these are non-modifiable characteristics routinely 
collected in clinic, these factors could be used to easily identify women who are most susceptible 
to membership in a poor HRQOL LP.  Characteristics associated with lower HRQOL LP 
membership were generally similar at 5- and 25-months including younger age at diagnosis, 
race, comorbid conditions, and receipt of chemotherapy. However, some distinct differences that 
may help inform better HRQOL support exist. For example, membership in the poorest HRQOL 
LP at 5-months was associated with White race as well as socioeconomic factors such as lack of 
partner support, and insurance coverage and type. At 25-months, Black race was actually 
associated with membership in the poorest HRQOL LP, but no other socioeconomic factors were 
associated with poorest HRQOL LP membership. Understanding which patient-level 
characteristics might be most associated with poor HRQOL LP membership at different phases 
of the BC care continuum helps inform HRQOL management strategies, which can vary over 
time 225.  For example, if clinicians are aware that particular characteristics are associated with 
worse HRQOL patterns at specific BC continuum phases, they might be better equipped to 
provide the necessary support for patients.  Conversely, if supportive resources such as 
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counseling or nursing support are limited, they could be targeted to the patients most in need. 
Furthermore, some modifiable patient factors such as obesity and smoking status were also 
strongly associated with membership in poorer HRQOL LPs as well as deteriorating to a worse 
LP over time, and could potentially be intervened upon in order to help support HRQOL 
management in women with BC.  
Limitations 
Our study was limited to Non-Hispanic White and Black women with Stage 1-3 disease 
residing in North Carolina from 2008-2013. As such, results may not be generalizable to women 
of other races/ethnicities, those with advanced stage BC, and women in other states. Although 
we restricted analyses to women who had completed their first survey within 9-months of BC 
diagnosis and their follow-up survey within 36-months of BC, the timing of the HRQOL 
assessments ranged and we were unable to determine how assessment timing may impact LP 
membership. Finally, although we had a large sample size, when we estimated individual MLMs 
for each 5-month HRQOL LP in order to predict transitions, our sample sizes for each model 
became small, which may partially explain why we did not find statistically significant predictors 
of LP transitions. Future studies with larger samples of women with BC should further explore 
predictors of LP transitions. 
Conclusions 
 LPA is a probabilistic model-based approach used to identify subgroups of individuals 
who share similar characteristics that might be associated with their HRQOL patterns.222 By 
identifying women with BC who are likely to belong to poor HRQOL LPs, this approach offers a 
unique opportunity for women with BC to be offered targeted HRQOL support early in the BC 
care continuum 222. This could potentially lead to downstream effects such as improved long-
term HRQOL, greater adjuvant treatment adherence, and ultimately, better BC outcomes (i.e., 
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BC recurrence and survival). Results from this work suggest that we can potentially use routinely 
collected patient characteristics to help identify women at increased risk for experiencing poor 
HRQOL during active treatment and survivorship phases of their BC care. These findings are 
clinically relevant, as there is a national emphasis on patient-centered care that encourages 
clinicians to routinely collect and monitor HRQOL through electronic health records 11, 13, 89, 92, 
187, 226. Furthermore, patient-level characteristics such as age at diagnosis and race are regularly 
collected in clinic and could easily be used to identify women at risk for poor HRQOL. If these 
women were identified following BC diagnosis, they could be connected to mental health 
specialists, support groups from the onset of active treatment, nutritionists to control weight gain 
or loss, and physical therapists to help manage physical and functional well-being ailments 
following treatments. Leveraging LP membership to preemptively anticipate HRQOL needs of 
women with BC is in line with providing cancer care that reflects patient needs, preferences, and 
values.  
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Table 3. Cohort Characteristics Collected at 5-months Post-diagnosis 
  Total Cohort 
  N=2,142 % 
Age at diagnosis * 
 
  
<35 years 79 4% 
35-50 years 922 43% 
50-64 years 745 35% 
65+ years 396 18% 
Race * 
 
  
White 1105 52% 
Black 1037 48% 
Smoking status * 
 
  
Never 1200 56% 
Former 577 27% 
Current 365 17% 
Marital status * 
 
  
Not married 899 42% 
Married 1243 58% 
Education level * 
 
  
<HS 166 8% 
HS & Post HS 1108 52% 
College+ 868 41% 
Insurance status * 
 
  
None 108 5% 
Private 1535 72% 
Public 499 23% 
Diabetes * 322 15% 
COPD * 53 2% 
Heart Disease * 106 5% 
Obesity * 1023 48% 
Hypertension * 969 45% 
Surgery * 
 
  
Not specified 17 1% 
Lumpectomy 1405 66% 
Mastectomy 720 34% 
Chemo * 1336 62% 
Radiation 1570 73% 
Herceptin * 308 14% 
Stage * 
 
  
I  936 44% 
II 837 39% 
III 256 12% 
HR positive 1599 75% 
HER 2 positive 336 16% 
Note: HS (High School), HR (Hormone receptor), COPD (Chronic Obstructive Pulmonary 
Disease) * indicates variables that were included in multivariable models. 
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Table 4. Domain-specific HRQOL by 5- and 25-month Latent Profiles 
    5-Month Scores 25-Month Scores 
  
Normed 
U.S 
 
LP 1 
 
LP 2 LP 3 LP 4 
 
LP 1 
 
LP 2 LP 3 LP 4 
  
Mean 
(SD) 
N=682 N=617 N=606 N=227 N=554 N=252 N=799 N=537 
Physical 22.1 (5.4) 
15.8 
(6.5) 
16.6 
(5.7) 
24.8 
(2.2) 
25.5 
(2.3) 
15.1 
(6.5) 
23.9 
(2.8) 
23.4 
(3.3) 
26.6 (1.3) 
Social 19.8 (6.8) 
18.6 
(5.5) 
25.2 
(2.3) 
24.6 
(2.7) 
27.3 
(0.9) 
17.3 
(6.5) 
17.8 
(5.9) 
24.2 
(3.1) 
26.4 (1.9) 
Emotional 19.4 (5.1) 
15.8 
(4.6) 
20.5 
(2.6) 
20.9 
(2.2) 
22.8 
(1.6) 
15.4 
(4.7) 
17.9 
(4.3) 
20.9 
(2.2) 
22.4 (1.8) 
Functional 18.3(6.9) 
14.4 
(5.6) 
17.9 
(5.4) 
22.9 
(3.5) 
26.5 
(1.4) 
12.7 
(5.4) 
21.1 
(4.3) 
21.9 
(3.4) 
26.9 (1.2) 
BC-
Specific 
N/A 
19.9 
(6.4) 
22.9 
(5.9) 
26.9 
(4.5) 
30.3 
(3.6) 
18.4 
(6.9) 
22.6 
(6.5) 
25.4 
(5.1) 
30.1 (3.6) 
Spiritual N/A 
33.5 
(8.4) 
43.9 
(3.6) 
41.3 
(4.7) 
47.8 
(0.5) 
31.5 
(9.9) 
41.1 
(4.8) 
40.2 
(6.2) 
45.8 (2.7) 
Note: Mean scores and standard deviations are presented above. Normed US scores are only 
available for Physical, Social, Functional and Emotional FACT-B domains and come from 
Brucker et al.215 
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Table 5. Unadjusted Latent Profile Transitions from 5- to 25-months 
5-months 25-months 
  LP 1 (N=554) LP 2 (252) LP 3 (N=799) LP 4 (N=537) 
LP 1 (N=682) 356 (52%) 114 (17%) 166 (24%) 46 (7%) 
LP 2 (N=617) 137 (22%) 65 (11%) 289 (47%) 126 (20%) 
LP3 (N=606) 49 (8%) 59 (10%) 288 (47%) 210 (35%) 
LP 4 (N=237) 12 (5%) 14 (6%) 56 (24%) 155 (65%) 
Note: LP (Latent profiles). The table above displays row percentages. Row 1 shows the number 
and percent of women who were in LP 1 at 5-months and who remained in LP 1 at 25-months, 
who transitioned to LP 2, LP 3 and LP 4.  
  
9
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Table 6. Factors Associated with 5-Month HRQOL Latent Profile Membership 
  LP 1 LP 2  LP 3 
  aOR 95% CI aOR 95% CI  aOR 95% CI 
Race (ref=White)     
 
   
 
  
Black 0.52 (0.35-0.75)*** 1.09 (0.74-1.62)  0.28 (0.18-0.43)*** 
Age at diagnosis (years) 0.95 (0.93-0.96)*** 0.98 (0.96-0.99)*  0.98 (0.96-1.0) 
Smoking status (ref=never)     
 
   
 
  
Former/Current 1.41 (1.10-1.81)** 1.25 (0.97-1.62)  1.09 (0.82-1.45) 
Marital status (ref=not married)     
 
   
 
  
Married 0.50 (0.35-0.72)*** 0.71 (0.48-1.03)  1.01 (0.56-1.78) 
Education level (ref=<HS)     
 
   
 
  
>HS, College 0.50 (0.78-1.43) 1.00 (0.73-1.36)  2.15 (1.49-3.09)*** 
Insurance status (ref=private)     
 
   
 
  
Public 3.09 (1.96-4.83)*** 1.32 (0.81-2.12)  1.35 (0.78-2.34) 
Uninsured 6.51 (2.12-20.1)*** 2.17 (0.66-7.15)  2.59 (0.64-10.43) 
COPD (ref=no) 267.68 (147.61-485.44)*** 330.4 (170.71-639.46)  64.91 (23.95-175.91)*** 
Obesity (ref=no) 1.43 (0.99-2.05) 1.80 (1.24-2.60)***  0.84 (0.56-1.28) 
Chemotherapy (ref=no) 1.85 (1.22-2.81)*** 4.92 (3.13-7.74)***  0.54 (0.34-0.88)** 
Note: Latent Profile (LP) 4 was used as the reference category. Models also included prevalence of diabetes, heart disease, obesity, 
hypertension, receipt of surgery, radiation, and Herceptin, tumor stage and grade. aOR (adjusted odds ratio), 95% CI (95% confidence 
interval). Statistical significance is denoted as: * <0.05, ** <0.01, *** <0.001 
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Table 7. Factors Associated with 25-Month HRQOL Latent Profile Membership 
  LP 1 LP 2 LP 3 
  aOR 95% CI aOR 95% CI aOR 95% CI 
Race (ref=White)             
Black 1.75 (1.18-2.60)** 1.03 (0.71-1.47) 0.47 (0.32-0.69)*** 
Age at diagnosis (years) 0.98 (0.96-1.00) 0.95 (0.93-0.97)*** 0.98 (0.96-0.99)* 
Smoking status (ref=never)             
Former/Current 1.39 (1.06-1.82)* 1.89 (1.49-2.42)*** 1.23 (0.96-1.60) 
Marital status (ref=not married)             
Married 1.02 (0.69-1.50) 0.65 (0.46-0.92)* 0.88 (0.61-1.28) 
Education level (ref=<HS)             
>HS 1.17 (0.85-1.60) 0.88 (0.65-1.17) 1.78 (1.30-2.44)*** 
Insurance status (ref=private)             
Public 1.29 (0.80-2.11) 2.79 (1.81-4.33)*** 1.06 (0.64-1.78) 
Uninsured 3.11 (0.94-10.27) 4.77 (1.53-14.82)** 2.04 (0.55-7.51) 
COPD (ref=no) 142.52 (78.84-257.65)*** 189.62 (118.23-304.10)*** 95.24 (48.62-185.55)*** 
Heart disease (ref=no) 3.45 (1.24-9.61)* 3.42 (1.27-9.19)* 1.85 (0.59-5.86) 
Obesity (ref=no) 2.16 (1.49-3.15)*** 1.94 (1.37-2.74)*** 0.96 (0.66-1.38) 
Chemo (ref=no) 1.92 (1.21-3.05)** 1.76 (1.15-2.69)** 0.93 (0.60-1.45) 
Stage 2/3 (ref=Stage 1) 1.45 (1.07-1.97)* 1.34 (1.01-1.78)* 1.12 (0.83-1.53) 
Note: Latent Profile (LP) 4 was used as the reference category. Models also included prevalence of diabetes, hypertension, receipt of 
surgery, radiation and Herceptin, and tumor grade. aOR (adjusted odds ratio), 95% CI (95% confidence interval).  Statistical 
significance is denoted as: * <0.05, ** <0.01, *** <0.001 
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Figure 3. Mean HRQOL Scores by 5-month Latent Profiles 
 
Note: Mean HRQOL domains by latent profile (LP) are presented above. PWB (Physical Well-
Being), SWB (Social Well-Being), EWB (Emotional Well-Being), FWB (Functional Well-
Being), BCC (Breast Cancer Specific Concerns), SPWB (Spiritual Well-Being). Normed US 
scores are only available for Physical, Social, Functional and Emotional FACT-B domains and 
come from Brucker et al. 215 
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Figure 4. Mean HRQOL Scores by 25-month Latent Profiles 
 
Note: Mean HRQOL domains by latent profile (LP) are presented above. PWB (Physical Well-
Being), SWB (Social Well-Being), EWB (Emotional Well-Being), FWB (Functional Well-
Being), BCC (Breast Cancer Specific Concerns), SPWB (Spiritual Well-Being). Normed US 
scores are only available for Physical, Social, Functional and Emotional FACT-B domains and 
come from Brucker et al. 215 
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CHAPTER 5: UNDERSTANDING RACIAL DIFFERENCES IN HEALTH-RELATED 
QUALITY OF LIFE IN A POPULATION-BASED COHORT OF BREAST CANCER 
SURVIVORS 
Introduction 
 Over 3 million women in the United States (U.S) are currently living with breast cancer 
(BC) or have a history of BC 60. Given that 5- and 10-year BC survival rates are 90% and 80%, 
respectively, most women diagnosed with BC become long-term survivors 59. As the number of 
women surviving BC grows, monitoring and characterizing changes in health-related quality of 
life (HRQOL), as well as identifying women at high-risk for long-term HRQOL deterioration 
during survivorship, is critical to ensuring patient-centered care across the BC care continuum.    
 Thirty percent of women experience poor psychosocial and physical HRQOL before, 
during, and after treatments 3, 96. Women with BC report greater levels of treatment-related 
symptoms compared to similarly aged healthy women 5, 100, 101. Studies have shown BC is a risk 
factor for poor mental health, and rates of depression are twice as high among adults with cancer 
than those without cancer 4, 5. 
 BC risk and burden varies systemically between Black and White women 135. Although 
BC incidence rates do not differ significantly between Black and Whites, Blacks are more likely 
to die from BC 59. Black women are more likely to be diagnosed at younger ages with more 
aggressive tumors 48. As Blacks are over-represented in lower socioeconomic groups, they may 
be more likely to experience diagnosis and treatment delays associated with worse survival 142 46. 
 Racial gaps in HRQOL are well-documented in BC, but differences are not uniform 
across ages or HRQOL domains 3, 14, 16-18, 42. Specifically, compared with their White 
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counterparts, Black women with BC report worse physical and functional HRQOL 42, 156. 
However, this may not be the case at different phases of BC care. A retrospective Medicare study 
found that while racial disparities in HRQOL were prevalent before cancer diagnosis, gaps in 
certain domains narrowed following exposure to the cancer care system 14. Once Black women 
are diagnosed with BC and engage with the health care system, Black-White differences may 
narrow because previously unaddressed needs are met, which positively impacts HRQOL 14. 
 To our knowledge, no study has assessed racial disparities in changes in individual 
HRQOL domains over time in a large, multi-payer, population-based cohort. Our objective was 
to determine whether or not HRQOL varied between White and Black women during active 
treatment, survivorship, and in changes between these two time points. To do this, racial 
differences in six HRQOL domains (i.e., physical, social, emotional, functional, and spiritual 
well-being, and BC-specific concerns) were examined between 5- and 25-months after diagnosis 
among Black and White women with BC in North Carolina. 
Methods 
Data 
 Data for this study came from the third phase of the Carolina Breast Cancer Study 
(CBCS-III). CBCS-III enrolled 3,000 women diagnosed with incident, invasive, pathologically 
confirmed BC between 2008 and 2013.  Participants spanned 44 counties in North Carolina and 
were identified using rapid case ascertainment 46. To ensure representation of young and Black 
women, eligible participants were sampled from four strata (sampling fractions in parentheses): 
Blacks under 50 years (100%), Blacks 50 years and older (60%), Whites under 50 years (40%), 
and Whites 50 years and older (15%) 46. As such, 50% of CBCS-III consists of Black women, of 
whom approximately half are under 50. CBCS-III includes women residing in rural and urban 
settings, with private and/or public insurance (and uninsured), and those of varying income 
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levels 46. In-person surveys were administered to women within 9-months of diagnosis, and at a 
median of 5.2 months post-diagnosis (referred to as the “5-month survey” and ranging from 1.8-
8.9 months) 46. Surveys collected data on demographics, socioeconomics and HRQOL 46, 188. 
Twenty-five months post-diagnosis women completed a follow-up mail-in survey, which 
included HRQOL questionnaires.  Participants completed informed consent, including 
permission for researchers to abstract medical records 46, 188. This study was approved by the 
Institutional Review Board at the University of North Carolina at Chapel Hill. 
Participants 
 As the study was interested in changes in HRQOL between active treatment and 
survivorship (in terms of diagnosis and primary treatment), the cohort was restricted to women 
who completed both 5-and 25-month surveys.  Furthermore, as the focus of this study was in 
Black-White differences in HRQOL, only Non-Hispanic Black and White women were included. 
Of the 2,998 women who completed a 5-month survey, 2,561 (85%) completed a 25-month 
survey. Additionally, 97 (4%) women were excluded because they identified as “other race” or 
Hispanic. Women with distant stage BC represented less than 3% of the cohort and were 
excluded to ensure tumor and treatment homogeneity. The final cohort included 2,142 women.  
Outcome 
HRQOL instruments included the Functional Assessment of Cancer Therapy for BC 
(FACT-B) and the Functional Assessment of Chronic Illness Therapy for Spiritual Well-Being 
(FACIT-SP). The FACT-B includes 5 domains: Physical Well-Being, Social Well-Being, 
Emotional Well-Being, Functional Well-Being, and BC-specific Concerns 56. The FACT-B has 
been validated and shown to be responsive among women with BC 56. Minimally important 
differences (MID) or smallest differences in HRQOL perceived as clinically meaningful are 2-
points per domain 195.  
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 The FACIT-SP is a validated chronic disease specific and includes the Spiritual Well-
Being domain 56. The FACIT-SP is the most commonly used instrument to measure spiritual 
well-being in cancer 192. As with the FACT-B, higher scores indicate better HRQOL 56 192.  
Independent Variable 
Self-reported race (Non-Hispanic Black or White). 
Covariates 
 Demographic and lifestyle characteristics included age at diagnosis, smoking status, 
body mass index, and comorbid conditions (e.g., diabetes, chronic obstructive pulmonary 
disease, obesity, hypertension, and heart disease). Socioeconomics included marital status, 
education, family income, urban/rural residence, and insurance status at 5-months. Given a high 
degree of collinearity between socioeconomic factors (r>0.80), only education and insurance 
status were included in our models. Treatment covariates included surgery, radiation, 
chemotherapy, and Herceptin. Although we examined racial differences by tumor stage, size, 
grade, nodal status, and hormone receptor (HR) status, due to collinearity (r>0.80), we only 
controlled for tumor stage and HR status.  
Statistical Analysis 
We compared characteristics between Black and White women using t-tests for 
continuous covariates and chi-square tests for categorical variables. We tested differences in 
unadjusted mean HRQOL scores for FACT-B and FACIT-SP domains between Black and White 
women. We also compared physical, functional, social and emotional well-being domains 215. 
Changes in HRQOL domains between 5- and 25-months were calculated as 5-month scores 
subtracted from 25-month scores. Positive changes show improvements and negative changes 
denote decrements. 
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 Analysis of covariance (ANCOVA) models were used to examine predictors of HRQOL 
at 25-months, adjusting for 5-month scores, demographics, comorbidities, socioeconomics, 
treatment, and tumor characteristics. Each model’s outcome was the 25-month HRQOL score. 
We ran one model per domain to isolate domain-specific predictors that may be masked by 
overall HRQOL score. Given a sample size of 2,142 women and significance level of 5%, we 
were powered at nearly 100% to detect minimally important differences (MIDs) for each 
domain. Analyses were performed in SAS 9.3 with two-sided statistical tests and a significance 
level of 5% for all analyses. 
Assessing Racial Disparities 
 We explored three approaches to assessing racial disparities to better understand if racial 
gaps in HRQOL existed and to identify potential mediators of HRQOL disparities. ANCOVA 
models controlling for race, treatment and tumor characteristics, but not socioeconomic factors 
were estimated. Differences in adjusted Least Square Means (LSMs) between Black and White 
women were tested for each domain. This was the study’s primary approach and is consistent 
with the Institute of Medicine’s (IOM) operationalization of racial disparities in health care, 
which conceptualizes race as a social construct linked to a range of mediating factors, including 
socioeconomic status 123. The IOM considers a disparity as the difference in quality of care 
between two racial groups that cannot be explained by clinical differences, health status or 
patient preferences 128. The motivation behind this approach is that minority groups are 
overrepresented in low socioeconomic groups; thus, including both race and socioeconomics in a 
model may underestimate racial differences 123. The following two approaches were 
implemented as sensitivity analyses to explore the extent to which racial differences were 
mediated by measurable socioeconomic factors.  
 ANCOVA models controlling for race and socioeconomic factors (and tumor and 
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treatment characteristics) were estimated. Differences in adjusted LSMs between Blacks and 
Whites were tested. This approach is the residual direct effect (RDE) of race on health care, 
because it controls for all measurable mediators of the relationship between race and the 
outcome, thereby resulting in a “race” parameter estimate reflecting the unmediated effect of 
race on HRQOL 128 130. 
 Models testing interaction terms between race and socioeconomic factors were estimated. 
This final approach treated race and socioeconomic status as distinct constructs which have 
independent and interactive effects on HRQOL 123. That is, socioeconomic status is on the causal 
pathway between race and HRQOL and may moderate associations 124. 
 As additional sensitivity analyses, we ran race-stratified models to determine if race 
modified relationships between individual characteristics and HRQOL. An age-stratified model 
was also run to evaluate if disparities existed among women below or above age 40, which is the 
age at which women begin mammography screening. Finally, models stratifying women by 
menopausal status were estimated to determine if relationships between race and HRQOL varied.  
Results 
Participant Characteristics 
Table 8 presents race-stratified characteristics of the cohort. Age at diagnosis, surgery 
type, receipt of Herceptin, and prevalence of COPD and heart disease did not differ significantly 
between groups. Compared to Whites, Blacks were less likely to be married, have public 
insurance, and less education. Diabetes, obesity and hypertension were twice as common among 
Blacks. Blacks were more likely than Whites to be diagnosed with later stage BC and receive 
aggressive treatments such as chemotherapy and radiation.  
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Unadjusted HRQOL 
During active treatment (5-month survey), mean physical well-being scores were 1.2-3.7 
points below U.S norm scores (Table 9) 215. White women reported physical and functional well-
being scores 2.5 and 1.9 points higher, respectively, than Blacks (p<0.0001). Blacks reported 
spiritual well-being scores 2.1 points higher than Whites at 5-months (p<0.0001).  
 During survivorship (25-month survey), Whites reported HRQOL scores above U.S 
norms across physical, social, emotional and functional well-being domains (Table 9, Figures 5-
8) 215. Blacks, however, reported physical well-being scores 1.2 points below U.S norms and 2.3 
points below their White BC counterparts (p<0.0001). Whites reported functional well-being 
scores 2.4 points higher on average than Blacks (p<0.0001), exceeding MID thresholds. Black 
women reported spiritual well-being scores 2-points higher than Whites (p<0.0001).  
 As women entered survivorship, MIDs of 2.3-2.5 points (improvements over time) were 
seen in physical well-being for Whites and Blacks. We did not observe meaningful changes for 
other domains (Table 9). On average, social well-being declined 1-point from 5- to 25-months 
for both groups, but was 1.7-3.0 points above U.S norms (Figure 6). From active treatment to 
survivorship, spiritual well-being declined 1-point for both groups while emotional well-being 
remained unchanged. On average, Black-White differences in HRQOL changes from 5- to 25-
months ranged from 0.1-0.8 points. Differences between Blacks and White in functional well-
being and BC-specific concerns changes from 5- to 25- months were statistically significant, but 
did not exceed MID thresholds.  
Adjusted HRQOL 
In models adjusting for characteristics in Table 8, older age was significantly associated 
with better HRQOL at 25-months across all domains (Table 10). Being a smoker was associated 
with 1.2-1.9-point decreases in HRQOL across domains except for social well-being.  Higher 
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education was associated with the largest increase in physical and functional HRQOL.  Obesity 
was significantly associated with decreases in BC-specific concerns.  
IOM 
We observed statistically significant racial differences in physical, emotional, functional 
and spiritual well-being  (Figure 11) during survivorship. Specifically, Whites had physical and 
functional well-being scores 0.5 (p<0.05) and 1.0 (p<0.0001) points higher, respectively, than 
Blacks. However, Blacks had emotional and spiritual well-being scores 0.5 (p<0.05) and 0.8 
(p<0.01) points, respectively, higher than Whites. Differences were statistically significant, but 
none exceeded 2-point MID thresholds. 
RDE 
 Once socioeconomics were added to adjusted models, emotional, functional, and 
spiritual well-being domains remained significantly different between Black and White women 
(Figure 5) during survivorship. Black race was significantly associated with a 0.5-point (p<0.01) 
increase in emotional well-being and a 1.2-point (p<0.01) increase in spiritual well-being, while 
White race was associated with a 0.5-point (p<0.05) increase in functional HRQOL. Although 
differences were statistically significant, none exceeded 2-point MID thresholds.  
Race and Socioeconomic Interactions 
Interaction terms between race and socioeconomic factors were not statistically 
significant at the 0.05 level.  
Sensitivity Analyses 
 In race-stratified models, patient and treatment characteristics had similar associations 
with HRQOL in terms of estimates’ direction, magnitude and significance for Blacks and Whites 
(results not shown). One notable difference was that among Black women, receipt of Herceptin 
was significantly associated with 0.8-1.2 point lower physical, emotional, functional and BC-
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specific concerns scores (p<0.01), but this association was not seen among Whites. White-Black 
Differences in HRQOL by age or menopausal status were not observed.  
Discussion 
 Domain-specific HRQOL patterns were examined to assess if Black and White women 
with BC are equally susceptible to poor HRQOL during active treatment and survivorship. Using 
the RDE approach, we found statistically significant, but not clinically meaningful Black-White 
differences in emotional and spiritual well-being at 25-months. Implementing the IOM approach, 
we again found small, but significant differences in physical, functional, emotional and spiritual 
well-being domains during survivorship. These findings are similar to other BC survivor studies 
that found racial differences in HRQOL following treatment were small and not clinically 
meaningful 227. Previous work attributed racial differences in HRQOL to BC stage, treatments, 
comorbidities, and socioeconomics related to health care access 228.  
 Racial differences in physical and functional HRQOL appear to be mediated by 
socioeconomics. Race coefficients for physical and functional well-being domains attenuated by 
50% once socioeconomics were controlled for, whereas emotional and social well-being 
coefficients remained unchanged. Gaps in spiritual well-being actually widened once 
socioeconomics were added to the model. Worse physical and functional HRQOL may be related 
to racial differences in access (e.g., financial barriers) to cancer care, which often emphasize 
management of physical and functional effects of cancer and its treatment 229. Thus, racial 
differences in access to care are more likely to impact physical and functional well-being.  
Furthermore, physical and functional HRQOL may be impacted by comorbid conditions such as 
obesity, diabetes and hypertension, all of which were more prevalent in Black women in our 
study. A systematic review of BC survivors concluded that, in general, Black women report 
worse physical and functional well-being than their White counterparts, however, once 
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demographic, socioeconomic and medical characteristics were adjusted for, physical and 
functional well-being differences between Black and White women attenuated, suggesting 
differences may be largely mediated by demographic and socioeconomic factors 44. 
Socioeconomic-related barriers to physical and functional well-being must be addressed to help 
narrow gaps in these domains. Potential ways to improve physical and functional HRQOL could 
be to help manage other comorbidities and promote greater physical activity. Black women with 
BC tend to report lower levels of physical activity, which has been associated with poorer 
physical well-being and overall HRQOL 3, 158. Studies have also confirmed that although BC 
survivors report less physical activity compared to the general population, Whites with BC have 
higher levels of physical activity compared to Blacks, which may facilitated by physical well-
being and vitality 42, 156, 158.  
 Our findings are consistent with previous work concluding that women with BC report 
greater levels of social support compared to healthy women their age 22. Increased social support 
among women with BC has been associated with better adjustment following primary BC 
treatments 229, 230. As such, it is not surprising that women in our study reported social well-being 
scores well above U.S norms during active treatment. Black women were less likely to be 
married, suggesting that their social support may have come from sources other than partners 
(i.e., community, religious organizations) 229. Previous studies also suggest Blacks experience 
positive growth following BC diagnosis and treatment, which may support social and emotional 
well-being 22, 159. 
 Black women consistently report the importance of spirituality in coping with BC 156, 160, 
162. Spirituality has been described as a source of hope and comfort for Black women struggling 
with the psychosocial burden of BC diagnosis and treatment 159. In fact, clinicians have been 
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recommended to promote spirituality as a coping mechanism among Black women with BC, as it 
may mitigate effects of BC on psychosocial health 44 159. This is consistent with our findings that 
Blacks reported significantly higher levels of emotional and spiritual well-being than Whites, 
even after adjusting for patient characteristics.  
 Emotional and spiritual well-being were the only HRQOL domains not attenuated by 
socioeconomic factors. Racial differences in spiritual well-being actually widened after adjusting 
for socioeconomics. At first, it seems this suggests emotional and spiritual well-being domains 
may not be impacted by socioecological burden Black women more often endure 156. Financial 
stressors, urban residence, job insecurity, and balancing multiple responsibilities (e.g., house, 
parental, job) make dealing with BC more difficult for Blacks 42, 44, 156. Following diagnosis, 
Black women struggle with these challenges, exacerbating physical and functional well-being, 
which often decline following BC treatment 42, 156. This is in line with our observations that 
physical and functional HRQOL were lower among Blacks during active treatment. Emotional 
and spiritual well-being domains, however, appear more resistant to life stressors affecting other 
domains due to increased spirituality and community support. Another possibility is that BC and 
socioeconomic factors actually impact emotional and spiritual well-being, but in a way that 
reinforces these domains. The Superwoman role, a theory stating Black women feel they must 
exude strength, suppress emotions, and demonstrate perseverance when faced with adversity, 
may partially explain this 231. If Black women do not allow themselves to acknowledge weakness 
or stress related to BC, self-reported emotional and spiritual well-being may not appear to suffer 
231. 
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Limitations 
 First, we only included Non-Hispanic Black and White women in North Carolina, 
limiting generalizability to women outside of the state and of other racial groups. As most 
women have initiated primary BC treatments by 5-months, there is no pre-treatment HRQOL 
measure. However, BC treatments (from medical records) were adjusted for in analyses. We 
were unable to control for unmeasured confounders such as patient preferences, culture, 
economic, political, and legal factors that may impact HRQOL.124 As such, even in conservative 
models, race coefficients encompassed unmeasurable factors such as institutional racism, 
different care seeking behavior and access to health care networks that are not determined by 
insurance status, education and income, introducing potential bias. 
Conclusion 
 The richness of CBCS-III made it an ideal platform to understand racial disparities in 
HRQOL among women with BC in North Carolina. Statistically significant racial differences in 
HRQOL changes (from active treatment to survivorship) were identified, but differences were 
not considered clinically meaningful. Results suggest socioeconomic factors may considerably 
mediate racial gaps in physical and functional HRQOL between White and Black women with 
BC. Supportive services should consider domain-specific findings to provide targeted HRQOL 
management across socio-demographic groups of women with BC.  
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Table 8. Cohort Characteristics by Race 
  Whites Blacks P-value 
  N=1,105 N=1,037   
Demographics           
Age at diagnosis         0.1327 
<35 39 4% 40 4%   
35-50 482 44% 440 42%   
50-64 363 33% 382 37%   
65+  221 20% 175 17%   
Smoking status         <0.0001*** 
Never 593 54% 607 59%   
Former 346 31% 231 22%   
Current 166 15% 199 19%   
Socioeconomics           
Married 802 73% 441 43% <0.0001*** 
Education          <0.0001*** 
<High School 47 4% 119 11%   
Completed High School  514 47% 594 57%   
College+ 544 49% 324 31%   
Insurance status         <0.0001*** 
None 30 3% 78 8%   
Private 917 83% 618 60%   
Public 158 14% 341 33%   
Comorbidities           
Diabetes  91 8% 231 22% <0.0001*** 
COPD 29 3% 24 2% 0.6443 
Heart Disease 51 5% 55 5% 0.4629 
Obesity 100 9% 190 18% <0.0001*** 
Hypertension 350 32% 619 60% <0.0001*** 
Treatments            
Surgery         0.2337 
Not specified 11 1% 6 <1%   
Lumpectomy 709 63% 696 66%   
Mastectomy 385 34% 335 32%   
Chemotherapy 627 57% 709 68% <0.0001*** 
Radiation 785 71% 785 76% 0.0149* 
Herceptin 143 13% 165 16% 0.0502 
Tumor characteristics           
Stage         <0.0001*** 
I  570 52% 416 40%   
II 416 38% 466 45%   
III 119 11% 155 15%   
Hormone Receptor Status         <0.0001*** 
Positive/Borderline 909 81% 690 65%   
Negative 196 18% 347 33%   
p<0.05 *, p<0.01 **, p<0.0001*** 
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Table 9. Unadjusted HRQOL Scores by Race and U.S Norms215 
    5-Month Scores 25-Month Scores 
5 to 25-month 
Changes 
  U.S Norms  White Black White Black White Black 
Physical 22.1 (5.4) 20.9 (6.0) 18.4 (6.8) 23.2 (5.3) 20.9 (6.3) 2.3 2.5 
Social 19.8 (6.8) 23.7 (4.5) 22.6 (5.1) 22.8 (5.3) 21.5 (6.2) -0.9 -1.1 
Emotional 19.4 (5.1) 19.4 (3.7) 19.3 (4.5) 19.5 (3.9) 19.5 (4.6) 0.1 0.2 
Functional 18.3(6.9) 20.1 (5.8) 18.2 (6.7) 21.8 (5.6) 19.4 (7.0) 1.7 1.2 
BC-Specific N/A 23.9 (6.1) 23.6 (6.9) 25.0 (6.3) 23.9 (7.5) 1.1 0.3 
Spiritual N/A 39.3 (7.9) 41.4 (7.1) 38.5 (8.7) 40.5 (8.1) -0.8 -0.9 
Means (standard deviations). Change was calculated as 5-month scores subtracted from 25-
month scores.  
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Table 10. Analysis of Covariance Models by HRQOL Domain 
  25-Month HRQOL 
  Physical Social Emotional Functional BC-Specific Spiritual 
5-Month HRQOL 0.46*** 0.68*** 0.54**** 0.52*** 0.58*** 0.68*** 
Demographics           
Black race (ref=white) -0.17 -0.18 0.54** -0.52* 0.04 1.12** 
Age at diagnosis 0.04** 0.03* 0.04*** 0.03* 0.06*** 0.04** 
Smoking status (ref=never) 
   
  
Former 0.08 -0.27 -0.02 -0.21 -0.31 0.31 
Current -1.34** -0.77* -1.32*** -1.84*** -2.03*** -2.25*** 
Socioeconomics           
Marital status  
(ref=not married) 
-0.08 -0.31 0.12 0.24 0.02 0.51 
Education level (ref=<HS) 
    
  
HS & Post HS 0.76 0.85* 0.56 1.75*** 0.39 0.36 
College+ 1.53** 0.77 0.63 1.95*** 0.57 0.16 
Insurance status (ref=private) 
   
  
Public -1.55*** 0.01 -0.43* -1.65*** -1.35*** -0.69 
Uninsured -1.72** -0.25 -0.01 -2.02*** -2.14*** -0.25 
Comorbid Conditions           
Diabetes (ref=no) -0.34 -0.48 -0.23 -0.33 0.52 0.34 
COPD (ref=no) -0.93 -0.59 -0.34 -1.45* -0.91 -0.01 
Heart Disease (ref=no) -1.04* -0.29 -0.88* -1.22* -0.51 -1.44* 
Obesity (ref=no) -0.90*** -0.05 -0.33* -0.66** -1.03*** -0.33 
Hypertension (ref=no) -0.11 -0.24 -0.25 -0.21 -0.25 -0.34 
Treatments              
Surgery (ref=lumpectomy) 
   
  
Mastectomy -0.29 -0.11 -0.07 -0.01 -0.56 -0.15 
Not specified 0.36 0.15 1.41 0.65 -0.57 1.89 
Chemotherapy 
(ref=none) 
0.24 -0.13 0.03 0.65* 0.52 -0.08 
Radiation (ref=none) 0.03 -0.03 -0.02 0.18 0.04 -0.12 
Herceptin (ref=none) -0.43 -0.11 -0.35 -0.51 -0.51 -0.35 
Tumor characteristics           
Stage (ref=Stage I) 
    
  
II -0.36 -0.23 -0.28 -0.31 -0.94** -0.13 
III -0.15 0.04 -0.18 -0.15 -1.09* -0.11 
HR negative 
(ref=positive) 
0.29 -0.31 0.21 0.27 -0.27 0.18 
p<0.05 *, p<0.01 **, p<0.0001* 25-month HRQOL scores are adjusted for HRQOL at 5-months. 
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Figures 5-8: HRQOL at 5- and 25-months by race with dotted line representing U.S norms 
 
Figure 5. Physical Well-Being at 5- and 25-months by Race 
 
 
Figure 6.  Social Well-Being at 5- and 25-months by Race 
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Figure 7. Emotional Well-Being at 5- and 25-months by Race 
 
 
Figure 8. Functional Well-Being at 5- and 25-months by Race 
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Figure 9. Breast Cancer-Specific Concerns at 5- and 25-months by Race 
 
 
Figure 10. Spiritual Well-Being at 5- and 25-months by Race 
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Figure 11. Adjusted Least Square Mean Differences in 25-Month Scores by HRQOL Domain 
 
Note: Blue dots represent adjusted LSM differences. Grey bars represent 95% confidence 
intervals. Differences calculated as White scores subtracted from Black scores. Negative 
differences indicate White women have higher HRQOL than Black women.  
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CHAPTER 6: INVESTIGATING ASSOCIATIONS BETWEEN HEALTH-RELATED 
QUALITY OF LIFE AND ENDOCRINE THERAPY UNDER-UTILIZATION IN 
WOMEN WITH EARLY STAGE BREAST CANCER 
Introduction 
 Breast cancer (BC) is a heterogeneous disease with several tumor subtypes, each of 
which respond differently to treatments.57 Hormone receptor positive (HR+) subtypes account 
for 80% of BCs and include tumors expressing receptors for estrogen or progesterone 
hormones.25, 57, 61 Following primary local treatment, sustained targeted therapy against hormone 
receptors using endocrine therapy (ET) improves the prognosis of these tumors significantly.57, 61 
3,4 ET, indicated for nearly all HR+ BCs, is recommended as a daily pill for 5 years following 
primary BC treatments.76 36, 77  
 ET is a highly effective adjuvant treatment associated with a 40% reduction in BC 
recurrence and 30% reduction in BC-related mortality.27-31, 78 Despite its clinical benefits, 10-
30% of HR+ women never initiate therapy and, among those who initiate, 50% are non-adherent 
by 5 years.27-31 Under-utilization is concerning, as women who are inconsistent in medication use 
or who discontinue ET before 5 years do not realize full benefits.31, 34, 78 Specifically, women 
who under-utilize ET have worse BC outcomes (i.e., BC recurrence and survival) compared to 
women who take ET for 5 years.34, 85  
 ET is associated with side effects and poor health-related quality of life (HRQOL).75 74 36 
As poor HRQOL following diagnosis may persist after primary treatments, HRQOL may 
interfere with adjuvant treatment decisions.108 19 Poorly managed HRQOL during active 
treatment may contribute to under-utilization, as poor HRQOL can hinder a woman’s ability to 
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cope with ET side effects as she struggles to acclimate to life after primary BC treatments.32-37 In 
this study, we operationalized under-utilization as not initiating or not adhering to ET.39  
 Although studies have collected data on poor HRQOL while women take ET, to our 
knowledge, no studies have examined associations between ET initiation and HRQOL prior to 
initiating.  Some work has evaluated relationships between HRQOL and non-adherence and non-
persistence, but results have been mixed, with some reporting no associations and others 
reporting that poor HRQOL is associated with non-adherence. 35, 50, 121 Findings from one recent 
study indicated that worse psychosocial HRQOL and greater patient distress were predictive of 
ET non-persistence.121  
Evidence from previous work should be interpreted with caution, as many studies 
employed post-ET initiation HRQOL assessments, which may be confounded by ET side effects 
and few employed BC-specific HRQOL instruments. 19, 21 Additionally, all studies were carried 
out in small cohorts of predominantly Non-Hispanic White women.50 35, 75 121 The objectives of 
our study were to examine associations between pre-ET HRQOL and non-initiation as well as 
HRQOL during active treatment and non-adherence in a large, racially and socio-economically 
diverse, population-based cohort of women with BC. Identifying associations between HRQOL, 
a modifiable factor, and inappropriate ET use offers opportunities for future interventions to 
reduce under-utilization, thus improving BC outcomes among HR+ women.  
Methods 
Data 
Three thousand women diagnosed with invasive BC between 2008-2013 in North 
Carolina were enrolled in the third phase of the Carolina Breast Cancer Study (CBCS-III) 
through rapid case ascertainment.46 188 Fifty percent of CBCS-III consists of Black women and 
50% of women are under age 50. CBCS-III includes women in rural and urban settings across 44 
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counties, those with private, public and no insurance, and women of varying income levels.46 
Four data sources were combined for this study: CBCS-III baseline  (“5-month survey”) medical 
record abstraction, pathology reports, and follow-up (“25-month survey”).225 Demographics, 
lifestyle, and HRQOL were collected in-person at a median post-diagnosis time of 5.2 months 
(1.8-8.9 months).46, 189 Participants consented for researchers to obtain and abstract medical 
records.46, 188, 189 Women completed a follow-up survey at a median of 25.1 months post-
diagnosis (20-36 months), which included adherence questions. Medical record abstraction data 
included comorbidities and treatments. Pathology reports included tumor stage, grade, and HR+ 
status. The Institutional Review Board at the University of North Carolina at Chapel Hill 
approved this study. 
Participants 
Of the 2,998 women enrolled in CBCS, we excluded women who: did not complete 
adherence questions (6%), identified as “other race” or Hispanic (3%), had distant stage BC or 
no surgery (3%), or their first survey occurred more than 9 months post-diagnosis (5%). Limited 
representations of other races and Hispanics precluded us from making inferences about these 
groups. The cohort was further restricted to women with HR+ BC to ensure ET eligibility 
(n=1,599).  Two separate cohorts were used for initiation and adherence analyses. ET initiation 
analyses were limited to 953 women who did not initiate ET before their 5-month survey. Of the 
1,599 women, adherence analyses were limited to 1,114 women who initiated ET and completed 
adherence questions.  
Outcomes 
Primary study outcomes were 1) whether or not a woman initiated ET and 2) whether or 
not she adhered to ET. Non-initiation was a binary variable obtained from medical records. Non-
adherence was categorized as a binary variable from 2 self-reported questions on the 25-month 
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survey: 1) “At this time, are you taking hormonal therapy pills?” and 2) “Over the past 2 weeks, 
how many days did you miss your hormonal pills?” Response options for the first question were 
“Yes, I am taking them exactly as prescribed by my doctor,” “Yes, I’m taking them, but not 
every day,” and “No, I stopped taking those pills.” If a woman responded she was taking pills as 
prescribed she was considered “adherent” and if she responded that she stopped taking pills she 
was considered “non-adherent.” Among women who reported not taking ET every day, self-
reported pill consumption in the past 2 weeks from a modified Morisky questionnaire was used 
to determine adherence. Those who missed 2 or fewer days in the last 2 weeks were considered 
“adherent” (>80%) and those who reported missing 3 or more days in the last 2 weeks were 
considered “non-adherent”(< 80%).78 Women who were non-adherent or who discontinued were 
grouped as “non-adherent” for analyses.  
HRQOL Instruments 
HRQOL was measured using the Functional Assessment of Cancer Therapy for BC 
(FACT-B) and Functional Assessment of Chronic Illness Therapy for Spiritual Well-Being 
(FACIT-SP). The FACT-B is BC-specific and includes physical, social, emotional and functional 
well-being, and BC-specific concerns.191 191 The FACIT-SP measured spiritual well-being. 56 
FACT-B and FACIT-SP domains were assumed to be continuous with higher scores representing 
better HRQOL. 
Key Independent Variable 
The primary explanatory HRQOL variable had 4 levels and was derived using a cluster-
based modeling approach, latent profile analysis (LPA).218 LPA used FACT-B and FACIT-SP 
domains from the 5-month survey to identify 4 latent profiles (LPs) of women who experienced 
distinct HRQOL patterns.  
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Covariates 
Self-reported demographic and lifestyle covariates: age at diagnosis, race (non-Hispanic 
Black and White), smoking, marital status, education, and insurance at 5-months. Comorbid 
conditions (e.g., diabetes, chronic obstructive pulmonary disease, obesity, hypertension, and 
heart disease) from the medical record were included. Tumor stage and grade; surgery type; and 
receipt of radiation, chemotherapy, and Herceptin were included in models.  
Statistical Analyses 
Unadjusted comparisons of demographics, comorbidities, tumor, and treatment 
characteristics across women in the 4 HRQOL LPs were performed using chi-square tests. As 
women who initiated ET by 5-months might differ from women who initiate after 5-monthis 
(i.e., earlier stage of disease, better access to care), characteristics of those who initiated before 
and after 5-months were compared. As sensitivity analyses, unadjusted and adjusted HRQOL 
scores (1) between women with HR+ and HR- BC; and (2) between women who initiated ET 
before or after 5-months were examined. 
 Multivariable logistic regression was used to estimate adjusted odds ratios (aORs) and 
95% confidence intervals (CI) between HRQOL LPs and the likelihood of not initiating or 
adhering to ET, separately. The best HRQOL LP (LP 4) was set as the reference group. As race 
and chemotherapy may be effect measure modifiers of associations between HRQOL and ET 
use, race- and chemotherapy-stratified models were estimated for non-initiation and non-
adherence outcomes, separately. In sensitivity analyses, associations were examined between 
continuous, rather than categorical, HRQOL measures and (1) non-initiation and (2) non-
adherence. As a final sensitivity analysis, non-adherence models were stratified by whether or 
not women initiated ET by their 5-month survey to determine if associations between HRQOL 
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and non-adherence varied by initiation timing. Analyses were performed in SAS 9.3 with two-
sided statistical tests and significance of 5%.  
Results 
5-month HRQOL LPs 
LP1 had the poorest HRQOL across all domains and LP4 reported the best HRQOL 
scores across domains (Figure 12). LP2 had physical and functional scores similar to LP 1, but 
LP 2 had higher social and spiritual well-being. LP3 was similar to LP4, but spiritual and social 
well-being were lower than LP2. 
Participant Characteristics 
Characteristics for the 1,599 HR+ women stratified by the 4 HRQOL LPs are presented 
in Table 11. Fifty-seven percent of women were in the 2 lowest LPs. Overall, women in poorer 
LPs (i.e., LPs 1 and 2) were more likely to be young, Black, unmarried, obese, had no insurance, 
Stage 2-3 BC, and received chemotherapy or Herceptin. There were patient-level differences 
between the 2 lowest LPs, but few differences between the 2 highest LPs. Compared to LP2, 
women in LP1 were more likely to be educated, unmarried, without insurance, earlier stage BC, 
and less likely to receive chemotherapy. Overall, women in LP1 received less aggressive BC 
treatments than LP2. Women in the 2 highest LPs (LPs 3 and 4) had similar demographic, tumor, 
and treatment characteristics. LP3 and 4 varied by race, with LP3 having a larger proportion of 
Whites.   
ET Use 
Among the 953 women who had not yet initiated ET at their 5-month survey, 16% never 
initiated ET. Among the 1,114 women who initiated ET according to their medical records, 19% 
were considered non-adherent. Factors associated with non-initiating and non-adherence 
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included younger age, Black race, higher education, public (versus private) insurance, breast-
conserving surgery (versus mastectomy), and not receiving chemotherapy or radiation.  
HRQOL and ET Initiation 
In adjusted and unadjusted analyses, among women who had not initiated ET at their 5-
month survey, there were no significant associations between HRQOL LPs and non-initiation 
(Table 12). Among non-chemotherapy users, LP1 membership was significantly associated with 
increased adjusted odds of non-initiation aOR 5.5 (95% CI 1.7-17.4) (Table 3). We found no 
significant adjusted associations among chemotherapy users or for Blacks and Whites (Table 3).  
HRQOL and ET adherence 
Among women who initiated ET, membership in poorer HRQOL LPs (LPs 1 and 2) was 
significantly associated with increased likelihood of non-adherence with unadjusted OR 2.4 
(95% CI 1.3-4.2) and OR 2.0 (95% CI 1.1-3.6), respectively (Table 12). After adjustment, ORs 
attenuated (LP1 aOR 2.2; 95% CI 1.2-4.0; LP2 aOR=1.9; 95% CI 1.1-3.6). Although not 
statistically significant, LP3 was associated with an elevated likelihood of non-adherence aOR 
1.5 (95% CI 0.8-2.8).  
Associations between LPs and non-adherence were not statistically significant among 
chemotherapy users, but among non-users, membership in the poorest LP was associated with 
increased adjusted odds of non-adherence aOR 2.1 (95% CI 1.2-5.1) (Table 13). Among Blacks, 
membership in the second lowest LP was associated with non-adherence aOR 2.5 (95% CI 1.1-
6.1), but for Whites, membership in LP1 was associated with non-adherence aOR 2.4 (95% CI 
1.1-5.6).  
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Sensitivity Analyses  
In unadjusted analyses using continuous, rather than categorical, HRQOL scores as 
predictors, we observed associations between better HRQOL and increased likelihood of non-
initiation, but in multivariable models, associations became small and non-statistically 
significant. In unadjusted models, better continuous HRQOL was associated with lower 
likelihood of non-adherence, but in multivariable analyses, continuous HRQOL was not 
associated with non-adherence. 
 There were 646 women who initiated ET before (“early initiators”) and 804 who initiated 
ET after their 5-month survey (“late initiators”). Compared to late initiators, early initiators had 
better HRQOL scores across domains with differences ranging from 1-4 points per domain. In 
multivariable models, differences dropped to below 1-point and became non-statistically 
significant.  
 Results from multivariable non-adherence analyses were similar when stratified by early 
and late initiators. The magnitude of associations between poor LPs and non-adherence was 
greater for early initiators (LP1 aOR 4.1, 95% CI 1.1-8.8 and LP2 aOR 3.1, 95% CI 1.4-11.9) 
compared to late initiators (LP1 aOR 1.8, 95% CI 1.2-3.9 and LP2 aOR 1.3, 95% CI 1.1-3.0).  
Regardless initiation timing, compared to the best HRQOL LP, membership in the 2 poorest LPs 
was associated with non-adherence.  
Discussion 
 To our knowledge, this is the first study to examine associations between HRQOL and 
ET under-utilization in a large, population-based, multi-payer HR+ BC cohort. Although we did 
not observe statistically significant associations between pre-ET HRQOL and non-initiation, 
aORs for LPs 1-3 were 1.9, 1.4, and 2.1, suggesting a trend toward associations between poor 
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HRQOL and non-initiation. We observed significant associations between worse HRQOL during 
active treatment and non-adherence with aORs ranging from 1.7-2.2.  
 Studies have demonstrated associations between social and provider support and ET use 
in BC.232 Greater support is associated with increased adherence.232, 233 Associations with social 
support are consistent with our results, as the 2 lowest LPs (most associated with under-
utilization) had higher percentages of unmarried women. Provider support is important because 
when patients feel supported and empowered to make treatment decisions in line with personal 
preferences, they are more likely to adhere to therapies.233, 234 Provider support might help 
manage HRQOL during active treatment. One study reported that while older age at diagnosis 
and side effects were unadjusted predictors of non-adherence, once demographics, treatments, 
and tumor characteristics were included, only social support and patient-centered care measures 
(i.e., patient role in decision-making) remained associated with non-adherence.234  
 Chemotherapy moderated associations between HRQOL and under-utilization. Women 
undergoing chemotherapy have worse HRQOL than women who do not undergo 
chemotherapy.98 118 101 Chemotherapy is associated with body image concerns, fear of recurrence 
and worse sexual functioning among women with BC.118 101 119 In this study, among non-
chemotherapy users, poor HRQOL was significantly associated with non-initiation and non-
adherence. Women undergoing chemotherapy may attribute poor HRQOL to the aggressive 
treatment, whereas women not receiving chemotherapy may associate poor HRQOL with ET, 
making them more likely to not adhere. Additionally, chemotherapy side effects may dissipate 
over time; enabling women to deal better with ET-related difficulties than those whose initial 
HRQOL was poor for other reasons.  Alternatively, women who experienced severe 
chemotherapy side effects may view problems encountered on ET as relatively tolerable. 
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HRQOL may be a useful screener for under-utilization among women who do not undergo 
chemotherapy.  More research is needed to disentangle possible explanations for our findings. 
 Associations between HRQOL and non-adherence were modified by race. Among 
Whites, membership in the poorest LP was significantly associated with non-adherence, but 
membership in the second poorest LP was associated with non-adherence for Blacks. Women in 
LP1 and LP2 reported poor physical and functional scores, but social and spiritual well-being 
were better in LP2.  Low physical and functional scores in both groups suggest these domains 
should be prioritized in clinical care, as they are potentially associated with increased likelihood 
of non-adherence. Moreover, previous studies indicate Black women with BC consistently report 
the importance of spirituality, including religious community support, in coping with their 
disease. 22, 156, 159, 160, 162 Some studies have documented associations between greater spirituality 
and lower likelihood of receiving recommended care (e.g., medication adherence, end-of-life 
care), which may partially explain our observed association between membership in LP2 (higher 
spiritual HRQOL) and non-adherence among Blacks.235, 236 A possible explanation for this 
association that has been described in the literature is that spirituality and religious community 
affiliation may be linked to a belief in “miraculous healing,” which may influence treatment 
decisions that are not necessarily in line with clinical recommendations.236 When Black women 
in LP2 experience poor physical and functional HRQOL, they may rely even more on religious 
communities for support. As such, identifying better ways to manage HRQOL (especially 
physical and functional), including culturally sensitive approaches that integrate spiritual support 
in the clinical setting (e.g., having religious leaders serve as lay health advisors), may help 
increase the likelihood for ET adherence in both White and Black women with BC.  
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Limitations 
Non-Hispanic White and Black women residing in North Carolina were included in this 
study, limiting generalizability to women in other states and of other races/ethnicities. However, 
CBCS-III is a large cohort, which provides broader inference with a population-based sample as 
opposed to a hospital or clinic-based sample. Additionally, women who initiated ET by 5-months 
were excluded from initiation analyses. We conducted sensitivity analyses to determine if these 
women differed in HRQOL and found that once patient characteristics were accounted for, no 
significant HRQOL differences between women who initiated ET before or after 5-months 
existed. Women who initiated ET by their 5-month survey were included in adherence analyses. 
As ET may negatively impact HRQOL, including these women could potentially confounded 
associations between HRQOL and non-adherence. Therefore, sensitivity analyses were 
conducted including stratifying models by whether or not a woman initiated before or after her 5-
month survey. As results were similar, all HR+ women were included in adherence analyses to 
increase generalizability of results to women with HR+ BC.  Finally, because ET adherence was 
self-reported, reliability of adherence data was not confirmed.  
Conclusion 
 Our findings suggest HRQOL measured soon after diagnosis can be used to identify 
women who may not initiate or adhere to ET during survivorship. HRQOL is modifiable and can 
be intervened on early in the BC continuum to help reduce under-utilization. Women with poor 
HRQOL during active treatment should receive targeted HRQOL support to reduce the risk of 
inappropriate adjuvant treatment decisions.40, 41 Those experiencing poor physical and functional 
well-being may be at greater risk for under-utilization, as lower scores in these domains were 
most associated with under-use. Furthermore, BC subgroups such as non-chemotherapy users 
and Blacks may especially benefit from additional physical and functional HRQOL management. 
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As Blacks present with more aggressive BC subtypes at younger ages and report worse physical 
and functional HRQOL, they might be more susceptible to under-utilization.42, 44, 57, 158, 237 48, 137, 
138 Reducing ET under-utilization among Black women may offer an opportunity to help reduce 
racial disparities in BC outcomes.  Using self-reported HRQOL as a potential indicator for 
inappropriate ET use is inexpensive and easy to do with validated HRQOL instruments, making 
these findings particularly appealing. Women most vulnerable to under-utilization should be 
identified early in the BC continuum and provided ongoing HRQOL management to support ET 
use and improve BC outcomes.31, 168 
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Table 11. Cohort Characteristics by 5-Month HRQOL Latent Profiles 
  LP 1 LP 2  LP 3  LP 4  P value 
  N=503 % N=412 % N=483 %  N=201 %   
Age at diagnosis                  <0.0001*** 
<35 years 22 4% 11 3% 15 3%  4 2%   
35-50 years 238 47% 190 46% 171 35%  63 31%   
50-64 years 167 33% 137 33% 181 37%  75 37%   
65+ years 76 15% 74 18% 116 24%  59 29%   
Race                  <0.0001*** 
Non-Hispanic White 263 52% 207 50% 330 68%  109 54%   
Non-Hispanic Black 240 48% 205 50% 153 32%  92 46%   
Smoking status                  <0.0001*** 
Never 237 47% 227 55% 265 55%  122 61%   
Former 143 28% 112 27% 149 31%  60 30%   
Current 123 24% 73 18% 69 14%  19 9%   
Marital status                  <0.0001*** 
Not married 262 52% 165 40% 158 33%  64 32%   
Married/partnered 241 48% 247 60% 325 67%  137 68%   
Education level                  <0.0001*** 
<HS 61 12% 23 6% 27 6%  13 6%   
HS & Post HS 241 48% 235 57% 201 42%  115 57%   
College+ 291 58% 154 37% 255 53%  73 36%   
Insurance status                  <0.0001*** 
None 48 10% 12 3% 16 3%  3 1%   
Private 304 60% 301 73% 387 80%  160 80%   
Public 151 30% 99 24% 80 17%  38 19%   
Diabetes 78 16% 68 17% 55 11%  31 15% 0.1295 
COPD 18 4% 12 3% 9 2%  0 0% 0.0316* 
Heart Disease 28 6% 29 7% 21 4%  7 3% 0.1923 
Obesity 251 50% 219 53% 187 39%  89 44% <0.0001*** 
Hypertension 237 47% 190 46% 186 39%  99 49% 0.0135* 
Surgery                  0.0058** 
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  LP 1 LP 2  LP 3  LP 4  P value 
  N=503 % N=412 % N=483 %  N=201 %   
Not specified 5 1% 3 1% 0 0%  1 0%   
Lumpectomy 327 65% 247 60% 334 69%  148 74%   
Mastectomy 171 34% 162 39% 149 31%  52 26%   
Chemotherapy 303 60% 293 71% 173 36%  75 37% <0.0001*** 
Radiation 363 72% 290 70% 340 70%  150 75% 0.6563 
Herceptin 75 15% 72 17% 37 8%  12 6% <0.0001*** 
Tumor stage                    
I  228 45% 154 37% 294 61%  125 62% <0.0001*** 
II 208 41% 188 46% 157 33%  62 31%   
III 67 13% 70 17% 32 7%  14 7%   
Tumor grade                  <0.0001*** 
Well differentiated 127 25% 75 18% 162 34%  55 27%   
Moderately differentiated 221 44% 184 45% 233 48%  96 48%   
Poorly differentiated/unknown 155 31% 153 37% 88 18%  50 25%   
Note: LP (latent profile). LP1 represented the worst HRQOL profile, relatively, and LP4 represented the best HRQOL profile, 
relatively. Statistical significance is denoted as follows:  p<0.05 *, p<0.01 **, p<0.0001* 
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Table 12. Unadjusted and Adjusted Associations between 5-Month HRQOL Latent Profiles and 
Endocrine Therapy Non-Initiation and Non-Adherence 
  ET Non-Initiation ET Non-Adherence 
  Unadjusted Adjusted Unadjusted Adjusted 
  OR 95% CI aOR  95% CI OR  95% CI aOR 95% CI 
5-Month LP (ref=LP4)                 
LP 1 1.1 (0.6-1.9) 1.9 (0.9-4.2) 2.4 (1.3-4.2)* 2.2 (1.2-4.0)* 
LP 2 0.8 (0.4-1.5) 1.4 (0.7-3.1) 2.0 (1.1-3.6)* 1.9 (1.1-3.6)* 
LP 3 1.5 (0.8-2.8) 2.1 (0.9-4.4) 1.6 (0.9-3.0) 1.7 (0.9-3.1) 
Adjusted models include all covariates listed in Table 1. * denotes statistical significance at the 
0.05 level. OR (odds ratio), aOR (adjusted odds ratio), CI (confidence interval), ET (endocrine 
therapy), LP (latent profile). LP 4 was the reference category for analyses.  
 
  
 133 
Table 13. Adjusted Associations between 5-Month HRQOL Latent Profiles and Endocrine 
Therapy Non-Initiation and Non-Adherence Stratified by Chemotherapy and Race 
  ET Non-Initiation ET Non-Adherence 
  aOR 95% CI aOR 95% CI 
Black women only (ref=LP 4)         
LP 1 1.3 (0.5-3.8) 1.9 (0.8-4.6) 
LP 2 1.2 (0.4-3.6) 2.5 (1.1-6.1)* 
LP 3 1.6 (0.5-4.7) 1.8 (0.8-4.5) 
White women only (ref=LP 4)         
LP 1 2.6 (0.8-8.1) 2.4 (1.1-5.6)* 
LP 2 1.4 (0.4-4.7) 1.4 (0.6-3.5) 
LP 3 2.1 (0.7-6.6) 1.4 (0.6-3.3) 
Chemotherapy-users (ref=LP 4)         
LP 1 1.1 (0.3-3.2) 1.8 (0.7-4.4) 
LP 2 1.4 (0.4-4.5) 1.5 (0.6-3.7) 
LP 3 1.4 (0.4-4.9) 1.3 (0.5-3.4) 
Non-chemotherapy users (ref=LP 4)         
LP 1 5.5 (1.7-17.4)** 2.1 (1.2-5.1)* 
LP 2 1.0 (0.3-3.2) 2.0 (0.8-5.1) 
LP 3 2.8 (0.9-7.9) 1.8 (0.8-3.9) 
Adjusted models include all covariates listed in Table 1. * denotes statistical significance at the 
0.05 level. aOR (adjusted odds ratio), CI (confidence interval), ET (endocrine therapy), LP 
(latent profile). LP 4 was the reference category for analyses.  
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Figure 12. Mean 5-month HRQOL Scores by Latent Profiles Compared to U.S Norms 
 
Note: Mean HRQOL scores were converted to Z-scores. LP (latent profile), Normed US scores 
are only available for Physical, Social, Functional and Emotional FACT-B domains and come 
from Brucker et al.215  
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CHAPTER 7: OVERALL FINDINGS AND IMPLICATIONS 
Objectives 
The overall goals of this dissertation were to gain a better understanding of health-related 
quality of life (HRQOL) patterns in women with breast cancer (BC) and to determine if HRQOL 
can be used to identify women at risk for under-utilization of adjuvant endocrine therapy (ET). 
We conducted three separate studies (Aims 1-3) in order to achieve these objectives.  In Aim 1, 
we employed a novel cluster-based modeling approach - latent profile analysis (LPA) - to 
identify latent profiles (LPs) of women with BC who experienced different HRQOL patterns 
during two distinct time points in the BC care continuum (i.e., active treatment and 
survivorship). We then determined if patient characteristics were associated with membership in 
the identified HRQOL LPs. In Aim 2, our objective was to understand how HRQOL of two 
racial groups (Non-Hispanic Whites and Non-Hispanic Blacks) might be differentially impacted 
during active treatment and survivorship phases of the BC care continuum. To do this, we 
assessed whether or not racial disparities existed at each of these two time points and in changes 
between the two time points in six HRQOL domains (e.g., physical, functional, emotional, 
social, and spiritual well-being, and BC-specific concerns). Finally, in Aim 3 we assessed if 
HRQOL could be used preemptively to identify women who might be at increased risk for 
under-utilizing adjuvant ET. To do this, we evaluated associations between active treatment 
HRQOL LPs and not initiating or not adhering to ET during survivorship in women with 
hormone receptor positive (HR+) BC. A deeper understanding of predictors of HRQOL patterns 
and ET under-use offers valuable insights into how to provide targeted care management for 
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women with BC who are most susceptible to poor HRQOL and into potential solutions for 
improving BC outcomes. 
Important Findings 
Each aim described above had notable study findings, which are described in detail by 
aim. 
Aim 1 
Through LPA, we identified four distinct HRQOL LPs of women with BC during active 
treatment and survivorship phases of the BC care continuum. Women in the poorest HRQOL LP 
had the lowest HRQOL scores across all six HRQOL domains, and women in the best HRQOL 
LP had the highest HRQOL scores across all of these domains. The second lowest HRQOL LP 
(LP 2) generally had poor physical, functional and BC-specific HRQOL, but fared much better in 
social, emotional and spiritual well-being. The second highest HRQOL LP had better physical 
and functional HRQOL compared to the two lowest LPs, but poorer psychosocial and spiritual 
HRQOL than LP 2.  
 After controlling for comorbid conditions, treatment and tumor characteristics, and 
lifestyle factors (e.g., smoking), we found that non-modifiable demographic and socioeconomic 
factors such as age at diagnosis, race, social support, insurance, and education were significantly 
associated with membership in poor HRQOL LPs at both 5- and 25-month after BC diagnosis. 
Specifically, younger age at diagnosis, lack of social support, and having public insurance or 
being uninsured was associated with an increased likelihood of being in a lower HRQOL LP. 
Although factors associated with LP membership were relatively similar at 5- and 25-months 
post-diagnosis, we observed a difference in associations between race on LP membership 
between these two time points. During active treatment, White race was significantly associated 
with membership in the poorest HRQOL LP (aOR 1.48, 95% CI 1.25-1.65), but at 25-months, 
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Black race (aOR 1.75, 95% CI 1.18-2.60) was significantly associated with membership in the 
lowest HRQOL LP. This suggests that non-modifiable demographic factors affecting a woman’s 
HRQOL may have varying effects at different points in the BC care continuum. As such, 
different socio-demographic groups might be at risk for compromised HRQOL at different points 
in their care trajectories.  
 Chemotherapy, an aggressive BC treatment, was also significantly associated with poor 
HRQOL LP membership (aOR 1.85, 95% CI 1.22-2.81 and aOR 1.92, 95% CI 1.21-3.05) at both 
5-months and 25-months, respectively, which was in line with the literature related to poor 
HRQOL associated with chemotherapy.101, 118, 119 Receipt of chemotherapy has been associated 
with long-term body image concerns, fear of recurrence and worse sexual functioning.101, 118 One 
study found that after adjusting for demographic, clinical and treatment characteristics, receipt of 
chemotherapy was a significant predictor of poorer long-term HRQOL.119  
 Prevalence of comorbid conditions and disease severity became stronger predictors of 
membership in the two poorest HRQOL LPs as women transitioned from active treatment and 
into survivorship. This finding is not surprising, as these factors may influence the types of 
adjuvant treatments women receive (i.e., chemotherapy, ET) and how difficult it is to adjust to 
“normal” life following primary BC treatments. Women with multiple comorbid conditions may 
struggle with the added burden of having to take oral ET for 5 years following completion of 
primary BC treatments.  
Aim 2 
During active treatment, mean physical well-being scores were significantly lower (1.2-
3.7 points) than U.S. norms for all women in our study. However, White women reported scores 
1.9-2.5 points higher than Black women, which was considered both clinically meaningful and 
statistical significant. Black women, however, reported spiritual well-being scores over 2-points 
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higher than White women in our study, which also exceed our 2-point threshold for clinical 
significance. These results are consistent with what we found in the racial disparities literature: 
Black women with and without cancer generally have worse physical and functional well-being 
compared to White women, but report better social and spiritual well-being through community 
support and increased religiosity. 22, 42, 156, 159, 160, 162 
 During the BC survivorship phase of our study, White women’s HRQOL scores 
rebounded to above U.S norms across physical, functional, social and emotional HRQOL 
domains. Black women continued to report mean physical well-being scores below U.S. norms 
and more than 2-points below their White counterparts at 25-months. However, as Black women 
moved from active treatment to survivorship, they sustained spiritual well-being scores 2-points 
higher than White women, suggesting that their spiritual or community support was sustained for 
the first two years of their BC care experience.  
 In terms of patterns of change in HRQOL between 5- and 25-months post-diagnosis, we 
observed small, statistically significant racial differences in HRQOL scores, but differences were 
not large enough to be considered clinically meaningful. This is consistent with previous studies 
documenting no racial disparities in HRQOL once treatment and tumor characteristics were 
taken into consideration.227, 228 Racial differences attenuated considerably when socioeconomic 
factors were included in our models and widened a bit when we allowed the race coefficient in 
our model to represent the socioeconomic factors. These results suggest socioeconomic factors 
may considerably mediate racial gaps in physical and functional HRQOL between White and 
Black women with BC.  
 Emotional and spiritual well-being were the only HRQOL domains in which racial 
differences were not attenuated by socioeconomic factors.  In fact, spiritual well-being gaps 
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between White and Black women actually widened when socioeconomic factors were included 
in models, suggesting that perhaps these factors may strengthen or reinforce this domain. 
Emotional and spiritual well-being domains appear more resistant to life stressors affecting other 
domains due to increased spirituality and community support. Another possibility is that BC and 
socioeconomic factors do impact emotional and spiritual well-being, but in a way that reinforces 
these domains. The Superwoman role, a theory stating that Black women may exude strength, 
suppress emotions, and demonstrate perseverance when faced with adversity, may partially 
explain this finding.231 If Black women do not allow themselves to acknowledge weakness or 
stress related to BC, self-reported emotional and spiritual well-being may not appear to suffer.231 
Aim 3 
Overall, poor HRQOL during active treatment was not significantly associated with a 
woman’s likelihood of ET initiation among HR+ women who had not initiated ET by the time 
their HRQOL was measured. We did find a significant association between poor HRQOL and an 
increased likelihood of non-initiation among women who did not receive chemotherapy (aOR 
5.5, 95% CI 1.7-17.4), which offers a potential group of women to target with HRQOL 
management. Although we did not find statistically significant associations between HRQOL 
and ET non-initiation, we did observe a consistent trend toward lower likelihood of initiation 
among women in worse HRQOL groups. The adjusted ORs for these trends were all well above 
1.0 with wide confidence intervals crossing 1.0.  A larger sample size would be required to 
further investigate if a significant association between poor HRQOL and lower likelihood of ET 
initiation exists, as our confidence intervals would narrow.  
 We observed significant associations between poor HRQOL (i.e., membership in the two 
poorest HRQOL LPs as described above) and an increased likelihood of ET non-adherence with 
aOR 2.2 (95% CI 1.2-4.0) in LP1 and aOR 1.9 (95% CI 1.1-3.6), in LP2, respectively. As we 
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saw in ET initiation analyses, a strong association between poor HRQOL and non-adherence was 
also observed among non-chemotherapy users (aOR 2.1, 95% CI 1.2-5.1). Our results suggest 
that women with poor HRQOL during active treatment may be at increased risk for ET under-
utilization (both non-initiation and non-adherence) and that women who do not undergo 
chemotherapy may especially benefit from early HRQOL screening to anticipate ET under-use. 
Implications for Clinical Practice 
These dissertation findings are particularly relevant for BC clinical practice. First, results 
from Aim 1 suggest that we can use non-modifiable patient characteristics such as age at 
diagnosis and race to preemptively identify women at increased risk for experiencing poor 
HRQOL during active treatment and survivorship phases of their BC care. By creating clinically 
meaningful HRQOL LPs with electronic health record data, clinicians could be made aware of 
patients that may be especially vulnerable to poor HRQOL during distinct phases of BC care.  
These findings have important clinical implications, as there is a national emphasis on patient-
centered care that encourages clinicians to routinely collect and monitor HRQOL through their 
electronic health records. 9-13 If approaches such as LPA were applied to clinical practice data 
and subgroups of women could be identified following BC diagnosis, we may see improvements 
in BC outcomes for women with poor HRQOL. Through early identification, women could be 
connected to mental health specialists, support groups from the onset of active treatment, 
nutritionists to control weight gain or loss, and physical therapists to help manage physical and 
functional well-being ailments following primary treatments. Clinics should consider using their 
own patient-reported HRQOL data to create clinically meaningful LPs to inform HRQOL 
management. Leveraging LP membership to anticipate HRQOL needs of women with BC is in 
line with providing cancer care that reflects patient needs and values and is a meaningful way to 
use electronic health record data collected in the clinic.  
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 Aim 2 conclusions highlight a need to address socioeconomic-related barriers to physical 
and functional well-being in order to help narrow gaps in these particular domains, which are 
consistently lower among Black women with BC than among White women with BC. Potential 
ways to improve physical and functional HRQOL could be to help manage other comorbidities 
(e.g., hypertension, diabetes) and to promote greater physical activity following BC diagnosis. 
Black women with BC tend to report lower levels of physical activity and higher rates of 
hypertension and diabetes, which have been associated with poorer physical well-being and 
overall HRQOL. 3, 158 Studies have also confirmed that although BC survivors report less 
physical activity compared to the general population, White women with BC have higher levels 
of physical activity than Black women with BC.3, 20, 158 If clinicians could connect BC patients 
with resources to support their physical and functional HRQOL throughout the BC care 
continuum, we may see gaps in these domains narrow considerably or disappear. Supportive BC 
services should consider domain-specific findings to provide targeted HRQOL management 
across socio-demographic groups of women with BC and recognize that different socio-
demographic groups require tailored support at distinct phases of the BC care continuum.  
 Arguably, our findings from Aim 3 have the greatest clinical relevance, as they suggest 
that HRQOL measured soon after BC diagnosis can be used to identify women who may not 
initiate or not adhere to ET during BC survivorship. We recommend that women with poor 
HRQOL during active treatment receive targeted HRQOL support to reduce the risk of 
inappropriate adjuvant treatment decisions.40, 41 Women experiencing poor physical and 
functional well-being during active treatment may be at greater risk for under-utilization 
(compared to women in the best HRQOL LP with high physical and functional well-being 
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scores), as low scores in these two particular domains appeared to be most associated with ET 
under-use in our study.  
 In Aim 2, we saw that physical and functional well-being scores were lower among Black 
women than White women, which leads us to wonder if targeting these particular domains would 
help address racial disparities both in HRQOL and ET-use. As Black women present with more 
aggressive BC subtypes at younger ages, they often experience worse BC outcomes (BC 
recurrence and survival).48, 57, 137, 138 Compared with their White counterparts, Black women with 
BC are known to report worse physical and functional HRQOL and, thus, might be more 
susceptible to ET under-utilization.42, 44, 158, 237 Reducing ET under-utilization among Black 
women with BC may offer an opportunity to help reduce racial disparities in BC outcomes.  
Results from Aim 3 have particular clinical appeal, as using post-diagnosis HRQOL screening as 
an indicator for poor future ET under-use is potentially inexpensive and easy to do with validated 
HRQOL instruments. Women who may be most vulnerable to ET under-utilization should be 
identified early in the BC care continuum and provided ongoing HRQOL management to support 
ET use and potentially improve BC outcomes.31, 168 
Implications for Research 
Findings from this dissertation offer opportunities for future work in the area of HRQOL, 
BC outcomes, and racial disparities. Below we highlight each of these opportunities by aim.  
 First, Aim 1 of this dissertation addresses limitations of using traditional approaches to 
assessing HRQOL patterns, which compare means and standard deviations and have been 
criticized for not truly representing heterogeneity in HRQOL experiences.75 That is, examining 
mean differences in HRQOL scores may lead us to miss outliers or subgroups, which are often 
masked by an overall HRQOL score.75 Aim 1 used two patient-centered approaches (LPA and 
LTA) to identify and characterize HRQOL patterns in women with BC. This approach has 
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tremendous value in HRQOL research, as it is a cluster-based model approach that identifies 
clinically meaningful subgroups of individuals with similar characteristics that might be 
associated with their HRQOL patterns.222 Future HRQOL work could benefit from using these 
methods when studying HRQOL patterns and outcomes.  
 Results from Aim 1 also inform potential interventions to target women who are more 
likely to experience poor HRQOL (i.e., members of the poorest HRQOL LPs). Aim 1 identified 
non-modifiable patient characteristics such as age at diagnosis, race, and marital status, which 
are routinely collected in clinic and could be used in interventions wishing to target women most 
susceptible to poor HRQOL following diagnosis or during BC survivorship.  Therefore, Aim 1 
contributes to a greater understanding of patient-level predictors of HRQOL patterns among 
women with BC and uses patient-level characteristics to identify subsets of women who are at 
risk for poor HRQOL.  
 Findings from Aim 2 also support the use of domain-specific HRQOL measures in future 
HRQOL work so that we can tease out domain-specific racial differences, which may be masked 
by an overall HRQOL score. Results from this particular aim highlight White-Black HRQOL 
differences that would likely have been missed had we simply used the overall FACT-B measure 
of HRQOL, which has been often used in other studies. In addition, Aim 2 also highlighted the 
importance of selecting the appropriate racial disparities approach (i.e., Institute of Medicine, 
Residual Direct Effect, race and socioeconomic interactions) for one’s particular research 
question, as conclusions from the varying approaches differ. The racial diversity (i.e., 50% of our 
sample is Black) of the CBCS dataset used in this dissertation makes contributions from Aim 2 
especially relevant for the racial disparities literature, as much of the previous work in HRQOL 
racial disparities has been done in samples with a much smaller minority representation. Results 
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from Aim 2 inform and support the development of more equitable approaches to domain-
specific HRQOL management for women with BC.  
 Results from Aim 3 of this dissertation inform future interventions that wish to target 
HRQOL, a modifiable factor, in order to potentially increase the likelihood of appropriate ET 
use. Given the age and racial diversity of this population-based cohort, results from Aim 3 are 
highly generalizable to women with BC in the United States. As such, Aim 3 fills an important 
gap in the literature, as much of the previous work has been done in exclusively Non-Hispanic 
White Medicaid or Medicare populations. We recommend that Aim 3 be repeated in datasets that 
capture ET adherence data in claims or through prescription refills in order to strengthen the 
association between poor HRQOL and increased likelihood of ET non-adherence. Using self-
reported adherence measures may introduce some misclassification if women are more or less 
likely to accurately report there ET adherence. However, conclusions from this aim contribute to 
the BC outcomes literature, as we identify a potential mechanism to preemptively identify 
women at risk for poor HRQOL, which may support women more appropriately receive life-
saving adjuvant treatments such as ET. 
Implications for Health Policy 
Findings from this dissertation are also relevant for health policy, as cancer care that 
considers patient-reported outcomes is consistent with the national emphasis on patient-centered 
care.9-11 12, 13 The number of women diagnosed with and surviving from BC in the U.S. is 
anticipated to grow by more than 20% between 2010 and 2020.238 A deeper understanding of the 
HRQOL patterns and needs of this specific population will allow us to provide care that is more 
line with patient needs and values. Previous work in this area has been limited, as studies were 
done in small samples of older, primarily White populations using generic HRQOL instruments, 
and treating HRQOL domains independently. As such, findings from other studies have not been 
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generalizable to the larger U.S. population, which has become increasingly diverse in terms of 
race, ethnicity, socio-economics, and culture.  
 The age and racial diversity of the population-based CBCS dataset is unparalleled for BC 
disparities research, as 50% of the sample is Black, 50% White, 50% less than 50 years of age 
and 50% older than 50 years. Many research studies struggle to have a large representation of 
minority groups, thus limiting their ability to draw recommendations that are generalizable to 
these under-represented populations. The racial composition of the CBCS dataset makes it an 
ideal platform for racial disparities work. Findings from this dissertation inform more equitable 
approaches to HRQOL management and suggest that greater efforts be made to support physical 
and functional well-being, especially among Black women with BC.  In doing so, we may be 
able to narrow some HRQOL racial gaps that currently exist, which may also have positive 
downstream effects on other health outcomes including medication adherence, BC recurrence, 
and death. These findings will be of interest to policy-makers aiming to reduce racial health 
disparities in the U.S.  
Limitations 
Only Non-Hispanic White and Non-Hispanic Black women residing in North Carolina 
were included in this dissertation (across all three aims), limiting generalizability to women in 
other states and of other races/ethnicities. We also excluded women with distant stage BC, as 
they are distinct from women with early stage BC in terms of prognosis, treatment burden and 
HRQOL outcomes. As such, as do not know if our conclusions would be similar in a metastatic 
BC population. In addition, across all three aims, as most women have initiated primary BC 
treatments by 5-months, there was no pre-treatment HRQOL measure available. However, BC 
treatments such as receipt of radiation, chemotherapy, surgery and Herceptin (obtained from 
medical records) were included all adjusted analyses.  
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 In Aim 1, we employed relatively exploratory approaches (LPA and LTA) with 
numerous model assumptions in order to identify HRQOL LPs. However, we used established 
statistical fit indices such as the Bayesian Information Criteria to ensure optimal model fit. We 
also assessed the robustness of our results by performing various sensitivity analyses. 
Furthermore, in Aim 1 LTA, restricted sample sizes may have limited our ability to detect 
statistically significant associations with LP transitions in our sample. Finally, we primarily 
focused on non-modifiable predictors of LP membership, which limits our ability to inform 
interventions aiming to target modifiable factors associated with poor HRQOL.   
 In Aim 2, we were unable to control for unmeasured confounders such as patient 
preferences, culture, and economic, political, and legal factors that may impact HRQOL and 
contribute to White-Black differences in HRQOL. Therefore, even in fully adjusted models (i.e., 
residual direct effect), race coefficients encompassed unmeasurable factors such as institutional 
racism, different care seeking behavior and access to healthcare networks that are not determined 
by insurance status, marital status, education and income, introducing potential bias. 
 Finally, in Aim 3 of this dissertation, ET adherence was classified from self-report data, 
which did not allow us to confirm the reliability of ET adherence. Furthermore, given the limited 
sample of HR+ women, we were unable to examine associations between poor HRQOL and non-
specific patterns of medication non-adherence such as quitting versus intermittent use or under-
use, which is not necessarily a limitation, but could be of interest in future studies.  
 Despite these notable limitations, CBCS-III is a large, multi-payer, age and racially 
diverse population-based cohort of women with BC in North Carolina, which allows us to draw 
broader inferences in comparison to other, less diverse study populations such as those from a 
single-institution or a clinical trial.  
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Future Directions 
 This dissertation offers valuable opportunities for continued work. Specifically, it 
supports the use of evidence-based interventions to target HRQOL soon after diagnosis in 
women with HR+ BC in order to help support future ET use. It is our recommendation that such 
interventions specifically focus on targeting physical and functional well-being, as these domains 
were particularly low in the two poorest HRQOL LPs and among Black women in our sample. 
The importance of focusing on physical and functional HRQOL was also observed in results 
from Aim 2, thus further supporting interventions that better meet physical and functional 
HRQOL needs. In doing so, potential interventions might help narrow racial gaps in HRQOL, 
because Black women with BC tend to have worse physical and functional HRQOL than their 
White counterparts. In addition, future work should consider exploring associations between 
HRQOL and under-utilization of other BC treatments including radiation, chemotherapy and 
Herceptin. This work could be extended beyond BC into other cancer types or chronic diseases 
such as diabetes and hypertension, where patients take medications for years and improving 
adherence to medications is of interest to providers.  
Conclusions 
Through this dissertation, we gained a greater understanding of non-modifiable 
demographic predictors of HRQOL patterns among women with BC in North Carolina and 
determined that a woman’s self-reported HRQOL soon after BC diagnosis can be used to 
identify women who may be at increased risk for under-utilization of ET. Results from this 
dissertation contribute to the HRQOL research field by 1) employing innovative approaches to 
identify clinically meaningful HRQOL patterns among women with BC, 2) determining 
individual-level characteristics that are associated with membership in HRQOL sub-groups, 3) 
contributing to the evidence pertaining to racial disparities in BC research by using three 
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competing approaches to assessing racial disparities in HRQOL, and 4) identifying an 
opportunity for future interventions to target women with BC at risk of ET under-utilization early 
in their BC care process by focusing on improvements to their HRQOL. 
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